Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION PUBLISHED IN 2008



Application No.: US20080003202A1  Published: 03/Jan/2008

Title: Modified interferon-beta (IFN-beta) polypeptides

Applicant/Assignee:

Application No.: 11/729266   Filing Date: 27/Mar/2007

Abstract:Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid molecules. The modified polypeptides exhibit increased protein stability, including increased resistance to proteases. Also provided are methods of treatment by administering modified interferon-beta polypeptides.

Priority: US20060787208P Applic. Date: 2006-03-28

Inventor: GUYON THIERRY [FR]; BORRELLY GILLES [FR]; DRITTANTI LILA [FR]; VEGA MANUEL [FR]


Application No.: US20080003271A1  Published: 03/Jan/2008

Title: Compositions with Several Hyaluronic Acid Fractions for Cosmetic Use

Applicant/Assignee: NOVOZYMES BIOPOLYMER A/S

Application No.: 11/769141   Filing Date: 27/Jun/2007

Abstract:The present invention provides a moisturizing, cosmetic, or anti-wrinkle product comprising at least two hyaluronic acid fractions, or salts thereof, wherein a fraction has an average molecular weight in the range of 8,000-100,000 Da, and a fraction has an average molecular weight in the range of 100,000-500,000 Da.

Priority: DK20060000865 Applic. Date: 2006-06-28; DK20060000937 Applic. Date: 2006-07-07; US20060819683P Applic. Date: 2006-07-10; US20060817766P Applic. Date: 2006-06-29

Inventor: ABDELLAOUI KHADIJA S [DK]; MALLE BIRGITTE M [DK]


Application No.: US20080003284A1  Published: 03/Jan/2008

Title: LEVOTHYROXINE COMPOSITIONS AND METHOS

Applicant/Assignee:

Application No.: 11/855852   Filing Date: 14/Sep/2007

Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.

Priority: US2003-425007 Applic. Date: 2003-04-28; US2002-077677 Applic. Date: 2002-02-15; US20010344762P Applic. Date: 2001-10-29; US20010344744P Applic. Date: 2001-10-29; US20010344763P Applic. Date: 2001-10-29; US20010345344P Applic. Date: 2001-10-29; US20010345343P Applic. Date: 2001-10-29; US20010347827P Applic. Date: 2001-10-29; US20010347828P Applic. Date: 2001-10-29; US20010353777P Applic. Date: 2001-10-29; US20010312483P Applic. Date: 2001-08-14; US20010312184P Applic. Date: 2001-08-14; US20010312206P Applic. Date: 2001-08-14; US20010312113P Applic. Date: 2001-08-14; US20010312114P Applic. Date: 2001-08-14; US20010312289P Applic. Date: 2001-08-14; US20010312273P Applic. Date: 2001-08-14; US20010312287P Applic. Date: 2001-08-14; US20010311552P Applic. Date: 2001-08-10; US20010311550P Applic. Date: 2001-08-10; US20010311549P Applic. Date: 2001-08-10; US20010311522P Applic. Date: 2001-08-10; US20010311523P Applic. Date: 2001-08-10; US20010311524P Applic. Date: 2001-08-10; US20010311525P Applic. Date: 2001-08-10; US20010269009P Applic. Date: 2001-02-15; US20010268998P Applic. Date: 2001-02-15

Inventor: FRANZ G A [US]; STRAUSS ELAINE A [US]; DIMENNA PHILLIP A [US]; GEMMA ROCCO L [US]


Application No.: US20080003285A1  Published: 03/Jan/2008

Title: Immediate Release Pharmaceutical Tablets With Height Greater Than Width

Applicant/Assignee:

Application No.: 11/569343   Filing Date: 23/May/2005

Abstract:An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal crosssection, and measuring the length of a line that is at right angle to the shorter sides.

Priority: US20040573042P Applic. Date: 2004-05-21; US20040573134P Applic. Date: 2004-05-21; WO2005US18633 Applic. Date: 2005-05-23

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20080003297A1  Published: 03/Jan/2008

Title: Taste-masking oral dosage form and method of preparing the same

Applicant/Assignee:

Application No.: 11/896753   Filing Date: 05/Sep/2007

Abstract:A taste-masking oral dosage form. The taste-masking oral dosage form comprises a pharmaceutically active ingredient, and a starch, wherein the pharmaceutically active ingredient is packaged by the starch to form a microparticle. A method of preparing the taste-masking oral dosage form is also disclosed.

Priority: TW20040104745 Applic. Date: 2004-02-25; US2004-839243 Applic. Date: 2004-05-06

Inventor: YANG CHIH-CHIANG [TW]; WANG WEN-CHE [TW]; CHEN HUI-YU [TW]


Application No.: US20080004313A1  Published: 03/Jan/2008

Title: Preparation of crystalline polymorphs of rimonabant hydrochloride

Applicant/Assignee: MAI DE LTD

Application No.: 11/818986   Filing Date: 18/Jun/2007

Abstract:This invention relates to three novel solvate forms of crystalline rimonabant hydrochloride (Form A, B, and C) and two novel crystalline polymorphic forms of rimonabant hydrochloride anhydrous (Form D and E), to processes for preparing such polymorphic forms or solvate forms, to pharmaceutical compositions containing them and to the use of them in medicine.

Priority: US20060816670P Applic. Date: 2006-06-28

Inventor: HUANG HUI MIN HE [US]; HUANG CAI GU [US]


Application No.: US20080008742A1  Published: 10/Jan/2008

Title: Chewy products and methods for making the same

Applicant/Assignee: CAPRICORN PHARMA, INC

Application No.: 11/819902   Filing Date: 29/Jun/2007

Abstract:Methods for producing chewable emulsion compositions and compositions produced from such methods are disclosed. The emulsion base may be prepared by contacting an aqueous phase and a nonaqueous phase in the presence of an emulsifier. The aqueous phase is prepared under conditions that permit no substantial moisture loss and reduced viscosity. The methods permit preparing chewable compositions for delivering confectionary items, nutriceuticals, vitamins, minerals and therapeutically active agents. The compositions may be sugar-free or sugar-containing. The active agent may be added to the emulsion base at a lower temperature compared to the temperature at which either the aqueous or nonaqueous phase is formed. The compositions may be further coated with taste-masking materials, enteric coating materials, or slow-release materials. The compositions may be formed into compressible tablets, beads, granules, or otherwise generally known dosage forms.

Priority: US20060806241P Applic. Date: 2006-06-29

Inventor: CHERUKURI SUBRAMAN R [US]


Application No.: US20080008743A1  Published: 10/Jan/2008

Title: Orally Dissolving Formulations of Memantine

Applicant/Assignee: FOREST LABORATORIES HOLDINGS LIMITED

Application No.: 11/774292   Filing Date: 06/Jul/2007

Abstract:Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.

Priority: US20060806700P Applic. Date: 2006-07-06

Inventor: DEDHIYA MAHENDRA G [US]; CHHETTRY ANIL [US]; SARKAR RANAJOY [US]


Application No.: US20080008751A1  Published: 10/Jan/2008

Title: Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof

Applicant/Assignee:

Application No.: 11/484487   Filing Date: 10/Jul/2006

Abstract:The present invention provides stable pharmaceutical compositions comprising a combination of active pharmaceutical ingredients. The pharmaceutical composition of the present invention comprises a moisture sensitive drug, in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, as an active ingredient, a second pharmaceutically active ingredient such as for example Hydrochlorothiazide, and at least one pharmaceutical excipient, wherein the moisture sensitive active pharmaceutical ingredient is wet granulated with a solution of at least one pharmaceutical excipient, and methods for preparing such stable pharmaceutical compositions.

Priority:

Inventor: FOX MICHAEL [IL]


Application No.: US20080008752A1  Published: 10/Jan/2008

Title: Pharmaceutical compositions of memantine

Applicant/Assignee:

Application No.: 11/524778   Filing Date: 20/Sep/2006

Abstract:The invention is directed to easily dissolved, stable dose proportional pharmaceutical compositions, comprising granulated memantine and methods of preparing the same. In particular, the invention is directed to granulated memantine pharmaceutical compositions in the form of film coated tablets.

Priority: US20060818823P Applic. Date: 2006-07-05

Inventor: HRAKOVSKY JULIA [IL]; SEBBAN HAGIT [IL]


Application No.: US20080008761A1  Published: 10/Jan/2008

Title: Pharmaceutical Formulation Administrable Orally In Terms Of A Taste, Consistency And A Dosing

Applicant/Assignee: CARDON PHAMACEUTICALS NV

Application No.: 11/722777   Filing Date: 04/Jan/2006

Abstract:A method for preparing a pharmaceutical formulation which is orally administrable in terms of a taste, consistency and a dosing, including the steps of (a) grinding a solid pharmaceutical formulation containing one or several active substances and excipients in such a way that a powder is obtained, and (b) mixing the powder with one or several excipients for transforming the powder into a formulation having a consistency suitable for the oral administration (gel, liquid, paste, . . . ) and with one or several excipients for masking the taste of the solid pharmaceutical formulation to be ground in order to obtain a formulation suitable for the oral administration in terms of taste, consistency and dosing. A device for carrying out the method is also disclosed.

Priority: FR20050000188 Applic. Date: 2005-01-07; WO2006IB00003 Applic. Date: 2006-01-04

Inventor: CARDON CHRISTIAN [BE]


Application No.: US20080008762A1  Published: 10/Jan/2008

Title: Steroid Formulation And Methods Of Treatment Using Same

Applicant/Assignee: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 11/791125   Filing Date: 17/Nov/2005

Abstract:The invention provides steroid-containing pharmaceutical compositions which are free of classical preservatives and preferably comprise a steroid that is sparingly soluble or substantially insoluble in water, particulate steroid having an average particle size of from about 2.2 to about 10 microns. The pharmaceutical compositions can be used to treat medical conditions, including ophthalmological and back pain conditions.

Priority: US20040628741P Applic. Date: 2004-11-17; WO2005US42332 Applic. Date: 2005-11-17

Inventor: ROBINSON MICHAEL R [US]; GRIMES GEORGE [US]; GRAVLIN LUISA V [US]; POTTI GOPAL K [US]; YUAN PENG [US]; CSAKY KARL G [US]


Application No.: US20080009502A1  Published: 10/Jan/2008

Title: Tadalafil solid composites

Applicant/Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLC

Application No.: 11/595481   Filing Date: 09/Nov/2006

Abstract:This invention relates to oral pharmaceutical compositions suitable for making pharmaceutical formulations for oral administration that provide for the rapid dissolution of the phosphodiesterase 5 inhibitor tadalafil. In particular, the pharmaceutical compositions comprise solid composites of tadalafil exhibiting high solubility and rate of dissolution. The invention further relates to methods of preparing these pharmaceutical formulations and the use of such pharmaceutical formulations for treating diseases associated with PDE5 inhibitors.

Priority: US20060819215P Applic. Date: 2006-07-07

Inventor: ZALIT ILAN [IL]; PAL BOAZ [IL]


Application No.: US20080014263A1  Published: 17/Jan/2008

Title: Amorphous eprosartan mesylate and process for the preparation thereof

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/879334   Filing Date: 17/Jul/2007

Abstract:Eprosartan mesylate substantially in an amorphous form is disclosed. A composition comprising eprosartan mesylate in a solid form, wherein at least about 80% by weight of the solid eprosartan mesylate is in an amorphous form is also disclosed. The present invention also provides a process for preparing eprosartan mesylate substantially in an amorphous form by providing a solution of eprosartan mesylate in one or more solvents capable of dissolving the eprosartan mesylate and substantially removing the solvent from the solution.

Priority: IN2006MU01134 Applic. Date: 2006-07-17

Inventor: CRASTO ANTHONY M [IN]; NAIK SAMIR J [IN]; JOSHI NARENDRA S [IN]; KHAN MUBEEN [IN]


Application No.: US20080014264A1  Published: 17/Jan/2008

Title: NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING LEVETIRACETAM

Applicant/Assignee: UCB, S.A

Application No.: 11/681490   Filing Date: 02/Mar/2007

Abstract:The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Priority: EP20060014537 Applic. Date: 2006-07-13; US20060807526P Applic. Date: 2006-07-17

Inventor: GOFFIN CAROLINE [BE]; BERWAER MONIQUE [BE]; BOONEN MICHAEL [BE]; DELEERS MICHEL [BE]; FANARA DOMENICO [BE]


Application No.: US20080014265A1  Published: 17/Jan/2008

Title: PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF

Applicant/Assignee: FERRING B. V

Application No.: 11/775695   Filing Date: 10/Jul/2007

Abstract:The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1,000 mum. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

Priority: US2006-486214 Applic. Date: 2006-07-14; US2003-425993 Applic. Date: 2003-04-30

Inventor: LOMRYD HAKAN [SE]; NICKLASSON HELENA [SE]; OLSSON LARS-ERIK [SE]


Application No.: US20080014275A1  Published: 17/Jan/2008

Title: PHARMACEUTICAL SUSPENSIONS AND RELATED METHODS

Applicant/Assignee:

Application No.: 11/457316   Filing Date: 13/Jul/2006

Abstract:A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

wherein the pharmaceutical suspension has a pH of from about 4 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]; KOCH EDWARD A [US]; RECHEN DANA J [US]


Application No.: US20080015188A1  Published: 17/Jan/2008

Title: Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives

Applicant/Assignee:

Application No.: 11/788771   Filing Date: 19/Apr/2007

Abstract:Provided are stable pharmaceutical compositions comprising from about 2.5% to about 20% of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative by weight of the composition and at least one pharmaceutically acceptable excipient, wherein the composition preferably has a total weight of less than 100 mg. Also provided are stable pharmaceutical compositions comprising a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative in a stabilizing-effective concentration and at least one pharmaceutically acceptable excipient. Further provided are methods for improving the stability of a pharmaceutical composition and methods for treating hypertension by administering a therapeutically effective amount of the stable pharmaceutical compositions of the invention.

Priority: US20060793495P Applic. Date: 2006-04-19; US20060802121P Applic. Date: 2006-05-22

Inventor: HRAKOVSKY JULIA [IL]; SEBBAN HAGIT [IL]


Application No.: US20080015211A1  Published: 17/Jan/2008

Title: TREATMENT OF INFLAMMATORY AND ULCERATIVE DISEASES OF THE BOWEL WITH OPIOID ANTAGONISTS

Applicant/Assignee:

Application No.: 11/735548   Filing Date: 16/Apr/2007

Abstract:Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with low dose opioid antagonists (e.g., naltrexone, nalmefene or naloxone), pharmaceutical compositions for use in such methods, and methods for the manufacture of such pharmaceutical compositions. An embodiment of the invention includes a method of pharmaceutical treatment comprising orally administering to a human subject having Crohn's disease or ulcerative colitis a therapeutic pharmaceutical composition once per day in the evening or at bedtime, wherein the pharmaceutical composition comprises form about 3 mg to about 4.5 mg of naltrexone, nalmefene, naloxone, or a hydrochloride salt thereof in an immediate release solid dosage formulation.

Priority: US20060745119P Applic. Date: 2006-04-19

Inventor: SMITH JILL P [US]; ZAGON IAN S [US]; ROGOSNITZKY MOSHE [IL]


Application No.: US20080020024A1  Published: 24/Jan/2008

Title: Fast dissolving orally consumable films

Applicant/Assignee:

Application No.: 11/897152   Filing Date: 29/Aug/2007

Abstract:A consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising at least one water soluble polymer, a taste masking effective amount of a sweetener, a mucosa-coating effective amount of a mucosa-coating agent and a pharmaceutically active agent having a sufficiently unpleasant taste that it is desirably masked by the sweetener.

Priority: US2003-423398 Applic. Date: 2003-04-25; US2003-423735 Applic. Date: 2003-04-25; US1999-395104 Applic. Date: 1999-09-14; US19980101798P Applic. Date: 1998-09-25

Inventor: KULKARNI NEEMA [US]; SORG ALBERT F [US]; KUMAR LORI D [US]


Application No.: US20080020038A1  Published: 24/Jan/2008

Title: Amorphous Aripiprazole and Process for the Preparation thereof

Applicant/Assignee: HELM AG

Application No.: 11/463062   Filing Date: 08/Aug/2006

Abstract:Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Priority: EP20060117595 Applic. Date: 2006-07-20

Inventor: STRITZKE KATJA [DE]; LOEFFLER UWE [DE]; GLAENZER KLAUS [DE]


Application No.: US20080020046A1  Published: 24/Jan/2008

Title: Pharmaceutical Formulations Comprising Metformin And A Fibrate, And Processes For Obtaining Them

Applicant/Assignee: FOURNIER LABORATORIES IRELAND LIMITED

Application No.: 10/586801   Filing Date: 24/Jan/2005

Abstract:Granulates have particles of metformin and particles of a fibrate. Pharmaceutical compositions contain such granulates. Processes prepare the granulates and the pharmaceutical compositions.

Priority: EP20040001499 Applic. Date: 2004-01-23; WO2005EP01524 Applic. Date: 2005-01-24

Inventor: DAWSON GORDON [CH]; MCCARTHY LEONARD [IE]


Application No.: US20080020055A1  Published: 24/Jan/2008

Title: Phenylephrine Pharmaceutical Formulations and Compositions for Colonic Absorption

Applicant/Assignee:

Application No.: 11/756881   Filing Date: 01/Jun/2007

Abstract:The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.

Priority: US20060810021P Applic. Date: 2006-06-01; US20060874830P Applic. Date: 2006-12-14

Inventor: MONTEITH DAVID [US]; O'MULLANE JOHN [US]; REO JOSEPH P [US]; NOWAK ROBERT T [US]; WAN JIANSHENG [US]; KABIR MOHAMMED A [US]; ABUTARIF MALAZ A [US]; FRITZ GLENN E [US]


Application No.: US20080021092A1  Published: 24/Jan/2008

Title: STABLE PHARMACEUTICAL COMPOSITIONS OF ORLISTAT

Applicant/Assignee:

Application No.: 11/620475   Filing Date: 05/Jan/2007

Abstract:The present invention relates to stable pharmaceutical compositions of orlistat for treatment or prevention of obesity and hyperlipidemia. The pharmaceutical compositions contain Orlistat form I, which does not convert to form II at the temperatures encountered during manufacturing of an orlistat dosage form.

Priority: IN2006DE00062 Applic. Date: 2006-01-06

Inventor: MURPANI DEEPAK [IN]; DEO KESHAV [IN]; VIJAN TARUN [IN]


Application No.: US20080021104A1  Published: 24/Jan/2008

Title: Liquid compositions of calcium acetate

Applicant/Assignee: LYNE LABORATORIES

Application No.: 11/878169   Filing Date: 20/Jul/2007

Abstract:The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.

Priority: US20060832093P Applic. Date: 2006-07-21

Inventor: TARALLO STEPHEN C [US]


Application No.: US20080026053A1  Published: 31/Jan/2008

Title: Capsule containing granular pharmaceutical compositions

Applicant/Assignee: SOVEREIGN PHARMACEUTICALS, LTD

Application No.: 11/494616   Filing Date: 28/Jul/2006

Abstract:A capsule for oral administration to a human subject. The capsule comprises at least two different pharmaceutical compositions in granular form. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Priority:

Inventor: DIXIT SURESH [US]; BROWN RALPH [US]; MENENDEZ JUAN CARLOS [US]; MUNNIRPALLAM KRIPESH [US]


Application No.: US20080026054A1  Published: 31/Jan/2008

Title: Novel anelgesic combination

Applicant/Assignee: NECTID INC

Application No.: 11/820947   Filing Date: 22/Jun/2007

Abstract:The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSIAD and a slow release tramadol for treating pain and pain related conditions.

Priority: US20070926575P Applic. Date: 2007-04-27

Inventor: SESHA RAMESH [US]


Application No.: US20080026056A1  Published: 31/Jan/2008

Title: Antibiotic-Based Pharmaceutical Formulation in Microcapsular Form

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: 11/631030   Filing Date: 25/May/2005

Abstract:The invention relates to oral antibiotic drugs. The object of the invention is to limit or even stop the increase in antibiotic resistance without sacrificing the requirements of (a) increased efficacy of oral antibiotics, particularly for pediatric applications, (b) tolerance, (c) broad spectra of activity, and (d) good patient compliance. This object is achieved by the invention, which proposes the use of modified-release microcapsules, comprising a core that contains at least one active principle AP1 formed of at least one antibiotic, and a coating for said core that governs the modified release of said active principle, for the manufacture of a drinkable or orally dispersible antibiotic pharmaceutical formulation that makes it possible to limit the increase in the antibiotic resistance of the target germs, this formulation being: capable of administration in one or two, preferably two, intakes per day, and definable as follows, relative to an immediate-release oral formulation (IRF*) comprising at least one active principle API, and for the same dose D of API as IRF*: Tmic>T*micof IRF*

Priority: FR20040051353 Applic. Date: 2004-06-28; WO2005FR50366 Applic. Date: 2005-05-25

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUEIX REMI [FR]; SOULA GERARD [FR]


Application No.: US20080026058A1  Published: 31/Jan/2008

Title: METHODS FOR TREATING AND PREVENTING MUCOSITIS

Applicant/Assignee:

Application No.: 11/829138   Filing Date: 27/Jul/2007

Abstract:Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis.

Priority: EP20060015732 Applic. Date: 2006-07-28

Inventor: BOMBARDELLI EZIO [IT]; MORAZZONI PAOLO [IT]


Application No.: US20080026059A1  Published: 31/Jan/2008

Title: Methods of Reducing Degradant Formation in Pharmaceutical Compositions of Varenicline

Applicant/Assignee: PFIZER INC

Application No.: 11/836832   Filing Date: 10/Aug/2007

Abstract:The invention relates to methods for reducing degradant formation in pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to methods for preparing formulations of varenicline wherein the dosage forms that are produced therefrom generate under specified storage conditions less than about 4% on a weight basis of the N-formyl and N-methyl degradation products.

Priority: US2004-848464 Applic. Date: 2004-05-18; US20030472098P Applic. Date: 2003-05-20

Inventor: WATERMAN KENNETH C [US]


Application No.: US20080026071A1  Published: 31/Jan/2008

Title: Microparticles for delivery of heterologous nucleic acids

Applicant/Assignee:

Application No.: 11/653792   Filing Date: 16/Jan/2007

Abstract:Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. Also provided are microparticles in the form of submicron emulsions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. The surface of the microparticles efficiently adsorb polypeptides, such as antigens, and nucleic acids, such as ELVIS vectors and other vector constructs, containing heterologous nucleotide sequences encoding biologically active macromolecules, such as polypeptides, antigens, and adjuvants. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and uses of the microparticle compositions for vaccines are also provided.

Priority: US2001-967464 Applic. Date: 2001-09-28; US20000236105P Applic. Date: 2000-09-28; US20010315905P Applic. Date: 2001-08-30

Inventor: O'HAGAN DEREK [US]; OTTEN GILLIS [US]; DONNELLY JOHN [US]; POLO JOHN [US]; BARNETT SUSAN [US]; SINGH MANMOHAN [US]; ULMER JEFFREY [US]; DUBENSKY THOMAS [US]


Application No.: US20080026981A1  Published: 31/Jan/2008

Title: Pharmaceutical Compositions

Applicant/Assignee:

Application No.: 10/593401   Filing Date: 22/Mar/2005

Abstract:A process for micronization of pharmaceutically active agents.

Priority: GB20040006515 Applic. Date: 2004-03-23; GB20040024727 Applic. Date: 2004-11-09; WO2005EP03062 Applic. Date: 2005-03-22

Inventor: MUHRER GERHARD [CH]; SCHNEEBERGER RICARDO [FR]; WIRTH WOLFGANG [CH]; BAUMBERGER ANTON [CH]


Application No.: US20080027110A1  Published: 31/Jan/2008

Title: Indolyl-3-glyoxylic acid derivatives having antitumor action

Applicant/Assignee: ASTA MEDICA AKTIENGESELLSCHAFT

Application No.: 11/894591   Filing Date: 20/Aug/2007

Abstract:The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.

Priority: DE19981014838 Applic. Date: 1998-04-02; US2002-309204 Applic. Date: 2002-12-04; US2001-810604 Applic. Date: 2001-03-19; US1999-285058 Applic. Date: 1999-04-02

Inventor: NICKEL BERND [DE]; SZELENYI ISTVAN [DE]; SCHMIDT JURGEN [DE]; EMIG PETER [DE]; REICHERT DIETMAR [DE]; GUNTHER ECKHARD [DE]; BRUNE KAY [DE]; LE BAUT GUILLAUME [FR]


Application No.: US20080031825A1  Published: 07/Feb/2008

Title: Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate

Applicant/Assignee:

Application No.: 11/573932   Filing Date: 21/Aug/2007

Abstract:A pharmaceutical composition comprising at least one effervescent agent and a fibrate and a process for making such composition. The fibrate is fenofibrate and the effervescent agent are in a dosage form. The dosage form increases dissolution and absorption of fenofibrate in biological conditions where the form contacts acidic gastric fluid after oral administration.

Priority: US20040603198P Applic. Date: 2004-08-20; WO2005US27901 Applic. Date: 2005-08-05

Inventor: CHEN YISHENG [US]; QIU YIHONG [US]; REILAND THOMAS L [US]


Application No.: US20080031862A1  Published: 07/Feb/2008

Title: Mitochondria-targeted antioxidants

Applicant/Assignee:

Application No.: 11/881630   Filing Date: 27/Jul/2007

Abstract:The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q10 (CoQ10), reduced CoQ10, or mixtures thereof and oxygenated dibenzo-alpha-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.

Priority: US20060835520P Applic. Date: 2006-08-04

Inventor: GHOSAL SHIBNATH [IN]


Application No.: US20080031939A1  Published: 07/Feb/2008

Title: Process for the preparation of armodafinil

Applicant/Assignee:

Application No.: 11/713490   Filing Date: 01/Mar/2007

Abstract:The invention encompasses processes for preparing intermediates, such as R-modafinic acid or (R)-C1-2 alkyl ester, of modafinic acid, and the conversion of the intermediates to armodafinil.

Priority: US20060778334P Applic. Date: 2006-03-01; US20060785812P Applic. Date: 2006-03-23; US20060878097P Applic. Date: 2006-12-28

Inventor: BRAUDE VIVIANA [IL]; MOSHKOVITS-KAPTSAN RINAT [IL]; CHEN KOBI [IL]; ADLER MIRI [IL]


Application No.: US20080031947A1  Published: 07/Feb/2008

Title: Orally dissolvable/disintegrable lyophilized dosage forms containing protected

Applicant/Assignee: CIMA LABS INC CEPHALON FRANCE

Application No.: 11/880503   Filing Date: 23/Jul/2007

Abstract:The present invention provides an orally dissolvable/disintegrable, lyophilized, dosage form adapted for direct oral dosing, including an active pharmaceutical ingredient ("API") containing particle which is coated with a lyophilizing solvent protective coating, which protects the form and/or attributes of the particle and/or API, and a matrix. There is also provided a method of making an orally dissolvable/disintegrable lyophilized dosage form in accordance with the present invention, and a method of treating a patient with a dosage form in accordance with the present invention.

Priority: EP20060291198 Applic. Date: 2006-07-24; EP20060291458 Applic. Date: 2006-09-18

Inventor: HAMED EHAB [US]; HILLMAN LISA [US]; KHANKARI RAJENDRA K [US]; MOE DEREK [US]; NGUYEN THANH-TAM [FR]


Application No.: US20080031950A1  Published: 07/Feb/2008

Title: Novel anelgesic combination

Applicant/Assignee: NECTID INC

Application No.: 11/894060   Filing Date: 20/Aug/2007

Abstract:The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSAID and a slow release tramadol for treating pain and pain related conditions.

Priority: US20070926575P Applic. Date: 2007-04-27

Inventor: SESHA RAMESH [US]


Application No.: US20080032937A1  Published: 07/Feb/2008

Title: Bioavailability and Improved Delivery of Alkaline Pharmaceutical Drugs

Applicant/Assignee:

Application No.: 11/844865   Filing Date: 24/Aug/2007

Abstract:Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

Priority: US2004-792273 Applic. Date: 2004-03-04; US2005-228230 Applic. Date: 2005-09-19; US20030452557P Applic. Date: 2003-03-07

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]


Application No.: US20080033027A1  Published: 07/Feb/2008

Title: Drug combination pharmaceutical compositions and methods for using them

Applicant/Assignee: VICUS THERAPEUTICS SPE 1, LLC

Application No.: 11/495191   Filing Date: 28/Jul/2006

Abstract:The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called "beta blockers", e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof.

Priority: WO2006US10510 Applic. Date: 2006-03-21; US20050664225P Applic. Date: 2005-03-21; US20050713526P Applic. Date: 2005-08-31; US20050735432P Applic. Date: 2005-11-10; US20050753436P Applic. Date: 2005-12-22

Inventor: BASCOMB NEWELL [US]; MAKI JOHN [US]; YOUNG FREDERIC S [US]


Application No.: US20080033030A1  Published: 07/Feb/2008

Title: Fluvastatin sodium pharmaceutical compositions

Applicant/Assignee:

Application No.: 11/710232   Filing Date: 23/Feb/2007

Abstract:Various fluvastatin compositions and methods for preparing them are described. One example is a controlled release pharmaceutical composition comprising fluvastatin and at least one non-ionic hydrophilic polymer, wherein the composition is substantially free of hydroxypropyl methylcellulose. Another example is a stable pharmaceutical composition comprising fluvastatin, preferably, fluvastatin sodium wherein the composition is substantially free of an alkalizing stabilizing agent. Another example is a stable controlled release pharmaceutical formulation, comprising fluvastatin, preferably, fluvastatin sodium, that is stable with a water content greater than 3.5 percent by weight.

Priority: US20060776526P Applic. Date: 2006-02-24

Inventor: CAPUA SIMONA D [IL]; COHEN YAEL R [IL]; YAFFEH RONIT [IL]; SHTERMAN NAVA [IL]; ZILBERMAN RINA [IL]


Application No.: US20080033032A1  Published: 07/Feb/2008

Title: Novel Polymorphs Of The Potassium Salt Of Atorvastatin

Applicant/Assignee: SANDOZ A/S

Application No.: 11/660913   Filing Date: 26/Aug/2005

Abstract:Novel polymorphs Forms I, II and III of the potassium salt of Atorvastatin, (betaR,deltaR)-2-(p-fluorophenyl)-beta, delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid, are obtained directly by precipitation of the potassium salt of Atorvastatin with ethanol (polymorph I), with 1-propanol (polymorph II) and by recrystallisation of polymorph I from 2-propanol (polymorph III).

Priority: DK20040001293 Applic. Date: 2004-08-27; WO2005DK00544 Applic. Date: 2005-08-26

Inventor: BECK FREDERIK B [DK]; FISCHER ERIK [DK]


Application No.: US20080038224A1  Published: 14/Feb/2008

Title: Modified interferon-beta (IFN-beta) polypeptides

Applicant/Assignee:

Application No.: 11/729267   Filing Date: 27/Mar/2007

Abstract:Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid molecules. The modified polypeptides exhibit increased protein stability, including increased resistance to proteases. Also provided are methods of treatment by administering modified interferon-beta polypeptides.

Priority: US20060787208P Applic. Date: 2006-03-28

Inventor: GUYON THIERRY [FR]; BORRELLY GILLES [FR]; DRITTANTI LILA [FR]; VEGA MANUEL [FR]


Application No.: US20080038316A1  Published: 14/Feb/2008

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/826833   Filing Date: 18/Jul/2007

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US2005-236426 Applic. Date: 2005-09-27; US20050709665P Applic. Date: 2005-08-19; US20040614484P Applic. Date: 2004-10-01; US20060831991P Applic. Date: 2006-07-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]


Application No.: US20080038332A1  Published: 14/Feb/2008

Title: Stable pharmaceutical formulation comprising atorvastatin calcium

Applicant/Assignee:

Application No.: 11/891243   Filing Date: 10/Aug/2007

Abstract:The invention relates to a stable pharmaceutical formulation comprising an intimate admixture or admixture of crystalline or amorphous atorvastatin calcium, and a stabilizing-effective amount of a water-insoluble alkaline excipient or a combination of one or more water-insoluble alkaline excipients thereof, a stabilizing-effective amount of an antioxidant or a combination of one or more antioxidants thereof, and at least one or more additional pharmaceutically acceptable inert excipients or carriers, and a method for the preparation of the said formulation by wet and dry granulation. The invention further relates to a stabilized intimate admixture of atorvastatin calcium, a water-insoluble alkaline excipient and an antioxidant and a method for the preparation of the said intimate admixture by co-precipitation and co-milling.

Priority: US20060836669P Applic. Date: 2006-08-10

Inventor: HUANG CAI GU [CN]; HUANG HUI MIN HE [CN]


Application No.: US20080038336A1  Published: 14/Feb/2008

Title: Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent

Applicant/Assignee:

Application No.: 11/527501   Filing Date: 27/Sep/2006

Abstract:This invention relates to a solid pharmaceutical composition that include a regulating agent of digestive and/or intestinal motility which has an agonist effect on peripheral mu, delta and kappa opiate receptors

and an antiflatulent for the treatment and regulation of intestinal motility and flatulence in mammals. More in particularly, the pharmaceutical composition includes: (a) at least a regulating agent of intestinal motility such as trimebutine

(b) at least an antiflatulent such as simethicone

(c) at least a flowability promoter

(d) one or more lubricant

(e) at least an extender/diluent

(f) at least a disintegrant

and, (g) at least a binder.

Priority: CO20060078456 Applic. Date: 2006-08-10

Inventor: ESQUEA MARTA LUZ TORRES [CO]; VERGARA RAUL BELLO [CO]


Application No.: US20080038338A1  Published: 14/Feb/2008

Title: Tetracycline Package Formulations

Applicant/Assignee:

Application No.: 11/763860   Filing Date: 15/Jun/2007

Abstract:The invention provides a rapidly disintegrating and dissolving multilayer tablet comprising at least a tetracycline in a first layer, a buffer in a second layer, and optionally, an inert layer separating the first and second layers. The multilayer tablets of the invention are useful for treating or preventing mucositis, when administered topically to the oral cavity.

Priority: US20060813949P Applic. Date: 2006-06-15

Inventor: SMITH ALEXANDER D [US]; COBB JOE [US]; BETTIS JOHN [US]; STAGNER WILLIAM C [US]; GOLD BRAD [US]


Application No.: US20080038341A1  Published: 14/Feb/2008

Title: Direct Compression Formulation And Process

Applicant/Assignee:

Application No.: 10/586059   Filing Date: 17/Jan/2005

Abstract:Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

Priority: US20040604274P Applic. Date: 2004-08-25; US20040537706P Applic. Date: 2004-01-20; WO2005EP00400 Applic. Date: 2005-01-17

Inventor: KOWALSKI JAMES [US]; LAKSHMAN JAY PARTHIBAN [US]; PATEL ARUN P [US]


Application No.: US20080038342A1  Published: 14/Feb/2008

Title: Stable Pharmaceutical Composition Comprising an Ace Inhibitor

Applicant/Assignee: NICHE GENERICS LIMITED

Application No.: 10/590816   Filing Date: 15/Feb/2005

Abstract:The present invention relates to a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof. In particular, the invention relates to a pharmaceutical composition, which comprises an ACE inhibitor, or a pharmaceutically acceptable salt or a derivative thereof, and a C16-C28 glyceride. ACE inhibitors useful in the present invention are susceptible to heat and/or mechanical stress-induced degradation. Preferred ACE inhibitors are ramipril, trandolapril, quinapril and pharmaceutically acceptable salts and derivatives thereof. The composition of the present invention may be for use as a medicament for the treatment or prevention of a cardiovascular disease, a coronary heart disease, a cerebrovascular disease, a peripheral vascular disease, arrhythmia, hypertension, cardiac failure, cardiovascular death, myocardial infraction, stroke or angina. The present invention further relates to a method of preparing the pharmaceutical composition of the present invention. The present invention also relates to a method of providing a stable pharmaceutical composition comprising an ACE inhibitor, or a pharmaceutically acceptable salt or derivative thereof, by incorporating a C16-C28 glyceride into the composition. The present invention further relates to a use of C16-C28 glyceride to provide a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof.

Priority: GB20040004420 Applic. Date: 2004-02-27; WO2005GB50016 Applic. Date: 2005-02-15

Inventor: BERGMAN JEFFREY [GB]; PILGAONKAR PRATIBHA S [IN]; RUSTOMJEE MAHARUK T [IN]; SURANA AMITA P [IN]; MULAGATH RIZWANA [IN]; KELKAR ATUL A [IN]


Application No.: US20080038343A1  Published: 14/Feb/2008

Title: PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROFOLIC ACID

Applicant/Assignee:

Application No.: 11/773689   Filing Date: 05/Jul/2007

Abstract:The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone

an estrogen, such as ethinylestradiol

a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate

and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.

Priority: US20060818512P Applic. Date: 2006-07-06

Inventor: KING KRISTINA [DE]


Application No.: US20080038345A1  Published: 14/Feb/2008

Title: MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT

Applicant/Assignee: BIOAVAIL LABORATORIES BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/774109   Filing Date: 06/Jul/2007

Abstract:The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Priority: US2007-751768 Applic. Date: 2007-05-22; US2006-475252 Applic. Date: 2006-06-27; US20050693906P Applic. Date: 2005-06-27

Inventor: OBEREGGER WERNER [CA]; ZHOU FANG [US]; MAES PAUL [CA]; TURCHETTA STEFANO [IT]; JACKSON GRAHAM [IE]; MASSARDO PIETRO [IT]; SALEH MOHAMMAD A [CA]


Application No.: US20080038347A1  Published: 14/Feb/2008

Title: Extended release tablet formulations of flibanserin and method for manufacturing the same

Applicant/Assignee:

Application No.: 11/837959   Filing Date: 13/Aug/2007

Abstract:The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.

Priority: EP20060118896 Applic. Date: 2006-08-14; EP20060017754 Applic. Date: 2006-08-25

Inventor: EISENREICH WOLFRAM [DE]; FRIEDL THOMAS [DE]; SOMMER FLORIAN [DE]; PEARNCHOB NANTHARAT [DE]; WAGNER KARL G [DE]


Application No.: US20080038356A1  Published: 14/Feb/2008

Title: Spray freeze-dried compositions

Applicant/Assignee:

Application No.: 11/797089   Filing Date: 30/Apr/2007

Abstract:A process for producing a powder comprises spray freeze-drying an aqueous solution or suspension comprising a pharmaceutical agent, said solution or suspension having a solids content of 20% by weight or more. The spray freeze-dried powder may be administered to a subject via a needleless syringe.

Priority: US2002-164594 Applic. Date: 2002-06-10; US20010296939P Applic. Date: 2001-06-08

Inventor: MAA YUH-FUN [US]; PRESTRELSKI STEVEN J [US]; BURKOTH TERRY L [US]


Application No.: US20080039385A1  Published: 14/Feb/2008

Title: Neublastin Variants

Applicant/Assignee: BIOGEN IDEC MA INC

Application No.: 11/573773   Filing Date: 18/Aug/2005

Abstract:Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.

Priority: US20040602825P Applic. Date: 2004-08-19; US20050694067P Applic. Date: 2005-06-24; WO2005US29637 Applic. Date: 2005-08-18

Inventor: ROSSOMANDO ANTHONY [US]; SILVIAN LAURA [US]; PEPINSKY R B [US]


Application No.: US20080044400A1  Published: 21/Feb/2008

Title: Targeted enzyme prodrug therapy

Applicant/Assignee:

Application No.: 11/824865   Filing Date: 02/Jul/2007

Abstract:The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.

Priority: US2004-008049 Applic. Date: 2004-12-09

Inventor: SCHELLENBERGER VOLKER [US]


Application No.: US20080044454A1  Published: 21/Feb/2008

Title: UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS

Applicant/Assignee: MONOSOLRX LLC

Application No.: 11/775484   Filing Date: 10/Jul/2007

Abstract:The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

Priority: US2004-768809 Applic. Date: 2004-01-30; WO2002US32575 Applic. Date: 2002-10-11; WO2002US32594 Applic. Date: 2002-10-11; WO2002US32542 Applic. Date: 2002-10-11; US2004-856176 Applic. Date: 2004-05-28; US20030443741P Applic. Date: 2003-01-30; US20020386937P Applic. Date: 2002-06-07; US20020414276P Applic. Date: 2002-09-27; US20020371940P Applic. Date: 2002-04-11; US20030473902P Applic. Date: 2003-05-28

Inventor: YANG ROBERT K [US]; FUISZ RICHARD C [US]; MYERS GARRY L [US]; FUISZ JOSEPH M [US]


Application No.: US20080044463A1  Published: 21/Feb/2008

Title: Bradykinin B2 Receptor Antagonist Peptide From Amphibian Skin

Applicant/Assignee:

Application No.: 10/544946   Filing Date: 06/Feb/2004

Abstract:A bradykinin B2-receptor antagonist peptide, kinestatin, isolated from toad (Bombina maxima) defensive skin secretion, and analogs thereof, is disclosed. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH2. Also disclosed are kinestatin analogs, prodrugs including the peptides, fusion peptides and multimeric peptides including the peptide sequences, pharmaceutical compositions including kinestatin and analogs thereof, prodrugs, fusion and multimeric peptides thereof, nucleic acids encoding kinestatin and analogs thereof, and nucleic acids encoding the fusion and multimeric peptides. Kinestatin and analogs thereof (including the prodrugs and multimeric and/or fusion peptides) can be used to treat and/or prevent disorders associated with bradykinin, including cardiovascular disorders, inflammation, asthma, allergic rhinitis, pain, angiogenesis and the like.

Priority: GB20030002624 Applic. Date: 2003-02-06; GB20030023193 Applic. Date: 2003-10-03; WO2004GB00473 Applic. Date: 2004-02-06

Inventor: SHAW CHRIS [GB]; HIRST DAVID [GB]; CHEN TIANBAO [GB]; O'ROURKE MARTIN [GB]; RAO PINGFAN [CN]


Application No.: US20080044468A1  Published: 21/Feb/2008

Title: Processes For The Preparation Of Oral Dosage Formulations Of Modafinil

Applicant/Assignee:

Application No.: 10/522223   Filing Date: 24/Jul/2003

Abstract:The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.

Priority: IN2002DE00771 Applic. Date: 2002-07-25; WO2003IB02962 Applic. Date: 2003-07-24

Inventor: SINGH ROMI BARAT [IN]; KUMAR PANANCHUKUNNATH MANOJ [IN]; NAGAPRASAD VISHNUBHOTLA [IN]; ROY SUNILENDU BHSHAN [IN]; MALIK RAJIV [AT]


Application No.: US20080044470A1  Published: 21/Feb/2008

Title: PHARMACEUTICAL COMPOSITION WITH CONTROLLED ACITVE INGREDIENT RELEASE FOR ACTIVE INGREDIENTS WITH GOOD SOLUBILITY IN WATER

Applicant/Assignee: ROEHM GMBH

Application No.: 11/695848   Filing Date: 03/Apr/2007

Abstract:A pharmaceutical preparation comprising: a) a core with an active ingredient and with an organic acid and/or the salt of an organic acid

and b) a coating which envelops the core and which comprises a polymer content of (meth)acrylate copolymers which have not more than 15% by weight of cationic or anionic groups, and which comprises at least 60% by weight of a (meth)acrylate copolymer which is composed of free-radically polymerized units of 93 to 98% by weight C1- to C4-alkyl esters of acrylic or of methacrylic acid and 7 to 2% by weight (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, wherein the active ingredient has a solubility in water of at least 10 g/l at 20 DEG C. and the coating comprises silicon dioxide particles having an average particle size in the range from 1 to 50 mum.

Priority: IN2006CH01465 Applic. Date: 2006-08-18

Inventor: PETEREIT HANS-ULRICH [DE]; RAVISHANKAR HEMA [IN]; BODINGE SHRADDH [IN]


Application No.: US20080045476A1  Published: 21/Feb/2008

Title: Methods and compositions using sulodexide for the treatment of diabetic nephropathy

Applicant/Assignee: ALFA WASSERMANN, INC

Application No.: 11/880274   Filing Date: 19/Jul/2007

Abstract:The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin. excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.

Priority: US2001-873234 Applic. Date: 2001-06-04; US20000209907P Applic. Date: 2000-06-07

Inventor: PALAZZINI ERNESTO [IT]; GAMBARO GIOVANNI [IT]


Application No.: US20080045487A1  Published: 21/Feb/2008

Title: Pharmaceutical formula for treating skin disease

Applicant/Assignee: KLEVER MODE, S.L

Application No.: 11/521073   Filing Date: 14/Sep/2006

Abstract:The present invention refers to a pharmaceutical formulation characterized in that it includes mainly clobetasolpropionate, minoxidil and 11 alpha hydroxyprogesterone as main active principles, besides other excipients, vitamins and/or minerals, and to its use in the treatment of skin diseases, mainly in the symptomatic treatment of psoriasis.

Priority: EP20060380229 Applic. Date: 2006-08-17

Inventor: BARRANCO ENRIQUE ROSSELL [ES]


Application No.: US20080045583A1  Published: 21/Feb/2008

Title: STABLE LEVETIRACETAM COMPOSITIONS AND METHODS

Applicant/Assignee:

Application No.: 11/836419   Filing Date: 09/Aug/2007

Abstract:Stable, liquid compositions of levetiracetam that are substantially or entirely free of preservatives, particularly parabens, and/or sugars, such as natural sugars and sugar alcohols. The liquid compositions preferably include oral solutions or suspensions, and may include pharmaceutically acceptable excipients.

Priority: US20060838440P Applic. Date: 2006-08-18

Inventor: DELMARRE DAVID [US]; CENTENO CARLOS-JULIAN SISON [US]; SURAPANENI NAGA MALLIKA [US]; GAO DANCHEN [US]


Application No.: US20080045600A1  Published: 21/Feb/2008

Title: BICALUTAMIDE COMPOSITIONS

Applicant/Assignee:

Application No.: 11/839672   Filing Date: 16/Aug/2007

Abstract:Pharmaceutical compositions comprising bicalutamide or its pharmaceutically acceptable salts, solvates, single isomers, enantiomers or mixtures thereof, and a hydrophilic excipient, processes for preparing the compositions and finished dosage forms containing them, and methods of use and treatment.

Priority: IN2006CH01449 Applic. Date: 2006-08-17; US20060827727P Applic. Date: 2006-10-02

Inventor: GAWANDE RAHUL S [IN]; BASETY SRIKANTH [IN]; KODIPYAKA RAVINDER [IN]; BHUSHAN INDU [IN]; MOHAN MALIATUR S [IN]


Application No.: US20080047230A1  Published: 28/Feb/2008

Title: Individualized pharmaceutical selection and packaging

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE

Application No.: 11/518540   Filing Date: 08/Sep/2006

Abstract:The present disclosure relates to methods and systems that may be used for individualized selection of one or more pharmaceutical agents and packaging of the one or more pharmaceutical agents.

Priority: US2006-453571 Applic. Date: 2006-06-14

Inventor: JUNG EDWARD K Y [US]; LEVIEN ROYCE A [US]; LORD ROBERT W [US]; MALAMUD MARK A [US]; RINALDO JOHN D [US]; WOOD LOWELL L [US]


Application No.: US20080050434A1  Published: 28/Feb/2008

Title: Novel Composition for Topical Delivery

Applicant/Assignee:

Application No.: 10/593136   Filing Date: 17/Mar/2005

Abstract:Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives

a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component

an aqueous phase

optionally containing one or more stabilizing agent

and other pharmaceutically acceptable excipients

and process for preparing such compositions are provided. Also provided is a method for the management/treatment of fungal, bacterial or microbial infections, inflammations, autoimmune conditions, or hormonal disorders which comprises administering a pharmaceutically effective amount of such pharmaceutical composition to a subject in need of such treatment. The compositions of the present invention are non-greasy and easily water washable, and provides an enhanced localization of hydrophobic and/or amphiphilic active ingredients on the skin.

Priority: IN2004DE00501 Applic. Date: 2004-03-18; WO2005IN00086 Applic. Date: 2005-03-17

Inventor: JAIN RAJESH [IN]; CHAND KOUR [IN]; SINGH SUKHJEET [IN]; SIHORKAR VAIBHAV [IN]


Application No.: US20080050449A1  Published: 28/Feb/2008

Title: Controlled release formulation of tolterodine

Applicant/Assignee:

Application No.: 11/726535   Filing Date: 21/Mar/2007

Abstract:The invention encompasses stable multiparticulate pharmaceutical compositions of tolterodine having at least one pharmaceutically acceptable excipient and at least two populations of multiparticulates each population having tolterodine or a salt thereof and the ratio of the populations is from 90:10 to 10:90 by weight, wherein after storage for 1 month at 40 DEG C. and 75% relative humidity the difference between the dissolution profile at 4 hours is no more than about 5% when compared to the dissolution profile at the time of manufacture.

Priority: US20060784573P Applic. Date: 2006-03-21

Inventor: ARIELI DAFNA [IL]; GOLD TOMER [IL]


Application No.: US20080051377A1  Published: 28/Feb/2008

Title: Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

Applicant/Assignee: DURAMED PHARMACEUTICALS, INC

Application No.: 11/889976   Filing Date: 17/Aug/2007

Abstract:The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.

Priority: US2006-645807 Applic. Date: 2006-12-27; US20050753399P Applic. Date: 2005-12-27

Inventor: AHMED SALAH U [US]; SHAIK MADHU S [US]; GUPTA SANJEEV K [US]


Application No.: US20080051411A1  Published: 28/Feb/2008

Title: Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof

Applicant/Assignee:

Application No.: 11/840477   Filing Date: 17/Aug/2007

Abstract:In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

Priority: US2004-880851 Applic. Date: 2004-06-30; WO2003EP14331 Applic. Date: 2003-12-16; US20020453694P Applic. Date: 2002-12-17

Inventor: CINK RUSSELL D [US]; PATERSON JOSEPH B JR [US]; GAO YI [US]; ZHANG GEOFF G Z [US]; LONG MICHELLE A [US]; MORRIS JOHN B [US]; ROSENBERG JOERG [DE]


Application No.: US20080051427A1  Published: 28/Feb/2008

Title: Pharmaceutical Compositions and Methods of Using Same

Applicant/Assignee:

Application No.: 11/750556   Filing Date: 18/May/2007

Abstract:A pharmaceutical composition is provided that comprises a solid dispersion of implitapide. Such solid dispersions may include implitapide and least one pharmaceutically acceptable excipient. In some embodiments, the disclosed solid dispersions comprise substantially amorphous implitapide.

Priority: EP20060010232 Applic. Date: 2006-05-18

Inventor: SCHUCKLER FRITZ [DE]


Application No.: US20080051460A1  Published: 28/Feb/2008

Title: PHARMACEUTICAL METHODS, DOSING REGIMES AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Applicant/Assignee: MYRIAD GENETICS, INCORPORATED

Application No.: 11/743522   Filing Date: 02/May/2007

Abstract:In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 mug per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Priority: US2004-889971 Applic. Date: 2004-07-12; US20030486769P Applic. Date: 2003-07-11; US20030517666P Applic. Date: 2003-11-05; US20040560685P Applic. Date: 2004-04-07

Inventor: HOBDEN ADRIAN [US]; ZAVITZ KENTON [US]; MATHER GARY [US]; HENDRIX SUZANNE [US]


Application No.: US20080057003A1  Published: 06/Mar/2008

Title: Powder inhaler formulations

Applicant/Assignee:

Application No.: 11/653887   Filing Date: 17/Jan/2007

Abstract:The present invention relates to new methods for the surface modification of powders. Furthermore the present invention relates to new, improved pharmaceutical dosage forms obtainable by the new methods for surface modification of drugs according to the invention and to the use of these pharmaceutical dosage forms within dry powder inhalation devices (DPI).

Priority: GB20010007106 Applic. Date: 2001-03-21; US2005-093491 Applic. Date: 2005-03-30; US2002-085972 Applic. Date: 2002-02-28

Inventor: BECHTOLD-PETERS KAROLINE [DE]; ROWLEY GEOFFREY [GB]; NGUYEN HANH [GB]


Application No.: US20080057004A1  Published: 06/Mar/2008

Title: ALBUMIN-INSULIN FUSION PROTEINS

Applicant/Assignee: COGENESYS, INC

Application No.: 11/835114   Filing Date: 07/Aug/2007

Abstract:Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.

Priority: US20060835976P Applic. Date: 2006-08-07; US20060850545P Applic. Date: 2006-10-10

Inventor: BELL ADAM C [US]; ROSEN CRAIG A [US]; SANYAL INDRAJIT [US]; ZHAO QINGHAI [US]


Application No.: US20080057038A1  Published: 06/Mar/2008

Title: TARGETED DRUG-CARRYING BACTERIOPHAGES

Applicant/Assignee:

Application No.: 11/850942   Filing Date: 06/Sep/2007

Abstract:The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions.

Priority: WO2006IL00309 Applic. Date: 2006-03-08; US20050659072P Applic. Date: 2005-03-08

Inventor: YACOBY IFTACH [IL]; RON ELIORA Z [IL]; SHABAT DORON [IL]; SHAMIS MARINA [IL]; BENHAR ITAI [IL]


Application No.: US20080057086A1  Published: 06/Mar/2008

Title: COLON-TARGETED ORAL FORMULATIONS OF CYTIDINE ANALOGS

Applicant/Assignee: PHARMION CORPORATION

Application No.: 11/849958   Filing Date: 04/Sep/2007

Abstract:The present invention provides an oral formulation of a cytidine analog, including, 5-azacytidine, for delivery to the lower gastrointestinal tract, including, the large intestine

methods to treat diseases associated with abnormal cell proliferation by treatment with the oral formulations of the present invention

and methods to increase the bioavailability of a cytidine analog upon administration to a patient by providing an oral formulation of the present invention.

Priority: US20060824320P Applic. Date: 2006-09-01

Inventor: ETTER JEFFREY B [US]


Application No.: US20080057123A1  Published: 06/Mar/2008

Title: Controlled Release Formulations

Applicant/Assignee: JAGOTEC AG

Application No.: 11/847012   Filing Date: 29/Aug/2007

Abstract:Controlled release oral dosage formulations containing one or more active agent, and methods of use thereof, are provided for the once-a-day treatment. The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. The core may contain one or more enteric materials or polymeric materials which modulates the release of the active agent.

Priority: US20060824043P Applic. Date: 2006-08-30; US20060824054P Applic. Date: 2006-08-30

Inventor: GRENIER PASCAL [FR]; NHAMIAS ALAIN [FR]; VERGNAULT GUY [FR]


Application No.: US20080057124A1  Published: 06/Mar/2008

Title: Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

Applicant/Assignee:

Application No.: 11/894729   Filing Date: 20/Aug/2007

Abstract:The invention relates to the use of N-substituted indole-3-glyoxylamides of the general and to pharmaceutical compositions having antitumor action.

Priority: DE19981014838 Applic. Date: 1998-04-02; DE19991046301 Applic. Date: 1999-09-28; US2003-686809 Applic. Date: 2003-10-17; US2000-492531 Applic. Date: 2000-01-27; US1999-285058 Applic. Date: 1999-04-02

Inventor: NICKEL BERND [DE]; BACHER GERALD [DE]; KLENNER THOMAS [DE]; BECKERS THOMAS [DE]; EMIG PETER [DE]; ENGEL JURGEN [DE]; BRUYNEEL ERIK [BE]; KAMP GUNTER [DE]; PETERS KIRSTEN [DE]


Application No.: US20080058246A1  Published: 06/Mar/2008

Title: Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Applicant/Assignee: MOUNTAIN VIEW PHARMACEUTICALS, INC

Application No.: 11/727641   Filing Date: 27/Mar/2007

Abstract:Methods are provided for the synthesis of polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and receptor-binding antagonists thereof, which conjugates retain unusually high receptor-binding activity. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, chemokines, growth factors and polypeptide hormones, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a higher level of receptor-binding activity than those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines, chemokines, growth factors and polypeptide hormones. The conjugates of the present invention also exhibit an extended half-life in vivo and in vitro compared to unconjugated cytokines, chemokines, growth factors and polypeptide hormones. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic, therapeutic and bioprocessing applications.

Priority: US2003-743295 Applic. Date: 2003-12-23; US20030479914P Applic. Date: 2003-06-20; US20020436020P Applic. Date: 2002-12-26

Inventor: BHASKARAN SHYAM S [US]; SHERMAN MERRY R [US]; SAIFER MARK G [US]; WILLIAMS L D [US]


Application No.: US20080058269A1  Published: 06/Mar/2008

Title: Insulin Releasing Peptides

Applicant/Assignee: UNVERSITY OF ULSTER

Application No.: 10/579581   Filing Date: 05/Sep/2006

Abstract:The present invention relates to peptides, or fragments thereof, isolated from the skin secretions of amphibians and which act as stimulators of insulin secretion and pancreatic beta cell function. The invention also encompasses peptide having at least 80%, preferably at least 85%, more preferably at least 90%, optionally more than 95%, sequence identity based on the ClustalW alignment method with the respective amino acid sequences of SEQ ID Nos. 1 to 17. Furthermore, the invention also includes peptides selected from the group comprising brevinins, dermaseptins and esculentins for stimulating insulin secretion by activation of physiological stimulus-secretion coupling pathways. These peptides are useful to stimulate insulin secretion and/or moderate blood glucose excursions. These peptides may be used for treatment of type 1 or type 2 diabetes mellitus.

Priority: GB20030026720 Applic. Date: 2003-11-17; WO2004EP13693 Applic. Date: 2004-11-17

Inventor: ABDEL-WAHAB YASSAR HASSAN ATEF [GB]; MARENAH LAMIN [GB]; ORR DAVID FRANCIS [GB]; MCCLEAN STEPHEN [GB]; FLATT PETER RAYMOND [GB]; SHAW CHRIS [GB]


Application No.: US20080058338A1  Published: 06/Mar/2008

Title: Stable Solid Dosage Forms of Aminopterin

Applicant/Assignee: SYNTRIX BIOSYSTEMS, INC

Application No.: 11/928257   Filing Date: 30/Oct/2007

Abstract:There is disclosed stable pharmaceutical compositions containing pharmaceutically acceptable salts of aminopterin surface deposited onto solid excipients. The stable pharmaceutical compositions are hermetically sealed from the atmosphere. The formation of degradation products of aminopterin is reduced or eliminated.

Priority: US2005-078614 Applic. Date: 2005-03-09; US20040552787P Applic. Date: 2004-03-12

Inventor: FARUQUI ABSAR [US]; ZEBALA JOHN A [US]; KAMEN BARTON A [US]


Application No.: US20080058345A1  Published: 06/Mar/2008

Title: Combination Therapy with Mecamylamine for the Treatment of Mood Disorders

Applicant/Assignee:

Application No.: 10/585562   Filing Date: 04/Jan/2005

Abstract:A combination therapy for treating mood disorders, including depressive disorders such as major depression, panic disorder, obsessive compulsive disorder, social anxiety disorder, seasonal affective disorder, and premenstrual dysphoria is provided herein. The combination therapy comprises administering an effettive amount of mecamylamine together with at least one agent for treatment of a mood disorder to a patient in need of treatment of the mood disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising mecamylamine and an additional agent, such as an SSRI, are also provided herein.

Priority: US20040534532P Applic. Date: 2004-01-06; US20040627250P Applic. Date: 2004-11-12; WO2005US00083 Applic. Date: 2005-01-04

Inventor: GEORGE TONY [CA]; SACCO KRISTI [US]; VESSICCHIO JENNIFER [US]


Application No.: US20080060645A1  Published: 13/Mar/2008

Title: Dry Powder Inhalant Composition

Applicant/Assignee:

Application No.: 11/934983   Filing Date: 05/Nov/2007

Abstract:Dry powder pharmaceutical compositions having improved stability comprising a bronchodilator drug in combination with a steroidal anti-inflammatory drug, dry powder inhalers comprising the same and their use in the treatment of respiratory disorders by inhalation.

Priority: GB20020008609 Applic. Date: 2002-04-13; US2005-510968 Applic. Date: 2005-05-09; WO2003GB01595 Applic. Date: 2003-04-10

Inventor: BULSARA PALLAV A [GB]; ROCHE TREVOR C [GB]


Application No.: US20080063704A1  Published: 13/Mar/2008

Title: Stable gabapentin compositions

Applicant/Assignee: NORTON HEALTHCARE LTD

Application No.: 10/585912   Filing Date: 15/Jan/2005

Abstract:The present invention provides a pharmaceutical composition of gabapentin wherein lactam level remains below 0.5% even after more than two years of storage at 25 to 30 DEG C. and 60% relative humidity.

Priority: GB20040000993 Applic. Date: 2004-01-16; WO2005US01423 Applic. Date: 2005-01-15

Inventor: WOOLFE AUSTEN JOHN [GB]


Application No.: US20080063705A1  Published: 13/Mar/2008

Title: Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride

Applicant/Assignee: KRKA, TOVARNA ZDRAVIL D.D., NOVO MESTO

Application No.: 11/577414   Filing Date: 19/Oct/2005

Abstract:The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.

Priority: DE200410051055 Applic. Date: 2004-10-19; WO2005EP11249 Applic. Date: 2005-10-19

Inventor: VRBINC MIHA [SI]; KOTAR-JORDAN BERTA [SI]; ZUPET ROK [SI]; SMRKOLJ MATEJ J [SI]


Application No.: US20080064711A1  Published: 13/Mar/2008

Title: Composition for treating oral cavity and Mucousal infections

Applicant/Assignee: J.P.M.E.D. LTD

Application No.: 11/807901   Filing Date: 29/May/2007

Abstract:The present invention provides a composition of matter for treating oral cavity infections and mucosal infections, said composition comprising: at least one anti-microbial drug

and at least one essential oil, in combination with a substantially, alcohol-free carrier system, said carrier system being selected from an isotonic system and a moderately hypertonic system, wherein the final composition isotonicity is between 140 and 480 miliosmolar.

Priority: IL20030158901 Applic. Date: 2003-11-17; IL20020152993 Applic. Date: 2002-11-21; US2005-535961 Applic. Date: 2005-05-20; WO2003IL00980 Applic. Date: 2003-11-19

Inventor: FRIEDMAN DORON I [IL]


Application No.: US20080069807A1  Published: 20/Mar/2008

Title: Cell-Derived Microparticles as Hemostatic Agents for Control of Hemorrhage and Treatment of Bleeding Disorders

Applicant/Assignee: UNIVERSITY OF MIAMI

Application No.: 11/792399   Filing Date: 07/Dec/2005

Abstract:Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.

Priority: US20040633417P Applic. Date: 2004-12-07; WO2005US44064 Applic. Date: 2005-12-07

Inventor: JY WENCHE [US]; JIMENEZ JOAQUIN J [US]; HORSTMANN LAWRENCE L [US]; AHN YEON S [US]; AHN EUGENE [US]


Application No.: US20080069846A1  Published: 20/Mar/2008

Title: Protease, a Gene Therefor and the Use Thereof

Applicant/Assignee: KOREAN RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Application No.: 11/853899   Filing Date: 12/Sep/2007

Abstract:The present invention relates to a protease, and more specifically to a protease derived from Aranicola proteolyticus, a gene coding for said enzyme, a gene expression system for said protease, a process for purifying the protease, and the uses of said protease in industrial applications, such as for example, detergents, cosmetics, leather processing agents, chemicals for laboratory research, solubilizing or softening agents for food, meat modifier, feed or food additives, or oil and fat separating agents, as well as pharmaceutical compositions.

Priority: KR20000005479 Applic. Date: 2000-02-03; US2001-958321 Applic. Date: 2001-10-03; WO2000IB02058 Applic. Date: 2000-12-29

Inventor: PARK HO-YONG [KR]; SON KWANG-HEE [KR]; PARK DOO-SANG [KR]; SHIN SANG-WOON [KR]; OH HYUN-WOO [KR]; KIM MI-GWANG [KR]; SHIN DONG-HA [KR]


Application No.: US20080069849A1  Published: 20/Mar/2008

Title: Novel Antimicrobial Peptides

Applicant/Assignee: DERMAGEN AB

Application No.: 11/718861   Filing Date: 17/Nov/2005

Abstract:The invention relates to the use of peptides, wherein at least one amino acid residue has been substituted to improve the efficacy of the antimicrobial peptide for the manufacturing of an antimicrobial composition. The composition can be used as a pharmaceutical composition to combat microorganisms, such as bacteria, virus, fungus, parasites as well as yeast.

Priority: SE20040002807 Applic. Date: 2004-11-17; US20040628110P Applic. Date: 2004-11-17; WO2005SE01737 Applic. Date: 2005-11-17

Inventor: SCHMIDTCHEN ARTUR [SE]; MALMSTEN MARTIN [SE]; WALSE BJORN [SE]


Application No.: US20080069873A1  Published: 20/Mar/2008

Title: Controlled release system and method for manufacturing the same

Applicant/Assignee:

Application No.: 11/837962   Filing Date: 13/Aug/2007

Abstract:The invention is directed to a pharmaceutical controlled release system for administration, particularly oral administration, of active substances with pH-dependent solubilities, comprising a) a core material containing or consisting of one or more pharmaceutically acceptable pH modifiers

b) optionally an insulating layer, c) a first layer containing or consisting of one or more pharmaceutically acceptable water-insoluble polymers

d) a second layer containing or consisting of at least one active substance having a pH-dependent solubility

e) a third layer containing or consisting of one or more pharmaceutically acceptable polymers having anionic or no ionic groups

and f) optionally a fourth layer, preferably in form of an outer coating layer. It is provided a pH-independent release profile of active substances having pH-dependent solubilities in vitro and vivo.

Priority: EP20060017754 Applic. Date: 2006-08-25

Inventor: PEARNCHOB NANTHARAT [DE]; FRIEDL THOMAS [DE]; WAGNER KARL G [DE]; SOMMER FLORIAN [DE]


Application No.: US20080069878A1  Published: 20/Mar/2008

Title: Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs

Applicant/Assignee:

Application No.: 11/847219   Filing Date: 29/Aug/2007

Abstract:The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 mug/mL at pH 6.8.

Priority: US20060841893P Applic. Date: 2006-08-31; US20060841760P Applic. Date: 2006-08-31

Inventor: VENKATESH GOPI [US]; BOLTRI LUIGI [IT]; COLOMBO ITALO [IT]; LAI JIN-WANG [US]; FLABIANI FLAVIO [IT]; MAPELLI LUIGI [IT]


Application No.: US20080069879A1  Published: 20/Mar/2008

Title: STABLE SOLID DOSAGE FORM CONTAINING AMORPHOUS CEFDITOREN PIVOXIL AND PROCESS FOR PREPARATION THEREOF

Applicant/Assignee:

Application No.: 11/742799   Filing Date: 01/May/2007

Abstract:The present invention relates to stable solid dosage form and a dry process for preparing amorphous cefditoren pivoxil solid dosage forms and coating the solid dosage form with one or more layers of aqueous dispersion of film forming agents.

Priority: IN2006DE01106 Applic. Date: 2006-05-02

Inventor: BHIWGADE RAVISHEKHAR [IN]; SINGH ROMI BARAT [IN]


Application No.: US20080069888A1  Published: 20/Mar/2008

Title: MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE FORM OF TRAMADOL

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/928908   Filing Date: 30/Oct/2007

Abstract:The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.

Priority: US2004-933479 Applic. Date: 2004-09-03; US2003-434266 Applic. Date: 2003-05-09; WO2003US04866 Applic. Date: 2003-02-21; US20020357851P Applic. Date: 2002-02-21

Inventor: SETH PAWAN [US]; MAES PAUL J [CA]


Application No.: US20080069891A1  Published: 20/Mar/2008

Title: Abuse resistant drug formulation

Applicant/Assignee: CIMA LABS, INC

Application No.: 11/900851   Filing Date: 13/Sep/2007

Abstract:A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.

Priority: US20060845126P Applic. Date: 2006-09-15; US20060845127P Applic. Date: 2006-09-15; US20060845128P Applic. Date: 2006-09-15; US20060845151P Applic. Date: 2006-09-15; US20060850456P Applic. Date: 2006-10-10

Inventor: HABIB WALID [US]; HAMED EHAB [US]; MOE DEREK [US]


Application No.: US20080075672A1  Published: 27/Mar/2008

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/703610   Filing Date: 06/Feb/2007

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20080075776A1  Published: 27/Mar/2008

Title: Topical Pharmaceutical Compositions Containing An Antiacne Compound And Antibiotic Compound

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/667283   Filing Date: 08/Nov/2005

Abstract:Pharmaceutical compositions suitable for the treatment of skin disorder are provided which include at least a therapeutically effective amount of at least on antiacne agent and at least one antibiotic agent as active pharmaceutical ingredients and a hydrophilic matrix capable of providing a constant and uniform release of the active pharmaceutical ingredients.

Priority: US20040625872P Applic. Date: 2004-11-08; WO2005IB03302 Applic. Date: 2005-11-08

Inventor: CHAUDHARI GHANSHYAM N [IN]; KHACHANE VASANT S [IN]; BHAMRE NITIN B [IN]; MACHARLA JAGANNATH [IN]


Application No.: US20080075788A1  Published: 27/Mar/2008

Title: DIAMMONIUM PHOSPHATE AND OTHER AMMONIUM SALTS AND THEIR USE IN PREVENTING CLOTTING

Applicant/Assignee:

Application No.: 11/859291   Filing Date: 21/Sep/2007

Abstract:The present invention relates to products, methods, and processes of various ammonium salts and their use as anti-coagulants.

Priority: US20060846312P Applic. Date: 2006-09-21

Inventor: LEE SAMUEL [US]; LOUIE STEPHANIE [US]; SCHWARDT JEFFREY D [US]; SLATER THOMAS A [US]; WENZ ROBERT [DE]


Application No.: US20080076804A1  Published: 27/Mar/2008

Title: METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION

Applicant/Assignee:

Application No.: 11/952024   Filing Date: 06/Dec/2007

Abstract:Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided.

Priority: US2006-537967 Applic. Date: 2006-10-02; US20060868870P Applic. Date: 2006-12-06; US20070894527P Applic. Date: 2007-03-13; US20050724138P Applic. Date: 2005-10-05

Inventor: FABRICANT JILL D [US]


Application No.: US20080076835A1  Published: 27/Mar/2008

Title: METHODS OF MODULATING MITOCHONDRIAL NAD-DEPENDENT DEACETYLASE

Applicant/Assignee:

Application No.: 11/839292   Filing Date: 15/Aug/2007

Abstract:The present invention provides methods for identifying agents that modulate a level or an activity of a mitochondrial NAD-dependent deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating mitochondrial NAD-dependent deacetylase activity in a cell. The invention further provides methods of modulating mitochondrial function by modulating the activity of mitochondrial NAD-dependent deacetylase.

Priority: US2003-444633 Applic. Date: 2003-05-22; US20020383069P Applic. Date: 2002-05-23

Inventor: VERDIN ERIC M [US]; NORTH BRIAN J [US]; SCHWER BJOERN [US]


Application No.: US20080081067A1  Published: 03/Apr/2008

Title: SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS OF VENLAFAXINE AND PROCESS FOR PREPARATION THEREOF

Applicant/Assignee:

Application No.: 11/841266   Filing Date: 20/Aug/2007

Abstract:The invention relates to sustained release pharmaceutical compositions of venlafaxine, process for preparing such compositions and method of using such compositions. Preferably, it relates to a sustained release pharmaceutical composition of venlafaxine comprising a first sustained release portion and a second sustained release portion wherein the first and the second sustained release portions are mixed in particular proportion in the formulation.

Priority: IN2006MU01627 Applic. Date: 2006-10-03

Inventor: MANISHKUMAR GUPTA [IN]; KAMALAKAR RAJHANS SUJAY [IN]; MATHURBHAI PATEL HASMUKH [IN]


Application No.: US20080081070A1  Published: 03/Apr/2008

Title: PHARMACEUTICAL FORMULATION WITH ENHANCED SOLUBILITY FOR THE DELIVERY OF CORTICOSTEROIDS

Applicant/Assignee: AURIGA LABORATORIES, INC

Application No.: 11/680276   Filing Date: 28/Feb/2007

Abstract:Formulations have been developed to improve the solubility of corticosteroids such as fluticasone proprionate in a composition designed to achieve localized release of the drug in the small intestine and/or colon. In one embodiment, solid dispersions of fluticasone are prepared wherein the drug is blended with or coated onto a highly water soluble substrate such as nonpareil (sugar beads) then coated with a layer of polymer soluble in small intestinal fluid, then coated with an enteric coating. The inner polymer layer controls release of the drug, and the enteric coating, a pH sensitive polymer that is broken down in the ileum and colon, controls localized release of drug at various sites within the gastrointestinal tract. The multilayer pharmaceutical composition can be in the form of pellets, tablets compressed from pellets or pellets packed into capsules. The release profile of the drug can be manipulated by (1) altering size or shape (i.e., surface area) and solubility of the inert substrate

(2) the ratio of drug to polymer, the polymer composition and solubility, the porosity of the polymer

(3) the drug form (i.e., free base or salt, or which salt)

and the thickness and/or surface area of the drug/polymer and/or enteric coating. In a preferred embodiment, the composition is administered orally. This may also be packaged to provide for an escalating or tapering dosage.

Priority: US20060825855P Applic. Date: 2006-09-15

Inventor: WILSON GLYNN [US]; RENNER GERHARD [DE]; RAVISHANKAR HEMA [IN]; PATIL PREETI [IN]


Application No.: US20080085306A1  Published: 10/Apr/2008

Title: Topiramate compositions and methods of enhancing its bioavailability

Applicant/Assignee: SPHERICS, INC

Application No.: 11/897940   Filing Date: 31/Aug/2007

Abstract:The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and improved pharmacokinetics are disclosed. A once-a-day administration of topiramate is advantageous over the multiple dose regimen both in terms of patient compliance and reduced adverse events, thus providing better treatment of the conditions for which the topiramate is indicated.

Priority: US20060841924P Applic. Date: 2006-08-31

Inventor: NANGIA AVINASH [US]; VERMA DAYA D [US]; JACOB JULES [US]


Application No.: US20080085308A1  Published: 10/Apr/2008

Title: Granules Comprising Paracetamol, a Nsaid and a Sugar Alchohol Made by Melt Extrusion

Applicant/Assignee: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Application No.: 11/659945   Filing Date: 08/Aug/2005

Abstract:A pharmaceutical composition comprising a granular component comprising a plurality of solidified melt granules of a sugar alcohol having a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and paracetamol contained therein.

Priority: GB20040017939 Applic. Date: 2004-08-12; GB20040017942 Applic. Date: 2004-08-12; WO2005GB03079 Applic. Date: 2005-08-08

Inventor: SHERRY ROBERT [GB]


Application No.: US20080085311A1  Published: 10/Apr/2008

Title: ANTIHISTAMINE-DECONGESTANT COMBINATIONS

Applicant/Assignee:

Application No.: 11/867076   Filing Date: 04/Oct/2007

Abstract:Multi-particulate pharmaceutical compositions comprising an antihistamine for immediate release and a decongestant for modified release.

Priority: IN2006CH01846 Applic. Date: 2006-10-05; US20070884936P Applic. Date: 2007-01-15

Inventor: TRIPATHI SANJAY S [IN]; NAMBALLA RAVI K [IN]; SHETTY VASANTH K [IN]; KANDARAPU RAGHUPATHI [IN]; IRUKULLA SRINIVAS [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR S [IN]


Application No.: US20080085314A1  Published: 10/Apr/2008

Title: Solid oral formulations for combination therapy

Applicant/Assignee:

Application No.: 11/494662   Filing Date: 27/Jul/2006

Abstract:A first, solid oral pharmaceutical composition includes an extended release acetaminophen, a non-steroidal anti-inflammatory drug, such as naproxen or ibuprofen, and a third drug capable of reducing gastric acid secretion, such as ranitidine or omeprazole. A second, solid oral pharmaceutical composition includes a non-steroidal anti-inflammatory drug and an agent for reducing gastric acid secretion.

Priority: US20050704018P Applic. Date: 2005-07-29

Inventor: SHALABY SHALABY W [US]


Application No.: US20080085315A1  Published: 10/Apr/2008

Title: Amorphous ezetimibe and the production thereof

Applicant/Assignee:

Application No.: 11/545350   Filing Date: 10/Oct/2006

Abstract:Ezetimibe compositions of enhanced bioavailability are described that contain ezetimibe with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products comprise solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising ezetimibe, a solubility-enhancing polymer and a single solvent, a solvent blend or solvent/non-solvent blend and then evaporating the mixture to form amorphous ezetimibe.

Priority:

Inventor: DONEY JOHN ALFRED [US]; BRZECZKO ALBERT WALTER [US]; SHORES CHRISTOPHER STEVEN [US]


Application No.: US20080085319A1  Published: 10/Apr/2008

Title: LIPIDS CONTAINING OMEGA-3 AND OMEGA-6 FATTY ACIDS

Applicant/Assignee: ENZYMOTEC LTD

Application No.: 11/872258   Filing Date: 15/Oct/2007

Abstract:A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

Priority: IL20030158552 Applic. Date: 2003-10-22; US2004-994175 Applic. Date: 2004-11-19; WO2004IL00957 Applic. Date: 2004-10-21

Inventor: DROR GAI B [IL]; PLAT DORIT [IL]; FARKASH ORLY [IL]; ZUABI RASSAN [IL]; BAR-ON ZOHAR [IL]; SHULMAN AVIDOR [IL]; PELLED DORI [IL]


Application No.: US20080085320A1  Published: 10/Apr/2008

Title: LIPIDS CONTAINING OMEGA-3 AND OMEGA-6 FATTY ACIDS

Applicant/Assignee: ENZYMOTED LTD

Application No.: 11/872440   Filing Date: 15/Oct/2007

Abstract:A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

Priority: IL20030158552 Applic. Date: 2003-10-22; US2004-994175 Applic. Date: 2004-11-19; WO2004IL00957 Applic. Date: 2004-10-21

Inventor: DROR GAI B [IL]; PLAT DORIT [IL]; FARKASH ORLY [IL]; ZUABI RASSAN [IL]; BAR-ON ZOHAR [IL]; SHULMAN AVIDOR [IL]; PELLED DORI [IL]


Application No.: US20080089930A1  Published: 17/Apr/2008

Title: Keratin-Based Powders and Hydrogel for Pharmaceutical Applications

Applicant/Assignee: KERAPLAST TECHNOLOGIES, LTD

Application No.: 11/945614   Filing Date: 27/Nov/2007

Abstract:A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried, leaving keratin solid which can be shredded into fibers and further ground into powder. Addition of water to the solid produces a hydrogel. The powder or hydrogel may be useful as an absorbent material, as a therapeutic for skin, or as an excipient. The keratin materials can be incorporated into nonwoven films. The hydrogel can be used as a biocompatible viscoelastic filler for implant applications. Another use for the absorbent keratin and keratin hydrogel is as an excipient in pharmaceutical and cosmetic applications.

Priority: US2003-409018 Applic. Date: 2003-04-08; US2000-638643 Applic. Date: 2000-08-14; US2000-587157 Applic. Date: 2000-06-05; US2000-528893 Applic. Date: 2000-03-20; US2000-512918 Applic. Date: 2000-02-25; US1999-394782 Applic. Date: 1999-09-13

Inventor: SILLER-JACKSON ARLENE J [US]; VAN DYKE MARK E [US]; TIMMONS SCOTT F [US]; BLANCHARD CHERYL R [US]; SMITH ROBERT A [US]


Application No.: US20080089935A1  Published: 17/Apr/2008

Title: Stable Solid Dispersion Of A Derivative Of Vinca Alkaloid And Process For Manufacturing It

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: 11/667998   Filing Date: 20/Dec/2005

Abstract:This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.

Priority: FR20040014069 Applic. Date: 2004-12-30; US2004-025348 Applic. Date: 2004-12-30; WO2005EP56965 Applic. Date: 2005-12-20

Inventor: BOUGARET JOEL [FR]; LEVERD ELIE [FR]; IBARRA MARIE-DOMINIQUE [FR]


Application No.: US20080090895A1  Published: 17/Apr/2008

Title: Novel Pharmaceutical Composition And Their Uses Thereof For Controlling The Different Forms Of Addiction To Drugs

Applicant/Assignee: TRIMARAN LIMITED

Application No.: 11/666981   Filing Date: 07/Nov/2005

Abstract:The invention relates to the necessaries of life, especially the field of therapeutics. The invention specifically relates to pharmaceutical compositions for helping users of addictive drugs to stop, said compositions being in the form of a combination of two medicaments consisting of a partial or full antagonist of dopaminergic receptors, especially receptors D2 and D3, and a prodopaminergic product, for oral, parenteral or transdermic administration. The invention also relates to method for controlling the different forms of addiction to legal or illegal drugs.

Priority: FR20040011810 Applic. Date: 2004-11-05; WO2005FR02775 Applic. Date: 2005-11-07

Inventor: SANCHEZ MARIO [FR]


Application No.: US20080095777A1  Published: 24/Apr/2008

Title: Immunogenic Composition for Use in Vaccination Against Staphylococcei

Applicant/Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A

Application No.: 11/575672   Filing Date: 20/Sep/2005

Abstract:The present application relates to immunogenic compositions comprising a mixture of staphylococcal antigens which combines antigen having different functions, for instance, combinations including a staphylococcal extracellular component binding protein and a staphylococcal transporter protein or a staphylococcal extracellular component binding protein and a staphylococcal regulator of virulence or toxin or a staphylococcal transporter protein and a staphylococcal regulator of virulence or toxin. Vaccines, methods of treatment, uses of and processes to make a staphylococcal vaccine are also described.

Priority: GB20040021082 Applic. Date: 2004-09-22; GB20040021078 Applic. Date: 2004-09-22; GB20040021081 Applic. Date: 2004-09-22; GB20040021079 Applic. Date: 2004-09-22; GB20050003143 Applic. Date: 2005-02-15; WO2005EP10184 Applic. Date: 2005-09-20

Inventor: CASTADO CINDY [BE]; LECRENIER NICOLAS P F [BE]; NEYT CECILE A [BE]; POOLMAN JAN [BE]


Application No.: US20080095791A1  Published: 24/Apr/2008

Title: Recombinant HIV-1 gp120 Immunogen with Three Different V3 Loops from Viruses of Different Clades

Applicant/Assignee: NEW YORK UNIVERSITY THE UNIVERSITY OF MASSACHUSETTS

Application No.: 11/772760   Filing Date: 02/Jul/2007

Abstract:A novel immunogenic HIV-1 Env, particularly gp120, DNA construct is disclosed in which either the V1/V2 loop and the V4 loop, or all three variable loops, including V3, are replaced with a V3 sequence each of which is from a different viral isolate. Preferably, each replacement V3 loop is a consensus sequence of V3 of a different clade. Such constructs are useful as immunogens as each presents three independent V3 epitopes, so that the immunized subject generates a more broadly reactive neutralizing antibody response than with conventional gp120 or V3 DNA or polypeptide immunogens. Also disclosed are methods of using the DNA construct to immunize a mammal, preferably a human, particularly in a priming regiment in which the DNA immunogen is followed by administration of a V3 fusion protein boosting immunogen.

Priority: US20060817344P Applic. Date: 2006-06-30

Inventor: ZOLLA-PAZNER SUSAN [US]; LU SHAN [US]; WANG SHIXIA [US]


Application No.: US20080095837A1  Published: 24/Apr/2008

Title: HUMAN GROWTH HORMONE FORMULATIONS

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 11/848034   Filing Date: 30/Aug/2007

Abstract:The present invention relates to dosage forms of human growth hormone, the use of an absorption enhancer to allow absorption of human growth hormone into the systemic circulation in a biologically active form, in particular after oral administration, as well as the use of oral dosage forms comprising human growth hormone and an absorption enhancer for the treatment of human growth hormone deficiencies and disorders associated therewith.

Priority: US20060824278P Applic. Date: 2006-08-31

Inventor: DINH STEVEN [US]; LIU PUCHUN [US]


Application No.: US20080095838A1  Published: 24/Apr/2008

Title: Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof

Applicant/Assignee: CLL PHARMA

Application No.: 10/519166   Filing Date: 24/Jun/2003

Abstract:The invention relates to an orally-administered, solid pharmaceutical composition comprising, in a single same phase, a lipophilic active principle, a surface active agent, a cationic polymer which is insoluble in water at pH greater than or equal to 5 and a mineral or organic acid. The invention also relates to the preparation method of same.

Priority: FR20020007831 Applic. Date: 2002-06-25; WO2003FR01933 Applic. Date: 2003-06-24

Inventor: ABOU CHACRA-VERNET MARIE-LINE [FR]


Application No.: US20080095844A1  Published: 24/Apr/2008

Title: SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS OF ALFUZOSIN AND PROCESS FOR PREPARATION THEREOF

Applicant/Assignee:

Application No.: 11/841148   Filing Date: 20/Aug/2007

Abstract:The present invention relates to sustained release pharmaceutical compositions comprising alfuzosin, a rate-controlling polymer and optionally one or more pharmaceutically acceptable excipients

process for preparing such compositions and method of using the compositions.

Priority: IN2006MU01758 Applic. Date: 2006-10-23

Inventor: KAMALAKAR RAJHANS SUJAY [IN]; MEGHRAJ BHUTADA PRAVIN [IN]; MATHURBHAI PATEL HASMUKH [IN]


Application No.: US20080095846A1  Published: 24/Apr/2008

Title: Pharmaceutical compositions of antihistamine and decongestant

Applicant/Assignee:

Application No.: 11/666923   Filing Date: 04/Nov/2004

Abstract:The present invention discloses a bilayer tablet composition comprising controlled or modified release decongestants such as pseudoephedrine or its salts or derivatives thereof with suitable pharmaceutical excipients with immediate release second layer comprising piperidinoalkanol compounds such as fexofenadine or its salts and derivatives thereof manufactured using just one functional excipient. The composition is useful particularly in the prophylaxis and treatment of allergic rhinitis.

Priority: WO2004IB03612 Applic. Date: 2004-11-04

Inventor: MUKHERJI GOUR [IN]; JAYADEV PATIL [IN]; MATE SIDHARTH [IN]


Application No.: US20080095850A1  Published: 24/Apr/2008

Title: Process for Granulating Particles

Applicant/Assignee:

Application No.: 11/665319   Filing Date: 31/Oct/2005

Abstract:The invention encompasses a process for granulating particles that produces homogeneous, free flowing, attrition resistant, uniform sized granules. When utilized with active pharmaceutical ingredients, such granules can be further processed into controlled released or taste-masked pharmaceutical formulations. Particularly, the process can be utilized to make an oral granule formulation of etoricoxib for treating pain and inflammation in patients that cannot swallow a tablet, such as young children and the elderly.

Priority: US20040624977P Applic. Date: 2004-11-04; WO2005US39238 Applic. Date: 2005-10-31

Inventor: HO JENNIFER S [US]; DUMONT HUBERT [CA]; MANCINELLI CHRISTOPHER [US]; SHELUKAR SUHAS D [US]


Application No.: US20080095855A1  Published: 24/Apr/2008

Title: Taste Masking Granules

Applicant/Assignee:

Application No.: 11/876214   Filing Date: 22/Oct/2007

Abstract:Pellets of granulated particles comprising at least one pharmaceutically active compound, which pellets are characterised in that a bad taste of a pharmaceutically active compound when taken by patients is reduced or eliminated, said pellets comprise a pharmaceutically active compound and further comprise an organic carboxylic acid and/or a surfactant and/or a hydrocolloid and said pellets are coated with an enteric film-forming composition comprising an enteric film-forming component and pharmaceutical compositions comprising such pellets.

Priority: AT20000000524 Applic. Date: 2000-03-28; US2005-145354 Applic. Date: 2005-06-03; US2002-240003 Applic. Date: 2002-09-26; WO2001EP03409 Applic. Date: 2001-03-26

Inventor: SCHWARZ FRANZ X [AT]


Application No.: US20080096825A1  Published: 24/Apr/2008

Title: Preparation and Use of Phlorizin Compositions

Applicant/Assignee:

Application No.: 11/738331   Filing Date: 20/Apr/2007

Abstract:The present invention concerns the isolation of phlorizin from plants of the genus Lithocarpus, phlorizin-containing compositions and their uses.

Priority: US20060794216P Applic. Date: 2006-04-21; US20060808018P Applic. Date: 2006-05-23

Inventor: EHRENKRANZ JOEL R L [US]


Application No.: US20080096826A1  Published: 24/Apr/2008

Title: Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments

Applicant/Assignee: UNIGEN PHARMACEUTICALS, INC

Application No.: 11/927061   Filing Date: 29/Oct/2007

Abstract:The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

Priority: US2004-932571 Applic. Date: 2004-09-01; US2003-427746 Applic. Date: 2003-04-30; US20030499742P Applic. Date: 2003-09-02; US20020377168P Applic. Date: 2002-04-30

Inventor: JIA QI [US]; BURNETT BRUCE [US]; ZHAO YUAN [US]


Application No.: US20080096827A1  Published: 24/Apr/2008

Title: Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments

Applicant/Assignee: UNIGEN PHARMACEUTICALS, INC

Application No.: 11/962363   Filing Date: 21/Dec/2007

Abstract:The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

Priority: US2004-932571 Applic. Date: 2004-09-01; US2003-427746 Applic. Date: 2003-04-30; US20030499742P Applic. Date: 2003-09-02; US20020377168P Applic. Date: 2002-04-30

Inventor: JIA QI [US]; BURNETT BRUCE [US]; ZHAO YUAN [US]


Application No.: US20080096945A1  Published: 24/Apr/2008

Title: Amorphous and Crystalline Forms of Losartan Potassium and Process For Their Preparation

Applicant/Assignee:

Application No.: 11/963269   Filing Date: 21/Dec/2007

Abstract:This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form V and solvates thereof, to processes for their preparation, to compositions containing them and to their use in medicine. This invention further relates to a novel process for preparing crystalline losartan potassium Form I and Form II.

Priority: US2002-293820 Applic. Date: 2002-11-13; US20010333034P Applic. Date: 2001-11-14; US20020401278P Applic. Date: 2002-08-05

Inventor: DOLITZKY BEN Z [IL]; WIZEL SHLOMIT [IL]; NISNEVICH GENNADY [IL]; RUKHMAN IGOR [IL]; KAFTANOV JULIA [IL]


Application No.: US20080096970A1  Published: 24/Apr/2008

Title: Stable Nateglinide Form B Compositions

Applicant/Assignee:

Application No.: 11/569382   Filing Date: 20/May/2005

Abstract:A process for preparing nateglinide Form B comprises dissolving nateglinide in a solvent and adding the solution, at temperatures of 40-45 DEG C., to a hydrocarbon liquid that is at temperatures of 40-45 DEG C. Then, water is added and the mixture is allowed to cool, producing crystals of nateglinide Form B.

Priority: US20040572689P Applic. Date: 2004-05-20; US20040586431P Applic. Date: 2004-07-08; US20050644614P Applic. Date: 2005-01-18; WO2005US17664 Applic. Date: 2005-05-20

Inventor: VENKATARAMAN SUNDARAM [IN]; NARSAPUR SHARAT PANDURANG [IN]; KHARKAR MANOJ RAMESH [IN]; BANGARUBABU RONGALI [IN]; SANDEEP MOHANTY [IN]; SAYANTANI PYNE [IN]; RAJU KAKARTAPUDI RANGA [IN]


Application No.: US20080096979A1  Published: 24/Apr/2008

Title: Aqueous Pharmaceutical Coating

Applicant/Assignee: RUBICON RESEARCH PVT. LTD

Application No.: 11/718825   Filing Date: 07/Nov/2005

Abstract:Novel, stable aqueous coating dispersions of wax or combination of waxes are described. The composition apart from wax includes an emulsifier and a plasticizer. The pharmaceutical applications of the dispersion include taste masking, stabilization and release retardation of drugs.

Priority: IN2004MU01201 Applic. Date: 2004-11-08; WO2005IN00361 Applic. Date: 2005-11-07

Inventor: PILGAONKAR PRATIBHA S [IN]; RUSTOMJEE MAHARUKH T [IN]; GANDHI ANILKUMAR S [IN]; NAIK JYOTI S [IN]


Application No.: US20080097388A1  Published: 24/Apr/2008

Title: Delivery System

Applicant/Assignee: DRUGTECH CORPORATION ROBERT C. CUCA ETAL

Application No.: 11/571863   Filing Date: 08/Jul/2005

Abstract:A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86 DEG F. for at least one month, without decomposition or instability of the emulsion.

Priority: US20040586273P Applic. Date: 2004-07-08; WO2005US24200 Applic. Date: 2005-07-08

Inventor: CUCA ROBERT C [US]; RILEY THOMAS C [US]; LEVINSON R SAUL [US]


Application No.: US20080102075A1  Published: 01/May/2008

Title: PHARMACEUTICAL COMPOSITIONS FOR TREATING ARTHRITIS AND INFLAMMATORY DISEASE

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 11/927475   Filing Date: 29/Oct/2007

Abstract:The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.

Priority: US2004-967092 Applic. Date: 2004-10-15; US2000-712813 Applic. Date: 2000-11-13; WO1999US10793 Applic. Date: 1999-05-14; US1998-081385 Applic. Date: 1998-05-14

Inventor: GATANAGA TETSUYA [US]; GRANGER GALE A [US]


Application No.: US20080102102A1  Published: 01/May/2008

Title: Methods And Compositions For Decreasing Saliva Production

Applicant/Assignee: NEUROHEALING PHARMACEUTICALS, INC

Application No.: 11/795210   Filing Date: 19/Jan/2006

Abstract:The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea.

Priority: US20050645147P Applic. Date: 2005-01-19; WO2006US02206 Applic. Date: 2006-01-19

Inventor: MERELLO MARCELO [AR]; FARBER NEAL M [US]; RON EYAL S [US]


Application No.: US20080102120A1  Published: 01/May/2008

Title: Solid Pharmaceutical Composition Comprising Valsartan

Applicant/Assignee:

Application No.: 11/794039   Filing Date: 23/Dec/2005

Abstract:This invention relates to a solid pharmaceutical composition containing valsartan particles characterized in that the D50 of said valsartan particles is 150 mum or below and that the valsartan particles have a maximum diameter of no more than 1100 mum, as determined by electron microscopy.

Priority: EP20040030782 Applic. Date: 2004-12-24; EP20050004433 Applic. Date: 2005-03-01; WO2005EP13963 Applic. Date: 2005-12-23

Inventor: VRBINC MIHA [SI]; VOVK JANIKA SLANC [SI]; RANGUS MARIJA [SI]; ZUPANCIC SILVO [SI]; BEVEC FRANCI [SI]; CERNOSA LIDIJA [SI]


Application No.: US20080102134A1  Published: 01/May/2008

Title: CONTROLLED RELEASE COLOR STABLE PHARMACEUTICAL DOSAGE FORM OF HMG-COA REDUCTASE INHIBITORS, FREE OF ALKALIZING OR BUFFERING AGENTS

Applicant/Assignee: LUPIN LIMITED

Application No.: 11/870744   Filing Date: 11/Oct/2007

Abstract:A color stable controlled release pharmaceutical dosage form comprising HMG CoA reductase inhibitor, rate controlling polymers and one or more pharmaceutical excipients wherein the granules are independent of particle size the pharmaceutical dosage form is free of alkalizing/buffering agents. A color stable controlled release pharmaceutical dosage form comprising Fluvastatin Sodium, hydroxypropyl methylcellulose polymer and hydroxypropyl cellulose, wherein the granules are independent of particle size.

Priority: IN2006KO01046 Applic. Date: 2006-10-11

Inventor: MISTRY DHANASHREE B [IN]; PANIGRAHI DHANANJAY [IN]; KUMAR T V [IN]; SEN HIMADRI [IN]


Application No.: US20080102140A1  Published: 01/May/2008

Title: USE OF SOLIDAGO VIRGAUREA IN THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS

Applicant/Assignee:

Application No.: 11/970589   Filing Date: 08/Jan/2008

Abstract:This invention teaches the use of Solidago virgaurea for treating and preventing H5N1 avian influenza, influenza virus, and HIV/AIDS. An herbal stock solution was extracted from the natural plant Solidago virgaurea. The herbal extract had anti-H5N1 avian influenza, anti-influenza, and anti-HIV/AIDS properties. Pharmaceutical compositions of Solidago virgaurea were prepared by adding excipients, adjuvants or carriers to this plant extract.

Priority: CN20061127149 Applic. Date: 2006-09-07; CN20061127150 Applic. Date: 2006-09-07; WO2007CN02084 Applic. Date: 2007-07-06

Inventor: LOU SHIRONG [CN]


Application No.: US20080103089A1  Published: 01/May/2008

Title: Compounds, Compositions, Formulations and Process for Preparation Thereof and Method of Treatment and Management of Acidity and Related Disorders

Applicant/Assignee:

Application No.: 11/661397   Filing Date: 30/Aug/2005

Abstract:Novel antacid preparations, methods of preparation of the same and a method of treating acidity related disorders using the said novel antacid composition are described. The antacid composition of this invention are based on use of proteins and their derivatives including their hydrolysates and enzymatic treatment products such as plasteins and their alkaline derivatives for actual acid neutralizing capacity or for discomfort relief or both. Alkaline derivatives having pH above 6.5 of proteins, protein hydrolysates, amino acid, amino acid mixtures and salts of amino acids are novel products.

Priority: IN2004MU00947 Applic. Date: 2004-09-01; WO2005IN00289 Applic. Date: 2005-08-30

Inventor: SAVANGIKAR CHITRA VASANT [IN]; SAVANGIKAR VASANT ANANTRAO [IN]


Application No.: US20080107726A1  Published: 08/May/2008

Title: COMPOSITIONS COMPRISING BETA-ADRENERGIC RECEPTOR ANTAGONISTS AND DIURETICS

Applicant/Assignee:

Application No.: 11/930467   Filing Date: 31/Oct/2007

Abstract:Pharmaceutical compositions comprise beta-adrenergic receptor blocking agents for controlled release and diuretics for immediate release. In an embodiment, a composition comprising metoprolol succinate is coated onto inert particles, and the particles are further coated with a polymer to provide controlled release of metoprolol. The coated particles are coated, granulated, or mixed with a composition comprising hydrochlorothiazide, then are compressed into tablets, or the coated particles are compressed into tablets and the tablets are coated with a composition comprising hydrochlorothiazide.

Priority: IN2006CH02034 Applic. Date: 2006-11-01; US20070890212P Applic. Date: 2007-02-16

Inventor: KHARWADE PRAMOD [IN]; BHUSHAN INDU [IN]


Application No.: US20080107749A1  Published: 08/May/2008

Title: WATER-DISPERSIBLE ORAL, PARENTERAL, AND TOPICAL FORMULATIONS FOR POORLY WATER SOLUBLE DRUGS USING SMART POLYMERIC NANOPARTICLES

Applicant/Assignee:

Application No.: 11/867918   Filing Date: 05/Oct/2007

Abstract:Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropyl acrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral

either water-soluble vinyl derivatives like vinylpyrolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivatives like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%

and acrylic acid (AA), at a molar ratio of about 10% to about 30%. The formed nanoparticles may be optionally surface functionalized using reactive groups present in AA, including PEGylation, or conjugation of moieties such as chemotherapeutics, contrasting agents, antibodies, radionucleides, ligands, and sugars, for diagnostic, therapeutic, and imaging purposes. The polymeric nanoparticles are preferably dispersed in aqueous solutions. The polymeric nanoparticles incorporate one or more types of medicines or bioactive agents in the hydrophobic core

on occasion, the medicine or bioactive agent may be conjugated to the nanoparticle surface via reactive functional groups. The polymeric nanoparticles are capable of delivering the said medicines or bioactive agents through oral, parenteral, or topical routes. The polymeric nanoparticles allow poorly water soluble medicines or bioactive agents, or those with poor oral bioavailability, to be formulated in an aqueous solution, and enable their convenient delivery into the systemic circulation.

Priority: US20060849684P Applic. Date: 2006-10-05; US20060866516P Applic. Date: 2006-11-20; US20070956760P Applic. Date: 2007-08-20

Inventor: MAITRA ARNIBAN [US]; FELDMANN GEORG [US]; BISHT SAVITA [US]


Application No.: US20080108557A1  Published: 08/May/2008

Title: Modified Proteins

Applicant/Assignee: NOVO NORDISK HEALTHCARE A/G

Application No.: 11/664199   Filing Date: 29/Sep/2005

Abstract:A method of conjugating peptides and proteins by means of glycosyltransferase is provided.

Priority: DK20040001479 Applic. Date: 2004-09-29; DK20050000090 Applic. Date: 2005-01-18; DK20050000175 Applic. Date: 2005-02-04; WO2005EP54901 Applic. Date: 2005-09-29

Inventor: BEHRENS CARSTEN [DK]; GARIBAY PATRICK WILLIAM [DK]; ZUNDEL MAGALI [DK]


Application No.: US20080111269A1  Published: 15/May/2008

Title: Granules, tablets and granulation

Applicant/Assignee:

Application No.: 11/979530   Filing Date: 05/Nov/2007

Abstract:The invention provides, inter alia, a method for producing granules from a powder, characterized in that a low compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating fine particles from the granules by entraining the fine particles in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules.

Priority: FI20060000990 Applic. Date: 2006-11-10; FI20060001146 Applic. Date: 2006-12-21; FI20070000521 Applic. Date: 2007-07-02

Inventor: POLITI GIOVANNI [FI]; HEILAKKA ERKKI [FI]


Application No.: US20080112895A1  Published: 15/May/2008

Title: Aqueous dronabinol formulations

Applicant/Assignee: INSYS THERAPEUTICS INC

Application No.: 11/891017   Filing Date: 06/Aug/2007

Abstract:A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.

Priority: US20060835738P Applic. Date: 2006-08-04

Inventor: KOTTAYIL S GEORGE [US]; GOSKONDA VENKAT R [US]; ZHU ZHONGYUAN [US]; KATTOOKARAN LINET [US]


Application No.: US20080112915A1  Published: 15/May/2008

Title: Dna Delivery with Gemini Cationic Surfactants

Applicant/Assignee:

Application No.: 10/577025   Filing Date: 25/Oct/2004

Abstract:The invention provides a delivery system for a biologically active agent comprising a gemini surfactant in admixture with the biologically active agent in a topical formulation for treatment of skin disorders or metabolic diseases. The invention also provides pharmaceutical compositions in topical formulations comprising the delivery system as set out above, in admixture with pharmaceutically acceptable carriers, diluents, excipients, or supplements suitable for application to the skin or mucosal membrane. Methods of preparation and use are also described.

Priority: US20030514197P Applic. Date: 2003-10-24; WO2004CA01870 Applic. Date: 2004-10-25

Inventor: FOLDVARI MARIANNA [CA]; VERRALL RONALD E [CA]; BADEA ILDIKO [CA]


Application No.: US20080113021A1  Published: 15/May/2008

Title: IBUPROFEN COMPOSITION

Applicant/Assignee:

Application No.: 11/877917   Filing Date: 24/Oct/2007

Abstract:The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a plurality of particles in a matrix. The particles contain an active ingredient, such as ibuprofen, and a first water soluble acid having a solubility greater than about 10 g/100 mL water at 20 DEG C.

and the matrix contains a second water soluble acid having a solubility less than about 5 g/100 mL water at 20 DEG C.

Priority: US20060854349P Applic. Date: 2006-10-25

Inventor: SHEN ROBERT [US]


Application No.: US20080113023A1  Published: 15/May/2008

Title: BILAYER TABLET COMPRISING TELMISARTAN AND DIURETIC

Applicant/Assignee:

Application No.: 11/560059   Filing Date: 15/Nov/2006

Abstract:The invention relates to a bilayer pharmaceutical tablet comprising a first layer containing 3 to 50 wt. % of telmisartan dispersed in a dissolving tablet matrix and a second layer containing a diuretic in a disintegrating tablet matrix as well as a processes for producing same.

Priority:

Inventor: NAKATANI MANABU [JP]; YOKOYAMA KAZUTOSHI [JP]; SAWADA TAKESHI [JP]


Application No.: US20080114072A1  Published: 15/May/2008

Title: N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof

Applicant/Assignee:

Application No.: 11/800173   Filing Date: 03/May/2007

Abstract:N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as MDL 72,527 and N,N'-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any other body tissue, and methods of making the compound thereof. Other methods include inhibiting acetyl polyamine oxidase in human prostate tissue or other human body tissue comprising administering a therapeutic amount of N,N'-bis(2,3-butadienyl)-1,4-butanediamine or a salt or solvate thereof to the human, and a method of determining oxidative stress in human prostate tissue or other human or animal body tissue comprising measuring a ratio of oxidized 2',7'-dichlorodihydrofluorescein diacetate fluorescence:DNA fluorescence and hydroethidine dye fluorescence ex vivo or in vivo.

Priority: US20060797142P Applic. Date: 2006-05-03

Inventor: BASU HIRAK S [US]; CHURCH DAWN R [US]; WOSTER PATRICK M [US]; WILDING GEORGE [US]


Application No.: US20080118525A1  Published: 22/May/2008

Title: Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

Applicant/Assignee:

Application No.: 11/730695   Filing Date: 03/Apr/2007

Abstract:In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention.

Priority: WO2006CA01650 Applic. Date: 2006-10-04

Inventor: DONINI OREOLA [CA]; ROZEK ANNETT [CA]; LENTZ SHANNON WAYNE [CA]


Application No.: US20080118554A1  Published: 22/May/2008

Title: Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant

Applicant/Assignee:

Application No.: 11/824537   Filing Date: 28/Jun/2007

Abstract:A pharmaceutical composition comprising a first therapeutic agent and a second therapeutic agent is described. A plurality of particles comprising (i) an interior comprising the second therapeutic agent and (ii) an exterior comprising a material for controlling the release of the second therapeutic agent may be disposed within a mixture, wherein the mixture comprises the first therapeutic agent. The first therapeutic agent may be a piperidinoalkanol, such as fexofenadine, and the second therapeutic agent may be a decongestant, such as pseudoephedrine. The interior may comprise an inner core and an intermediate layer disposed over the inner core, wherein the second therapeutic agent is contained in the intermediate layer. Methods of treating congestion with a pharmaceutical composition comprising a piperidinoalkanol and a decongestant are also described.

Priority: US20060817411P Applic. Date: 2006-06-30

Inventor: ARI-PARDO LIMOR [IL]; ANTLER SIVAN [IL]; ZILBERMAN RINA [IL]


Application No.: US20080118555A1  Published: 22/May/2008

Title: Stable pharmaceutical composition containing desloratadine

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/584287   Filing Date: 20/Oct/2006

Abstract:Stable pharmaceutical compositions for oral administration are provided comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, a lactose-based excipient and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25 DEG C. to about 40 DEG C. and a relative humidity of about 60% to about 75% for at least 1 month. Also provided are stable pharmaceutical compositions for oral administration comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and a lactose-based excipient and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25 DEG C. to about 40 DEG C. and a relative humidity of about 60% to about 75% for at least 1 month.

Priority: IN2005MU01320 Applic. Date: 2005-10-20; US20060801683P Applic. Date: 2006-05-19

Inventor: KRISHNAN ANANDI [IN]; SRINIVAS ARRA GANGA [IN]; TAMRAGOURI DEEPIKA V BHAT [IN]


Application No.: US20080118557A1  Published: 22/May/2008

Title: SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE

Applicant/Assignee: SUPERNUS PHARNACEUTICALS, INC

Application No.: 11/941475   Filing Date: 16/Nov/2007

Abstract:Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Priority: US20060859502P Applic. Date: 2006-11-17

Inventor: LIANG LIKAN [US]; WANG HUA [US]; BHATT PADMANABH P [US]; VIEIRA MICHAEL L [US]


Application No.: US20080119492A1  Published: 22/May/2008

Title: Compositions and methods for treating cancer and other diseases characterized by abnormal cell proliferation

Applicant/Assignee:

Application No.: 11/374312   Filing Date: 28/Jul/2006

Abstract:The present invention relates to compositions and methods for treating cancer and other disease states characterized by abnormal cell proliferation. In particular, the present invention relates to certain novel non-nucleoside pharmacologically active compounds that alter telomere and telomerase functions, regulate cell proliferation and/or treat cancer and other diseases characterized by abnormal cell proliferation. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell proliferation, and to treat cancer or to inhibit the proliferation of the rumor cells, and to treat other proliferative conditions.

Priority: US20050704184P Applic. Date: 2005-07-29

Inventor: LEHN JEAN-MARIE [FR]; MERGNY JEAN-LOUIS [FR]; PETITJEAN ANNE [CA]; TEULADE-FICHOU MAIA-PAULE [FR]; TCHIRKOV ANDREI [FR]; VERRELLE PIERRE [FR]


Application No.: US20080124383A1  Published: 29/May/2008

Title: Use Of Anti-Cytokine Agents For Treating Carpal And Tarsal Tunnel Syndrome

Applicant/Assignee:

Application No.: 11/563920   Filing Date: 28/Nov/2006

Abstract:Methods for treating carpal tunnel syndrome and tarsal tunnel syndrome in a subject involve providing an effective amount of an anti-cytokine agent at or near inflammation in the carpal or tarsal tunnel. Anti-cytokine agents, such as, TNF-a inhibitors, NF-kappaB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors, IL-10, Interferon-gamma (IFN-?) act to prevent further inflammation initiated by cytokine factors. One embodiment includes, adding with the anti-cytokine agent one or more of an antibiotic or analgesic. Delivery of the anti-cytokine agent may be provided to the inflamed tissue of the carpal or tarsal tunnel by injection, implantation, or a transdermal patch. These agents, individually or in combination, directly address the underlying inflammation that causes the discomfort, pain, and restricted movement associated with carpal and tarsal tunnel syndrome.

Priority:

Inventor: ZANELLA JOHN M [US]


Application No.: US20080124389A1  Published: 29/May/2008

Title: Nanoparticulate and Controlled Release Compositions Comprising Cyclosporine

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 11/568692   Filing Date: 12/Apr/2006

Abstract:The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.

Priority: US20050670836P Applic. Date: 2005-04-12; WO2006US13631 Applic. Date: 2006-04-12

Inventor: JENKINS SCOTT A [US]; LIVERSIDGE GARY [US]


Application No.: US20080125347A1  Published: 29/May/2008

Title: AMINO ACID SUBSTITUTED MOLECULES

Applicant/Assignee: ALLOZYNE, INC

Application No.: 11/743608   Filing Date: 02/May/2007

Abstract:The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Priority: US20060796752P Applic. Date: 2006-05-02; US20060796701P Applic. Date: 2006-05-02; US20060796907P Applic. Date: 2006-05-02

Inventor: GRABSTEIN KENNETH H [US]; WANG AIJUN [US]; NAIRN NATALIE WINBLADE [US]


Application No.: US20080125453A1  Published: 29/May/2008

Title: PHENYLEPHRINE TANNATE, PYRILAMINE TANNATE AND DEXTROMETHORPHAN TANNATE SALTS IN PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: TIBER LABORATORIES, LLC

Application No.: 12/028312   Filing Date: 08/Feb/2008

Abstract:Compositions of tannate salts of phenylephrine, pyrilamine, and dextromethorphan produced by a method that allows for the in-situ conversions and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving salts of phenylephrine, pyrilamine, and dextromethorphan in a solvent and mixing with a dispersing agent and tannic acid to generate tannate salts. The tannate salts may be further processed without further purification or isolation to single dosage forms, such as tablets and suspension.

Priority: US2003-645977 Applic. Date: 2003-08-22; US2001-047578 Applic. Date: 2001-10-26

Inventor: KIEL JEFFREY S [US]; THOMAS H GREG [US]; MANI NARASIMHAN [US]


Application No.: US20080125759A1  Published: 29/May/2008

Title: CONVECTION-ENHANCED DRUG DELIVERY DEVICE AND METHOD OF USE

Applicant/Assignee: CODMAN & SHURTLEFF, INC

Application No.: 12/024402   Filing Date: 01/Feb/2008

Abstract:An implantable drug delivery system includes an infusion pump assembly with a fluid outlet, a fluid delivery pathway extending from the pump outlet to a target tissue site

and a controlled release material unit positioned in the fluid delivery pathway to release a drug or bioactive material into the delivery pathway. The pump assembly delivers fluid as a high flow infusion flow in said pathway, entraining drug material released by the release unit and establishing a pressure gradient at the distal end of the pathway that results in convection-enhanced transport such that the released drug(s) or treatment material enter the target tissue site with enhanced penetration depth and/or concentration. The pump delivers a carrier fluid that may reside in an external or in an implanted reservoir, or that may be an endogenous fluid, such as plasma or CSF.

Priority: US2002-092954 Applic. Date: 2002-03-06

Inventor: KONIECZYNSKI DAVID D [US]; DEXTRADEUR ALAN J [US]; ROHR WILLIAM L [US]


Application No.: US20080131409A1  Published: 05/Jun/2008

Title: Methods and compositions for the treatment of medical disorders

Applicant/Assignee:

Application No.: 11/891138   Filing Date: 08/Aug/2007

Abstract:In general, the invention relates to marrow-derived adult progenitor cells (MAPCs) and their use in methods of treating various medical disorders, typically caused by or involving loss of cells or loss of cell function. These cells, when administered, e.g., intranasally, can cross the blood brain barrier and terminally differentiate into cholinergic neurons or otherwise localize and terminally differentiate.

Priority: US20060836513P Applic. Date: 2006-08-09

Inventor: CATALDO ANNE [US]; CHEN CHUN-WEI [US]; COHEN BRUCE M [US]


Application No.: US20080131466A1  Published: 05/Jun/2008

Title: VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT

Applicant/Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTE

Application No.: 11/862122   Filing Date: 26/Sep/2007

Abstract:Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Priority: US20060847404P Applic. Date: 2006-09-26

Inventor: REED STEVEN G [US]; CARTER DARRICK [US]


Application No.: US20080131472A1  Published: 05/Jun/2008

Title: Sulfated Depolymerized Derivatives of Exopolysaccharides (Eps) from Mesophilic Marine Bacteria, Method for Preparing Same, and Uses Thereof in Tissue Regeneration

Applicant/Assignee: UNIVERSITE RENE DESCARTIES PARIS 5

Application No.: 11/629579   Filing Date: 06/Jun/2005

Abstract:The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 mug(m)g/ml.

Priority: FR20040006405 Applic. Date: 2004-06-14; WO2005FR01379 Applic. Date: 2005-06-06

Inventor: SENNI KARIM [FR]; GUENICHE FARIDA [FR]; YOUSFI MYRIAM [FR]; FIORETTI FLORENCE [FR]; GODEAU GASTON-JACQUES [FR]; COLLIEC-JOUAULT SYLVIA [FR]; RATISKOL JACQUELINE [FR]; SINQUIN CORINNE [FR]; RAGUENES GERARD [FR]; COURTOIS ANTHONY [FR]; GUEZENNEC JEAN [FR]


Application No.: US20080131507A1  Published: 05/Jun/2008

Title: Method of forming a tablet

Applicant/Assignee: SCOLR PHARMA, INC

Application No.: 11/906303   Filing Date: 01/Oct/2007

Abstract:A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.

Priority: US2006-633322 Applic. Date: 2006-12-04

Inventor: HITE MICHAEL [US]; FEDERICI CATHY [US]; BRUNELLE ALAN [US]; TURNER STEPHEN [US]


Application No.: US20080132530A1  Published: 05/Jun/2008

Title: Use of polymorphic forms of rifaximin for medical preparations

Applicant/Assignee: ALFA WASSERMANN S.P.A

Application No.: 11/873841   Filing Date: 17/Oct/2007

Abstract:The present invention relates to Rifaximin polymorphic forms alpha, beta and gamma, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.

Priority: IT2003MI02144 Applic. Date: 2003-11-07; US2005-135651 Applic. Date: 2005-05-24; WO2004EP12490 Applic. Date: 2004-11-04

Inventor: VISCOMI GIUSEPPE C [IT]; CAMPANA MANUELA [IT]; CONFORTINI DONATELLA [IT]; BARBANTI MIRIAM [IT]; CALANNI FIORELLA [IT]


Application No.: US20080138402A1  Published: 12/Jun/2008

Title: Highly inhibited starch fillers for films and capsules

Applicant/Assignee:

Application No.: 11/600980   Filing Date: 17/Nov/2006

Abstract:The invention provides the addition of highly inhibited starch filler to gelatin-free films and soft capsules. The addition of the highly inhibited starch filler raises the solid levels during processing without substantially increasing the melt viscosity. The resultant films and capsules are transparent.

Priority:

Inventor: LI ZHIXIN [US]; SHORE MICHELE MERRETTE [US]; TRKSAK RALPH [US]


Application No.: US20080138404A1  Published: 12/Jun/2008

Title: EXTENDED RELEASE FORMULATIONS OF CARVEDILOL

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/945422   Filing Date: 27/Nov/2007

Abstract:An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof

one or more hydrophilic polymers

one or more pharmaceutically acceptable excipients

and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.

Priority: US20060868880P Applic. Date: 2006-12-06

Inventor: WALSH EDWIN [IE]; YOUNG ANN MARIE [IE]; JACKSON GRAHAM [IE]


Application No.: US20080138405A1  Published: 12/Jun/2008

Title: SIROLIMUS NANODISPERSION

Applicant/Assignee:

Application No.: 11/951910   Filing Date: 06/Dec/2007

Abstract:The present invention relates to a nanodispersion composition comprising sirolimus and a surface modifier wherein effective average particle size of Sirolimus is more than 400 nm and process for preparation thereof.

Priority: IN2006DE02614 Applic. Date: 2006-12-06

Inventor: RAHEJA PRAVEEN [IN]; KAUSHIK ATUL [IN]; GANDHI RAJESH [IN]; SINGH ROMI BARAT [IN]; MATHUR RAJEEV SHANKER [IN]


Application No.: US20080138406A1  Published: 12/Jun/2008

Title: COMPOSITION FOR TREATMENT OF PAIN IN BONES AND JOINTS

Applicant/Assignee:

Application No.: 11/950013   Filing Date: 04/Dec/2007

Abstract:The present invention is a composition delivering effective amounts of Glucosamine, Devils Claw, and SAM in a single dosage unit.

Priority: US20060868948P Applic. Date: 2006-12-07

Inventor: MORROW JARRET [US]


Application No.: US20080138411A1  Published: 12/Jun/2008

Title: Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 10/556492   Filing Date: 19/Dec/2003

Abstract:The present invention relates to modified release pharmaceutical compositions for oral administration and more particularly to modified release pharmaceutical compositions of a form of at least one selective serotonin re-uptake inhibitor selected from the group consisting of a selective serotonin reuptake inhibitor, racemic mixtures thereof, enantiomers thereof, pharmaceutically-acceptable salts thereof and combinations thereof.

Priority: CA20022415154 Applic. Date: 2002-12-24; WO2003CA01986 Applic. Date: 2003-12-19

Inventor: MAES PAUL JOSE [FR]; MUHURI GOUTAM [CA]


Application No.: US20080138421A1  Published: 12/Jun/2008

Title: Pharmaceutical compositions comprising fesoterodine

Applicant/Assignee: UCB PHARMA GMBH

Application No.: 11/811327   Filing Date: 07/Jun/2007

Abstract:The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

Priority: US20060812149P Applic. Date: 2006-06-09

Inventor: ARTH CHRISTOPH [DE]; KOMENDA MICHAEL [DE]; BICANE FATIMA [DE]; PAULUS KERSTIN [DE]; IRNGARTINGER MEIKE [DE]; LINDNER HANS [DE]


Application No.: US20080138422A1  Published: 12/Jun/2008

Title: Analgesic Compositions

Applicant/Assignee: PHARMAKODEX LTD

Application No.: 11/883204   Filing Date: 30/Jan/2006

Abstract:The present invention relates to pharmaceutical compositions comprising an analgesic agent and providing controlled release of the agent for improved treatment and prevention of pain and pain-related conditions, such as pain-related sleep disturbance. The present invention is particularly concerned with self-administered compositions.

Priority: GB20050001809 Applic. Date: 2005-01-28; WO2006GB50025 Applic. Date: 2006-01-30

Inventor: STANIFORTH JOHN [GB]


Application No.: US20080138453A1  Published: 12/Jun/2008

Title: Chickpea Extracts As Therapeutic Agents And Foods In The Treatment And Prevention Of Obesity And Non-Insulin-Depenent Diabetes

Applicant/Assignee: JUMPSUN BIO-MEDICINE (SHANGHAI) CO., LTD

Application No.: 11/908008   Filing Date: 06/Mar/2006

Abstract:This invention discloses the uses of chickpea (Cicer arietinum) extract in the preparation of food for the prevention and treatment of obesity and non-insulin-dependent diabetes (NIDD). The invention provides a therapeutic agent and food containing chickpea extract for the prevention and treatment of obesity and NIDD. In this invention, the effect of chickpea extract to the high fat diet fed mice tested by the experiment proves that the chickpea extract can significantly decrease the levels of triglyceride, cholesterol and low density lipoproteins caused by high fat diet taken in a long period of time. Additionally, it is found in the experiments that the chickpea extract can improve the hyposensitivity to insulin. The preparation of the extract is also disclosed herein.

Priority: CN20051024231 Applic. Date: 2005-03-07; JP20050321602 Applic. Date: 2005-11-04; WO2006CN00328 Applic. Date: 2006-03-06

Inventor: GU YUANJUN [CN]; YUE XIAOHUA [CN]; YANG YING [CN]


Application No.: US20080139465A1  Published: 12/Jun/2008

Title: Large Scale Preparation of Alpha-1 Proteinase Inhibitor and Use Thereof

Applicant/Assignee: KAMADA LTD

Application No.: 10/572523   Filing Date: 23/Jun/2005

Abstract:A process suitable for processing scaled-up amounts of source material in the range of tens of kilograms for the purification of alpha-1 proteinase inhibitor (API) from a mixture of unpurified proteins is provided. More particularly, a process for the purification of API from blood plasma or from plasma fractions to obtain pharmaceutical grade API on a commercial scale is provided. The API produced by the process is highly pure (at least 90% API out of the total protein) and highly active (at least 90% active API). Pharmaceutical compositions comprising the purified API and methods of using same are also described.

Priority: IL20030158053 Applic. Date: 2003-09-22; US20030503902P Applic. Date: 2003-09-22; WO2004IL00881 Applic. Date: 2004-09-22

Inventor: BAUER SHABTAI [IL]


Application No.: US20080139483A1  Published: 12/Jun/2008

Title: DRUG COMBINATION FOR HYPERTENSIVE DISORDERS

Applicant/Assignee:

Application No.: 11/953937   Filing Date: 11/Dec/2007

Abstract:Therapeutic combinations and pharmaceutical compositions are provided comprising ambrisentan and an inhibitor of renin activity or release. Such combinations and compositions are useful to treat hypertensive disorders, particularly pulmonary hypertension conditions such as pulmonary arterial hypertension, to prevent cardiovascular adverse events related thereto, to enhance pulmonary function and to extend time to clinical worsening in a subject having a pulmonary hypertension condition.

Priority: US20060869661P Applic. Date: 2006-12-12

Inventor: GORCZYNSKI RICHARD J [US]


Application No.: US20080139501A1  Published: 12/Jun/2008

Title: Hyaluronic Acid Linked With a Polymer of an Alpha Hydroxy Acid

Applicant/Assignee: NOVOZYMES BIOPOLYMER A/S

Application No.: 11/722729   Filing Date: 23/Dec/2005

Abstract:The invention concerns a product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid has been partially or fully linked or crosslinked with a polymer of an alpha hydroxy acid. The invention also concerns manufacture of the product, uses of the product of the invention in the field of biodegradable plastic materials for the preparation of sanitary and surgical articles, in the pharmaceutical and cosmetic fields

including the various articles made with the same in such fields.

Priority: DK20040002029 Applic. Date: 2004-12-30; WO2005DK00826 Applic. Date: 2005-12-23

Inventor: ABDELLAOUI KHADIJA SCHWACH [DK]; VERT MICHEL [FR]; PRAVATA LAURENT [FR]


Application No.: US20080139524A1  Published: 12/Jun/2008

Title: Pharmaceutical formulation comprising a metaloporphyrin and method for its purification and use

Applicant/Assignee: STATE UNIVERSITY

Application No.: 11/825146   Filing Date: 02/Jul/2007

Abstract:Pharmaceutical formulation for the prophylaxis, pretreatment and treatment of a poisoning caused by exposure to (either singly or as a mixture of agents) organophosphorus cholinesterase inhibitors, vesicating agents, polycyclic aromatic hydrocarbons, and aflatoxin B1. This invention is characterized by active substance comprised of a metaloporphyrin molecule with an associated metal moiety (Cu, Mg) of suitable purity and chemical composition to provide a bioavailable oral dosage form to attain predictable concentrations in target tissues and bodily fluids (plasma, bronchial secretions, etc.) sufficient to counteract the effects of toxic substances through chemical complexation or catalysis of toxin degradation. Although these metaloporphyrins are semisynthetic products of chlorophyll, the preferred starting material is chlorophyll a (Chla) extracted and purified from Spirulina pacifica or other sources. A specific method is invented to achieve a critical combination of purity and yield beyond those currently available.

Priority: US20060817978P Applic. Date: 2006-06-30; US20070923842P Applic. Date: 2007-04-16

Inventor: BAILEY GEORGE S [US]; JUBERT CAROLE [US]; MATA JOHN E [US]; GUSTAFSON SCOTT [US]; DUNFIELD J S [US]


Application No.: US20080139580A1  Published: 12/Jun/2008

Title: IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS

Applicant/Assignee: NEUROGEN CORPORATION

Application No.: 11/855386   Filing Date: 14/Sep/2007

Abstract:Compounds of Formula I are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

Priority: US2004-898690 Applic. Date: 2004-07-23; US20030490006P Applic. Date: 2003-07-25; US20040543083P Applic. Date: 2004-02-09

Inventor: XIE LINGHONG [US]; HAN BINGSONG [US]; XU YUELIAN [US]; MAYNARD GEORGE [US]; CHENARD BERTRAND L [US]; SHAW KENNETH [US]; GAO YANG [US]


Application No.: US20080139642A1  Published: 12/Jun/2008

Title: Artemisinin (Qinghaosu) Derivatives, Their Preparation Methods And Their Use, And Pharmaceutical Compositions Containing The Same

Applicant/Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Application No.: 11/883652   Filing Date: 27/Jan/2006

Abstract:The invention provides a type of artemisinin derivatives having following structure I, its preparation method and use, as well as a pharmaceutical composition containing such artemisinin derivatives and its use. The artemisinin derivatives of the present invention and their pharmaceutical composition containing the artemisinin derivatives. have immunosuppressive activities and can be used more safely. The composition which comprises the artemisinin derivatives can be formulated into long-term dosage forms such as tablet, pellet and the like, and have wider productive and use value.

Priority: CN20051023824 Applic. Date: 2005-02-04; WO2006CN00182 Applic. Date: 2006-01-27

Inventor: LI YING [CN]; ZUO JIANPING [CN]; YANG ZHONGSHUN [CN]; ZHOU WENLIANG [CN]; SUI YI [CN]; WANG JUNXIA [CN]; ZHANG YU [CN]; ZHOU YU [CN]; WU JINMING [CN]


Application No.: US20080139645A1  Published: 12/Jun/2008

Title: Solid Pharmaceutical Compositions Containing Benzofuran Derivatives

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 11/955565   Filing Date: 13/Dec/2007

Abstract:The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Priority: FR19970007795 Applic. Date: 1997-06-23; US2000-446601 Applic. Date: 2000-04-03; WO1998FR01285 Applic. Date: 1998-06-19

Inventor: ABRAMOVICI BERNARD [FR]; GAUTIER JEAN-CLAUDE [FR]; GROMENIL JEAN-CLAUDE [FR]; MARRIER JEAN-MARIE [FR]


Application No.: US20080139655A1  Published: 12/Jun/2008

Title: SUSTAINED-RELEASE COMPOSITION AND METHOD OF USE THEREOF

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 11/850063   Filing Date: 05/Sep/2007

Abstract:A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.

Priority: US20060824985P Applic. Date: 2006-09-08; US20060828276P Applic. Date: 2006-10-05

Inventor: BORTZ JONATHAN [US]; GRIMSHAW MICHAEL [US]; ERKOBONI DAVID F [US]; DICKUS MICHAEL F [US]


Application No.: US20080145354A1  Published: 19/Jun/2008

Title: PEGYLATION OF THERAPEUTIC AGENTS

Applicant/Assignee: UNIVERSITY OF SOUTH CAROLINA

Application No.: 12/041908   Filing Date: 04/Mar/2008

Abstract:The present invention relates to a method for determining the modification conditions of a therapeutic agent comprising (1) assaying the biological activity of a first modified therapeutic agent after the first modified therapeutic agent has been administered to a subject

(2) assaying the biological activity of the first modified therapeutic agent after at least one booster dose of the first modified therapeutic agent has been administered to said subject

(3) carrying out (1) and (2) with an additional modified therapeutic agent that has been modified differently than the first modified therapeutic agent

and (4) comparing the biological activity of the first modified therapeutic agent with the biological activity of the additional modified therapeutic agent. The present invention also relates to modified therapeutic agents.

Priority: US2001-972245 Applic. Date: 2001-10-09; US20000239268P Applic. Date: 2000-10-12

Inventor: ROBERTS JOSEPH [US]; SETHURAMAN NATARAJAN [US]


Application No.: US20080145409A1  Published: 19/Jun/2008

Title: COMPOSITION FOR THE TREATMENT AND PREVENTION OF PEPTIC ULCER

Applicant/Assignee:

Application No.: 11/612549   Filing Date: 19/Dec/2006

Abstract:The present invention relates to a composition and methods of administering the composition, comprising Citronellol and its analogues and derivatives, to humans and other mammalian animals with peptic ulcers induced by alcohol consumption, H. pylori infection, stress and/or intake of nonsteroidal anti-inflammatory medications.

Priority:

Inventor: HUANG MIN CHANG [TW]; SHANE GUANG-TZUU [TW]; YANG CHANG-HUA [TW]; CHEN KUO-YEN [TW]


Application No.: US20080145410A1  Published: 19/Jun/2008

Title: Manufacture process

Applicant/Assignee:

Application No.: 12/001132   Filing Date: 10/Dec/2007

Abstract:The present invention relates to a new iron containing phosphate adsorbent and its use e.g. for treating hyperphosphataemia.

Priority: EP20060126101 Applic. Date: 2006-12-14; EP20060126122 Applic. Date: 2006-12-14

Inventor: AMBUHL MICHAEL [CH]; GESSIER-VIAL CORINE [FR]; HARTMANN CHRISTA [CH]; KAUFMANN DANIEL [CH]; KUSTERS ERNST [DE]; MEIER ULRICH [CH]; MEYER ANDREAS [DE]; SEKKAT NABILA [CH]


Application No.: US20080145417A1  Published: 19/Jun/2008

Title: PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION APOMORPHINE, 6AR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF

Applicant/Assignee: AXON BIOCHEMICALS B.V

Application No.: 12/033646   Filing Date: 19/Feb/2008

Abstract:An efficient pharmaceutical formulation for the treatment of an affliction selected from the group consisting of Parkinson's disease, restless legs syndrome and erectile dysfunction. Said composition comprises at least one member selected from the group consisting of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof in the form of the base or the pharmaceutically acceptable salts or solvates thereof as an active ingredient in a pharmaceutical preparation suited for oral or intraduodenal administration.

Priority: SE20010002036 Applic. Date: 2001-06-08; US2004-478692 Applic. Date: 2004-04-30; WO2002SE01106 Applic. Date: 2002-06-07

Inventor: WIKSTROM HAKAN [NL]; DIJKSTRA DURK [NL]; CREMERS THOMAS IVO FRANCISCUS [NL]


Application No.: US20080145425A1  Published: 19/Jun/2008

Title: PHARMACEUTICAL COMPOSITION OF ZOLPIDEM

Applicant/Assignee: PLIVA RESEARCH & DEVELOPMENT LIMITED

Application No.: 11/611305   Filing Date: 15/Dec/2006

Abstract:A pharmaceutical composition comprising a Zolpidem hemitartrate starting material comprised of form A, the composition containing less than about 8% by weight of water. The starting material typically comprises less than about 0.1% by weight of forms of Zolpidem other than Form A.

Priority:

Inventor: MARIJA LELJAK [HR]; SNJEZANA MIRIC [HR]; SILJKOVIC ZVONIMIR [HR]; MESTROVIC ERNEST [HR]


Application No.: US20080145433A1  Published: 19/Jun/2008

Title: DARUSENTAN ORAL DOSAGE FORM

Applicant/Assignee: GILEAD COLORADO, INC

Application No.: 11/935474   Filing Date: 06/Nov/2007

Abstract:A solid discrete orally deliverable pharmaceutical dosage form comprises darusentan and one or more pharmaceutically acceptable excipients

wherein (a) the darusentan is in solid particulate form having a mean particle size of about 5 to about 200 mum and is present in the dosage form in an amount of about 1 to about 600 mg

and (b) the dosage form exhibits at least about 90% dissolution of the darusentan in 30 minutes in a standard in vitro dissolution test. A method for lowering blood pressure, for example in a patient having resistant hypertension, comprises administering such a dosage form once daily to the patient.

Priority: US20060865113P Applic. Date: 2006-11-09

Inventor: GERBER MICHAEL J [US]; GORCZYNSKI RICHARD J [US]; RODEN ROBERT L [US]; SHAH PRAFUL K [US]


Application No.: US20080145438A1  Published: 19/Jun/2008

Title: Micro- and nano-particulate drugs and methods of making thereof

Applicant/Assignee:

Application No.: 11/823476   Filing Date: 26/Jun/2007

Abstract:A micro and nano-particulate drug comprising a drug substance and a surfactant in which the drug and surfactant form a eutectic mixture. The matrix formed between the drug substance and the surfactant has a melting point less than the decomposition temperature of the drug substance and thus provides the advantages of reduced irritation due to the melting process without the prior art problem of decomposition of the drug substance. In one embodiment, crystals are formed while the mixture is cooled at room temperature under high shear conditions. In a second embodiment, a flowable material may be formed which also contains the drug and that may be incorporated into a pharmaceutical delivery system is also disclosed. Methods of preparing the micro and nano-particulate drug crystals and non-crystalline substance are also contemplated in the inventive subject matter.

Priority: US2001-022799 Applic. Date: 2001-12-20

Inventor: BOGUE BEUFORD ARLIE [US]


Application No.: US20080146509A1  Published: 19/Jun/2008

Title: COMPOSITIONS FOR DELIVERING PARATHYROID HORMONE AND CALCITONIN

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 12/036466   Filing Date: 25/Feb/2008

Abstract:The present invention relates to a composition comprising a delivery agent, parathyroid hormone, and calcitonin. This composition exhibits increased delivery of parathyroid hormone and/or calcitonin and is useful for the treatment of osteoporosis. The composition also permits simultaneous oral delivery of parathyroid hormone and calcitonin. The composition of the present invention may be formulated into a dosage unit form, such as an oral dosage unit form. The invention also provides a method for administering parathyroid hormone and calcitonin to an animal in need thereof by administering the composition of the present invention.

Priority: US2004-787857 Applic. Date: 2004-02-25; US2003-435514 Applic. Date: 2003-05-09; US20020379501P Applic. Date: 2002-05-09

Inventor: GOLDBERG MICHAEL M [US]


Application No.: US20080146603A1  Published: 19/Jun/2008

Title: Combinations comprising antimuscarinic agents and beta-adrenergic agonists

Applicant/Assignee:

Application No.: 12/070298   Filing Date: 15/Feb/2008

Abstract:Combinations comprising (a) a beta2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2006-409157 Applic. Date: 2006-04-21; US2005-141428 Applic. Date: 2005-05-31

Inventor: GRAS ESCARDO JORDI [ES]; LLENAS CALVO JESUS [ES]; RYDER HAMISH [ES]; ORVIZ DIAZ PIO [ES]


Application No.: US20080146615A1  Published: 19/Jun/2008

Title: Pharmaceutical Compositions Comprising Amorphous Benzimidazole Compounds

Applicant/Assignee: DR. REDDY'S LABORATORIES LIMITED DR. REDDY'S LABORATORIES, INC

Application No.: 11/722247   Filing Date: 20/Dec/2005

Abstract:Compositions comprising amorphous substituted benzimidazole compounds.

Priority: IN2004CH01401 Applic. Date: 2004-12-20; WO2005US46393 Applic. Date: 2005-12-20

Inventor: BHUSHAN INDU [IN]; VERMANI KAVITA [IN]; KODIPYAKA RAVINDER [IN]; MEHTA PAVAK [IN]; MOHAN MAILATUR SIVARAMAN [IN]


Application No.: US20080152709A1  Published: 26/Jun/2008

Title: CLONIDINE COMPOSITION AND METHOD OF USE

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 11/959879   Filing Date: 19/Dec/2007

Abstract:A pharmaceutical composition comprises clonidine or a pharmaceutically acceptable salt or prodrug thereof. The composition, when administered to a patient in an amount delivering a clonidine dose of about 0.1 to about 2 mg/day, exhibits clonidine release properties providing a 24-hour profile of plasma clonidine concentration that (a) does not substantially or protractedly fall below about 0.2 ng/ml and exhibits a peak concentration that is therapeutically effective and does not cause unacceptable side effects in the patient

and/or (b) exhibits a peak that substantially coincides with or closely anticipates a time of maximum plasma concentration of a catecholamine occurring in a diurnal cycle of a patient having a catecholamine-mediated disease or disorder. A method for treating a disease or disorder for which clonidine is indicated in a patient comprises administering such a composition one to three times daily in a dose of about 0.1 to about 2 mg/day to the patient.

Priority: US20060871559P Applic. Date: 2006-12-22

Inventor: BORTZ JONATHAN DAVID [US]


Application No.: US20080152719A1  Published: 26/Jun/2008

Title: Multiparticulate Pharmaceutical Form Comprising Pellets With a Matrix Which Influences the Delivery of a Modulatory Substance

Applicant/Assignee: ROEHM GMBH

Application No.: 11/815677   Filing Date: 03/Mar/2006

Abstract:The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) optionally a neutral core (nonpareilles), b) an inner controlling layer comprising a substance having a modulating effect, which is embedded in a matrix which influences the delivery of the modulatory substance and which comprises pharmaceutically usable polymers, waxes, resins and/or proteins, and where appropriate an active ingredient, c) an active ingredient layer comprising an active pharmaceutical ingredient and, where appropriate, a substance having a modulating effect, d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth) acrylate copolymers where the outer controlling layer has a thickness from 20 to less than 55 mum and contains 0,1 to 10% by weight of glycerol monostearate, where the multiparticulate pharmaceutical form contains 20 to 60% by weight of the pellets, which are compressed in mixture with 80 to 40% by weight of an outer phase which consists from 50 to 100% by weight of a cellulose or a derivate of cellulose and optionally 0 to 50% by weight of further pharmaceutical excipients.

Priority: IN2005CH00325 Applic. Date: 2005-03-29; WO2006EP01950 Applic. Date: 2006-03-03

Inventor: PETEREIT HANS-ULRICH [DE]; LIZIO ROSARIO [DE]; RAVISHANKAR HEMA [IN]; SAMEL ASHWINI [IN]


Application No.: US20080153756A1  Published: 26/Jun/2008

Title: Novel Peptides and Methods for the Treatment of Inflammatory Disorders

Applicant/Assignee: AUCKLAND UNISERVICES LIMITED

Application No.: 11/874356   Filing Date: 18/Oct/2007

Abstract:Novel peptides, nucleic acids encoding them, and derivatives of the peptides are described. The peptides and nucleic acids are of use in modulating alpha4 integrin function and in treating alpha4 integrin-mediated inflammatory disorders.

Priority: AU20050901973 Applic. Date: 2005-04-19; WO2006NZ00079 Applic. Date: 2006-04-19

Inventor: KRISSANSEN GEOFFREY WAYNE [NZ]; KANWAR RUPINDER KAUR [NZ]; WOODS KATHERINE [NZ]


Application No.: US20080153845A1  Published: 26/Jun/2008

Title: TRPV1 ANTAGONISTS AND USES THEREOF

Applicant/Assignee: REDPOINT BIO CORPORATION

Application No.: 11/926911   Filing Date: 29/Oct/2007

Abstract:The present invention is directed to the use of TRPV1 antagonists as inhibitors of certain taste perceptions and functions. The invention is also directed to, among other things, compositions comprising the TRPV1 antagonists that can be used in pharmaceutical, food, and other products to inhibit certain taste functions and perceptions.

Priority: US20060854678P Applic. Date: 2006-10-27

Inventor: PALMER R KYLE [US]; LONG DANIEL [US]; DEVANTIER HEATHER [US]; LEE S PAUL [US]; BUBER M N TULU [US]; BRYANT ROBERT [US]


Application No.: US20080153888A1  Published: 26/Jun/2008

Title: ALPHA-2-DELTA LIGAND/NSAID THERAPEUTIC TREATMENT OF LOWER URINARY TRACT DISORDERS

Applicant/Assignee: RECORDATI IRELAND LIMITED

Application No.: 11/962552   Filing Date: 21/Dec/2007

Abstract:The invention relates to a method of treating at least one symptom of lower urinary tract disease in a subject in need of treatment comprising administering to said subject a combination of an alpha2delta calcium channel subunit (A2d) ligand and a non-steroidal anti-inflammatory drug (NSAID), wherein the administered amounts of A2d ligand and NSAID together comprise a therapeutically effective amount of an active combination of agents. The combination of A2d ligand and NSAID can result in a synergistic therapeutic effect, wherein the combined effect is greater than the additive effect resulting from separate, single administration of A2d ligand or NSAID. Combination of A2d ligand and NSAID is particularly useful in treatment of lower urinary tract disease which manifests symptoms of urinary incontinence.

Priority: US20060871719P Applic. Date: 2006-12-22

Inventor: LEONARDI AMEDEO [IT]; GUARNERI LUCIANO [IT]; ANGELICO PATRIZIA [IT]


Application No.: US20080153896A1  Published: 26/Jun/2008

Title: Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof

Applicant/Assignee:

Application No.: 11/777503   Filing Date: 13/Jul/2007

Abstract:The invention provides polymorphic forms of the HMG-CoA reductase inhibitor (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid, hemi calcium salt. The invention also provides methods for preparing these polymorphic forms, pharmaceutical formulations containing these polymorphic forms and methods of using the polymorphic forms of this HMG-CoA reductase inhibitor.

Priority: IN2006DE01629 Applic. Date: 2006-07-14

Inventor: YADAV GYAN CHAND [IN]; BAQER MOHAMMAD [IN]; PANDYA VISHWESH P [IN]


Application No.: US20080159977A1  Published: 03/Jul/2008

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/825604   Filing Date: 05/Jul/2007

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20080160002A1  Published: 03/Jul/2008

Title: PHARMACEUTICAL COMPOSITIONS FOR TREATING ARTHRITIS AND INFLAMMATORY DISEASE

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 11/927485   Filing Date: 29/Oct/2007

Abstract:The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.

Priority: US2004-967092 Applic. Date: 2004-10-15; US2000-712813 Applic. Date: 2000-11-13; WO1999US10793 Applic. Date: 1999-05-14; US1998-081385 Applic. Date: 1998-05-14

Inventor: GATANAGA TETSUYA [US]; GRANGER GALE A [US]


Application No.: US20080160048A1  Published: 03/Jul/2008

Title: Nucleic Acid Constructs

Applicant/Assignee: POWDERJECT VACCINES, INC

Application No.: 10/575087   Filing Date: 11/Oct/2004

Abstract:A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter sequence comprises: (a) a hCMV immediate early promoter sequence

(b) exon 1 and at least a part of exon 2 of the hCMV major immediate early gene

and (c) a heterologous intron provided in place of the intron A region of the hCMV major immediate early gene.

Priority: US20030509936P Applic. Date: 2003-10-10; WO2004GB04279 Applic. Date: 2004-10-11

Inventor: FULLER JAMES [US]


Application No.: US20080160066A1  Published: 03/Jul/2008

Title: PHOSPHOLIPID DERIVATIVES OF DHA AND METHODS FOR TREATING RESPIRATORY FAILURE USING THE SAME

Applicant/Assignee:

Application No.: 12/040958   Filing Date: 03/Mar/2008

Abstract:Taught are pharmaceutical compositions comprising at least one phospholipid having at least one docosahexaenoyl (DHA) residue, such as a lecithin-DHA-type phospholipid, and methods for treating or preventing respiratory failure of a patient comprising administering these pharmaceutical compositions to a patient in need of such treatment or prevention.

Priority: FR20050008956 Applic. Date: 2005-09-01; WO2006FR01988 Applic. Date: 2006-08-25

Inventor: PIERONI GERARD [FR]; COSTE THIERRY [FR]


Application No.: US20080160080A1  Published: 03/Jul/2008

Title: AMORPHOUS SOLID DISPERSIONS

Applicant/Assignee: SANOFI-AVENTIS U.S. LLC

Application No.: 12/029691   Filing Date: 12/Feb/2008

Abstract:Disclosed are amorphous solid dispersion formulations comprising 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide.

Priority: WO2006US33022 Applic. Date: 2006-08-24; US20050712150P Applic. Date: 2005-08-29

Inventor: JACOBS IRWIN C [US]; HIGGINS JOHN D [US]; GUILLOT MICAEL [US]; FRANSON NANCY M [US]; ROCCO WILLIAM L [US]; ABU-IZZA KHAWLA ABDULLAH [US]


Application No.: US20080160082A1  Published: 03/Jul/2008

Title: Controlled release compositions comprising Nimesulide

Applicant/Assignee: PANACEA BIOTEC LIMITED

Application No.: 11/978162   Filing Date: 26/Oct/2007

Abstract:A controlled release pharmaceutical composition for peroral administration including a single unit fast release fraction and a single unit extended release fraction which includes nimesulide as an active drug upto 99% w/w of the composition, one or more release controlling materials from 0.1% to 99% w/w of the composition and pharmaceutical excipients from 0% to 90% w/w of the composition. The nimesulide is present in the fast release fraction and in the extended release fraction.

Priority: IN1999DE01297 Applic. Date: 1999-09-28; US2003-089020 Applic. Date: 2003-03-27; WO2000IN00094 Applic. Date: 2000-09-27

Inventor: SINGH AMARJIT [IN]; JAIN RAJESH [IN]


Application No.: US20080160083A1  Published: 03/Jul/2008

Title: COMPOSITION AND METHOD FOR TREATMENT OF PREMENSTRUAL SYMPTOMS

Applicant/Assignee:

Application No.: 11/968246   Filing Date: 02/Jan/2008

Abstract:The present invention is a composition delivering effective amounts of Chasteberry Extract, Pyridoxine, and Magnesium in a single dosage unit and a method of treating PMS and related disorders with the composition.

Priority: US20070883204P Applic. Date: 2007-01-03

Inventor: MORROW JARRET [US]


Application No.: US20080161244A1  Published: 03/Jul/2008

Title: Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes

Applicant/Assignee: UUTECH LIMITED

Application No.: 12/001449   Filing Date: 11/Dec/2007

Abstract:The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

Priority: GB19990007216 Applic. Date: 1999-03-29; GB19990017565 Applic. Date: 1999-07-27; US2005-090825 Applic. Date: 2005-03-25; US2002-937687 Applic. Date: 2002-01-08; WO2000GB01089 Applic. Date: 2000-03-29

Inventor: O'HARTE FINBARR PAUL MARY [GB]; FLATT PETER RAYMOND [GB]


Application No.: US20080161335A1  Published: 03/Jul/2008

Title: Oral formulations

Applicant/Assignee:

Application No.: 11/985094   Filing Date: 14/Nov/2007

Abstract:A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.

Priority: US20060858870P Applic. Date: 2006-11-14

Inventor: VLADYKA RONALD S [US]; DALGARNO DAVID C [US]; IULIUCCI JOHN D [US]


Application No.: US20080166334A1  Published: 10/Jul/2008

Title: COMBINATION ENZYME FOR CYSTIC FIBROSIS

Applicant/Assignee:

Application No.: 12/054343   Filing Date: 24/Mar/2008

Abstract:A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients.

Priority: US2005-232180 Applic. Date: 2005-09-21; US20040613666P Applic. Date: 2004-09-28

Inventor: FALLON JOAN M [US]


Application No.: US20080167249A1  Published: 10/Jul/2008

Title: PROTECTIVE FACTORS AGAINST INFLAMMATION, BURNS AND NOXIOUS STIMULI

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM

Application No.: 11/750408   Filing Date: 18/May/2007

Abstract:Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of histone H2A and fibrinopeptide A, and preferred derivatives of these peptides are disclosed. Pharmaceutical compositions and methods of using these peptides are also disclosed. The extracts, peptides and pharmaceutical compositions according to the invention are useful for the prevention and treatment of inflammatory conditions and exposure to noxious stimuli.

Priority: IL20010145181 Applic. Date: 2001-08-29; US2004-790888 Applic. Date: 2004-03-01; WO2002IL00713 Applic. Date: 2002-08-29; US2006-527162 Applic. Date: 2006-09-25; WO2005IL00328 Applic. Date: 2005-03-23; US20040555334P Applic. Date: 2004-03-23; US20060831216P Applic. Date: 2006-07-17

Inventor: WORMSER URI [IL]


Application No.: US20080167362A1  Published: 10/Jul/2008

Title: Celecoxib compositions

Applicant/Assignee: PFIZER, INC

Application No.: 12/013873   Filing Date: 14/Jan/2008

Abstract:Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.

Priority: US1999-451641 Applic. Date: 1999-11-30; US19980110333P Applic. Date: 1998-11-30

Inventor: GAO DANCHEN [US]; HLINAK ANTHONY J [US]; MAZHARY AHMAD M [US]; TRUELOVE JAMES E [US]; VAUGHN MARGARET V [US]


Application No.: US20080170996A1  Published: 17/Jul/2008

Title: Compositions and Methods for Stimulation of Lung Innate Immunity

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 11/830622   Filing Date: 30/Jul/2007

Abstract:Embodiments of the invention include compositions, formulations and methods for the enhancement of a subject's biological defenses against infection, for example the subject's innate immunity against infection. Aspects of the invention provide a rapid and temporal enhancement or augmentation of biological defenses against microbial infection.

Priority: US20060833857P Applic. Date: 2006-07-28

Inventor: DICKEY BURTON F [US]; TUVIM MICHAEL [US]; CLEMENT CECILIA G [US]


Application No.: US20080171059A1  Published: 17/Jul/2008

Title: METHODS AND COMPOSITIONS FOR INCREASED PRIMING OF T-CELLS THROUGH CROSS-PRESENTATION OF EXOGENOUS ANTIGENS

Applicant/Assignee:

Application No.: 11/834910   Filing Date: 07/Aug/2007

Abstract:Methods for eliciting in an animal in need thereof a cell-mediated immune response specific to an antigen, the method comprising providing an antigen preparation comprising particles on the surface of which the antigen is attached, and administering the antigen preparation to the animal, wherein the particles are taken up by antigen presenting cells (APC) of the animal via phagocytosis, forming a phagosome inside the APC, wherein the antigen is attached to the surface of the particle in such a way that the antigen is released in the phagosome before the phagosome fuses with a late endosome or a lysosome, and wherein the antigen is cross-presented on a Class I MHC molecule. Also provided are particulate antigen preparations or particulate vaccines that can be delivered to an animal in need thereof for vaccination against, for preventing or treating, a disease related to the antigen, such as cancer and a viral infection.

Priority: US20060835873P Applic. Date: 2006-08-07

Inventor: HOWLAND SHANSHAN WU [US]; OLD LLOYD [US]; WITTRUP K DANE [US]


Application No.: US20080171083A1  Published: 17/Jul/2008

Title: Pharmaceutical Compositions Comprising an Amphiphilic Starch

Applicant/Assignee: VECTURE LIMITED

Application No.: 11/578271   Filing Date: 14/Apr/2005

Abstract:The present invention relates to controlled or sustained release solid pharmaceutical compositions, to pharmaceutical excipients for use in the manufacture of such compositions and to methods of producing such compositions and excipients. The controlled or sustained release excipients include a release controlling excipient comprising an amphiphilic starch.

Priority: GB20040008308 Applic. Date: 2004-04-14; WO2005GB50051 Applic. Date: 2005-04-14

Inventor: STANIFORTH JOHN [GB]; TALWAR NARESH [GB]


Application No.: US20080171084A1  Published: 17/Jul/2008

Title: Pharmaceutical semi-sold composition of isotretinoin

Applicant/Assignee: GALEPHAR M/F

Application No.: 11/892363   Filing Date: 22/Aug/2007

Abstract:An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle

Priority: WO2000BE00111 Applic. Date: 2000-09-22; WO2001BE00163 Applic. Date: 2001-09-21; US2003-380619 Applic. Date: 2003-07-30

Inventor: VANDERBIST FRANCIS [BE]; SERVAIS CECILE [BE]; BAUDIER PHILLIPPE [BE]


Application No.: US20080171085A1  Published: 17/Jul/2008

Title: Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration

Applicant/Assignee: NATROL, INC

Application No.: 11/652444   Filing Date: 11/Jan/2007

Abstract:A novel biphasic pharmaceutial or nutraceutical composition delivers both an immediate and a sustained dose of a pharmaceutical or nutraceutical agent in the same unit dose. An oral unit dose of melatonin includes melatonin in a sustained-release matrix contained in a solid phase, such as a tablet of capsule, and also includes melatonin in a film dispersed on the surface of the solid phase. Approximately 80 to 90 weight percent of the total amount of melatonin of each unit is contained in the sustained-release matrix and the remainder in the film. The novel composition permits a mammal, including a human being, to both rapidly fall asleep and remain asleep for a desired period of time by releasing an immediate-release dose and a sustained-release dose of melatonin.

Priority:

Inventor: ELNEKAVE DAHLIA [US]; SUNDARAM GOPI MOHAN [US]; YATCILLA MICHAEL TODD [US]


Application No.: US20080171089A1  Published: 17/Jul/2008

Title: Stable anti-nausea oral spray formulations and methods

Applicant/Assignee:

Application No.: 12/004409   Filing Date: 21/Dec/2007

Abstract:Stable formulations of selective 5-hydroxytryptamine receptor antagonists for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration are provided. A preferred embodiment includes ondansetron in a concentration of about 5.1 to about 5.2% w/w

propylene glycol in a concentration of about 60.1 to about 60.3% w/w

water in a concentration of about 5.3 to about 5.4% w/w

and ethanol in a concentration of about 27.1 to about 27.3% w/w. Additional preferred embodiments are preservative free and/or non-aqueous or primarily non-aqueous.

Priority: US20060876484P Applic. Date: 2006-12-22

Inventor: BLONDINO FRANK E [US]; CHEN CARRIE [US]


Application No.: US20080171797A1  Published: 17/Jul/2008

Title: METHODS OF MODULATING MITOCHONDRIAL NAD-DEPENDENT DEACETYLASE

Applicant/Assignee:

Application No.: 11/860409   Filing Date: 24/Sep/2007

Abstract:The present invention provides methods for identifying agents that modulate a level or an activity of a mitochondrial NAD-dependent deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating mitochondrial NAD-dependent deacetylase activity in a cell. The invention further provides methods of modulating mitochondrial function by modulating the activity of mitochondrial NAD-dependent deacetylase.

Priority: US2003-444633 Applic. Date: 2003-05-22; US20020383069P Applic. Date: 2002-05-23

Inventor: VERDIN ERIC M [US]; NORTH BRIAN J [US]; SCHWER BJOERN [US]


Application No.: US20080175855A1  Published: 24/Jul/2008

Title: PEPTIDE USEFUL IN IMMUNOMODULATION

Applicant/Assignee: CURETECH LTD MOR-RESEARCH APPLICATIONS LTD

Application No.: 11/957128   Filing Date: 14/Dec/2007

Abstract:The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.

Priority: IL20010145926 Applic. Date: 2001-10-15; US2006-411832 Applic. Date: 2006-04-27; US2004-821283 Applic. Date: 2004-04-09; WO2002IL00831 Applic. Date: 2002-10-15

Inventor: HARDY BRITTA [IL]; RAITER ANNAT [IL]; KLAPPER LEAH [IL]


Application No.: US20080175872A1  Published: 24/Jul/2008

Title: Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid

Applicant/Assignee: OSMOTICA CORP

Application No.: 11/859063   Filing Date: 21/Sep/2007

Abstract:A controlled release dosage form containing lercanidipine, or a salt thereof, a performance-enhancing acid, and at least one other pharmaceutical excipient exhibits enhanced in vitro dissolution of lercanidipine, enhanced storage stability based upon the reduced degradation of lercanidipine, and/or enhanced in vivo bioavailability of lercanidipine as compared to an otherwise similar controlled release dosage form excluding the performance-enhancing acid but containing the same amount of lercanidipine.

Priority: US20060827360P Applic. Date: 2006-09-28

Inventor: ABALO ESTEBAN A [AR]; RICCI MARCELO A [AR]; MEYER GLENN A [US]; CARRAUD PABLO F A [AR]


Application No.: US20080175873A1  Published: 24/Jul/2008

Title: MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/947883   Filing Date: 30/Nov/2007

Abstract:The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

Priority: US2006-445198 Applic. Date: 2006-06-02; US20050686461P Applic. Date: 2005-06-02; US20050691282P Applic. Date: 2005-06-17

Inventor: ZHOU FANG [US]; MAES PAUL [FR]; FRISBEE STEVEN [US]


Application No.: US20080175888A1  Published: 24/Jul/2008

Title: Combination Therapy Comprising Actinidia and Steroids and Uses Thereof

Applicant/Assignee:

Application No.: 12/015193   Filing Date: 16/Jan/2008

Abstract:Disclosed is a combination of an Actinidia preparation and one or more steroids, and the use of such a combination to prevent and/or treat allergic and non-allergic inflammatory conditions or diseases, to alleviate at least one symptom of such conditions or diseases, and/or to regulate an immune response in a mammal.

Priority: WO2006US06437 Applic. Date: 2006-02-24; US20070885210P Applic. Date: 2007-01-16; US20050656838P Applic. Date: 2005-02-25; US20050656839P Applic. Date: 2005-02-25

Inventor: LINDEMANN JULIE [US]; FOGG-JOHNSON NANCY ELLEN [US]; CRONIN PATTI [US]; BELOFSKY GIL [US]; STULL DEAN P [US]


Application No.: US20080175906A1  Published: 24/Jul/2008

Title: Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof

Applicant/Assignee:

Application No.: 12/003234   Filing Date: 20/Dec/2007

Abstract:The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof.

Priority: US20060875827P Applic. Date: 2006-12-20

Inventor: AHMED SALAH U [US]; SETHIA SUNDEEP [US]; CHOWDHURY TAHSEEN A [US]


Application No.: US20080176787A1  Published: 24/Jul/2008

Title: Parathyroid hormone analogues and methods of use

Applicant/Assignee:

Application No.: 11/890248   Filing Date: 02/Aug/2007

Abstract:The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

Priority: US2007-799816 Applic. Date: 2007-05-02; US2007-650918 Applic. Date: 2007-01-05; US2006-517146 Applic. Date: 2006-09-06; US20070925639P Applic. Date: 2007-04-20; US20050714905P Applic. Date: 2005-09-06; US20060834980P Applic. Date: 2006-07-31; US20060837972P Applic. Date: 2006-08-15; US20070905693P Applic. Date: 2007-03-07

Inventor: MORLEY PAUL [CA]; STOGNIEW MARTIN [US]; MACDONALD BRIAN [US]; MERUTKA GENE SCOTT [US]; PALEPU NAGESH [US]


Application No.: US20080176791A1  Published: 24/Jul/2008

Title: NOVEL ALBUMIN-FREE FACTOR VIII FORMULATIONS

Applicant/Assignee: BAXTER INTERNATIONAL INC UNIVERSITY OF CONNECTICUT

Application No.: 11/764770   Filing Date: 18/Jun/2007

Abstract:A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine

1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine

1 mM to 5 mM calcium salt

100 mM to 300 mM NaCl

and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch

1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine

1 mM to 5 mM calcium salt

100 mM to 300 mM NaCl

and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl

1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine

1 mM to 5 mM calcium salt

and a buffering agent.

Priority: US2006-434634 Applic. Date: 2006-05-15; US2003-610723 Applic. Date: 2003-07-01; US2000-507011 Applic. Date: 2000-02-22; US1999-452752 Applic. Date: 1999-12-01; US1999-255279 Applic. Date: 1999-02-22

Inventor: BESMAN MARC [US]; BJORNSON ERIK [US]; JAMEEL FEROZ [US]; KASHI RAMESH [US]; PIKAL MICHAEL [US]; TCHESSALOV SERGUEI [US]; CARPENTER JOHN [US]


Application No.: US20080176927A1  Published: 24/Jul/2008

Title: Compositions of stable tiacumicins

Applicant/Assignee: OPTIMER PHARMACEUTICALS, INC

Application No.: 12/008751   Filing Date: 14/Jan/2008

Abstract:The present invention is related to pharmaceutical compositions of one or more tiacumicins that exhibit improved stability, and methods of treatment using such formulations. The formulations contain one or more tiacumicins, such as difimicin, and one or more antioxidants, such as butylated hydroxytoluene, and, optionally, one or more pharmaceutically acceptable excipients.

Priority: US20070881137P Applic. Date: 2007-01-19

Inventor: SANGHVI SUKETU [US]; ROACH MARK [US]; ZHOU JOSEPH F [US]; MITTLEBERG ERIC MICHAEL [US]; HE PING [US]


Application No.: US20080181854A1  Published: 31/Jul/2008

Title: Pimecrolimus Foam Composition Containing Hexylene Glycol, Optionally Oleyl Alcohol, Dimethylisosorbide and/or Medium Chain Triglycerides

Applicant/Assignee: NOVARTIS AG

Application No.: 11/547226   Filing Date: 07/Apr/2005

Abstract:Pharmaceutical foam compositions substantially free of ethanol and comprising pimecrolimus in a carrier vehicle comprising a mixture of oily solvents amounting to at least 40% of the total weight of the composition and consisting of: i) hexylene glycol

ii) optionally oleyl alcohol

and iii) dimethylisosorbide and/or medium chain triglycerides

and additionally: iv) when oleyl alcohol is absent, water in an amount of less than 25%

v) at least one consistency agent

vi) at least one preservative

and vii) at least one surfactant/emulgator

and propellant gas for foaming

and optionally further conventional excipients. They are indicated for use in the treatment of various skin, nail and mucosal diseases.

Priority: GB20040008070 Applic. Date: 2004-04-08; GB20040008076 Applic. Date: 2004-04-08; WO2005EP03669 Applic. Date: 2005-04-07

Inventor: EINI MEIR [IL]; FRIEDMAN DORON [IL]; HIRSCH STEFAN [DE]; MEYENBURG SABINE [DE]; SEKKAT NABILA [CH]; TAMARKIN DOV [IL]


Application No.: US20080181932A1  Published: 31/Jul/2008

Title: COMPOSITIONS FOR ORAL DELIVERY OF PHARMACEUTICALS

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 12/021438   Filing Date: 29/Jan/2008

Abstract:The invention provides methods and compositions for the oral delivery of pharmaceutically active agents. In particular, the compositions generally comprise a plurality of pharmaceutically active agents embedded in a matrix that is substantially erodable when contacted with an aqueous medium. The compositions may also include an inner core comprising an inert material. The compositions may be introduced into the oral cavity of a subject by liquid beverage or food product comprising a composition of the invention.

Priority: US20070887227P Applic. Date: 2007-01-30

Inventor: BORTZ JONATHAN DAVID [US]; BRADY PAUL TIMOTHY [US]; LAGOVIYER YURY [US]


Application No.: US20080181933A1  Published: 31/Jul/2008

Title: Chewing Gum Compositions of Varenicline

Applicant/Assignee: PFIZER INC

Application No.: 11/816731   Filing Date: 09/Mar/2006

Abstract:A chewing gum composition including a water insoluble base portion

a water soluble portion

and a therapeutically effective amount of varenicline or its pharmaceutical acceptable salt thereof. A method for reducing nicotine addiction and aiding in the cessation or lessening of tobacco use in an individual by administering to an oral cavity of an individual a chewing gum composition including an effective amount of varenicline or its pharmaceutical acceptable salt thereof

and chewing the gum composition to cause the varenicline or its pharmaceutical acceptable salt thereof to be released from the chewing gum composition into the oral cavity of the individual. A method of manufacturing a chewing gum composition.

Priority: US20050664094P Applic. Date: 2005-03-21; WO2006IB00735 Applic. Date: 2006-03-09

Inventor: JOHNSON BARBARA ALICE [US]; ZIEGLER CARL BERNARD [US]


Application No.: US20080181943A1  Published: 31/Jul/2008

Title: COMBINATION OF A LONG-ACTING HYPNOTIC AGENT AND A SHORT-ACTING HYPNOTIC AGENT AND THERAPEUTIC USE THEREOF

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 12/029011   Filing Date: 11/Feb/2008

Abstract:The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative and a melatonin receptor agonist

and a long-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine, an antagonist of receptors 5HT2A and a calcium ion modulator, for the treatment of sleep disorders. The invention also relates to galenic formulations containing said combinations.

Priority: FR20050008643 Applic. Date: 2005-08-19; WO2006FR01830 Applic. Date: 2006-07-27

Inventor: CUINE ALAIN [FR]; DECOBERT MICHEL [FR]; FRANCON DOMINIQUE [FR]; SAUNAL HENRY [FR]


Application No.: US20080181948A1  Published: 31/Jul/2008

Title: SOLID PHARMACEUTICAL DOSAGE FORMULATIONS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/939640   Filing Date: 14/Nov/2007

Abstract:The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.

Priority: US20060859271P Applic. Date: 2006-11-15

Inventor: BERNDL GUNTHER [DE]; ROSENBERG JOERG [DE]; LIEPOLD BERND [DE]; FASTNACHT KATJA [DE]; JUNG TINA [DE]; ROTH WOLFGANG [DE]; BREITENBACH JOERG [DE]; MORRIS JOHN [US]; KLEIN CHERI E [US]; CAI YAN [US]; ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Application No.: US20080181952A1  Published: 31/Jul/2008

Title: Perfusive Organ Hemostasis

Applicant/Assignee: PLUROMED, INC LAHEY CLINIC, INC

Application No.: 11/954109   Filing Date: 11/Dec/2007

Abstract:Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.

Priority: US20070893993P Applic. Date: 2007-03-09; US20060874062P Applic. Date: 2006-12-11

Inventor: VOGEL JEAN-MARIE [US]; WILKIE JAMES A [US]; MADRAS PETER N [US]


Application No.: US20080182888A1  Published: 31/Jul/2008

Title: Novel Crystalline Compounds

Applicant/Assignee:

Application No.: 11/961695   Filing Date: 20/Dec/2007

Abstract:The present invention relates to a novel crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium and its use in pharmaceutical preparations.

Priority: IN2005MU00780 Applic. Date: 2005-07-01; WO2006GB50179 Applic. Date: 2006-06-30

Inventor: GORE VINAYAK G [IN]; PEHERE ASHOK D [IN]; GAIKWAD AVINASH C [IN]; VIJAYKAR PRIYESH S [IN]


Application No.: US20080187584A1  Published: 07/Aug/2008

Title: Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

Applicant/Assignee: TEVA PHARMACEUTICALS USA, INC

Application No.: 12/077458   Filing Date: 18/Mar/2008

Abstract:Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method. Preferably, the paroxetine hydrochloride is paroxetine hydrochloride hemihydrate.

Priority: US2004-891561 Applic. Date: 2004-07-14; US2002-330616 Applic. Date: 2002-12-27; US20010344120P Applic. Date: 2001-12-28; US20020366351P Applic. Date: 2002-03-21

Inventor: COHEN RAKEFET [IL]; FOX MICHAEL [IL]


Application No.: US20080187588A1  Published: 07/Aug/2008

Title: Formulations With Controlled Release Of Active Ingredient

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/579925   Filing Date: 10/May/2005

Abstract:The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts, hydrates, solvates and/or polymorphic forms thereof as active ingredient, and to the production thereof. The invention further relates to the use of these novel pharmaceutical dosage forms as medicaments, and to their use for producing medicaments for the treatment and/or prevention of disorders in humans and animals.

Priority: DE200410023069 Applic. Date: 2004-05-11; WO2005EP05023 Applic. Date: 2005-05-10

Inventor: ZULEGER SUSANNE [DE]; SERNO PETER [DE]; HANING HELMUT [DE]; PAULI KERSTIN [DE]; HEINIG ROLAND [DE]


Application No.: US20080188567A1  Published: 07/Aug/2008

Title: Crystalline polymorphs of desvenlafaxine succinate and their preparations

Applicant/Assignee: MAI DE LTD

Application No.: 11/982622   Filing Date: 05/Nov/2007

Abstract:The present invention is directed to two new polymorph Form V and Form F of desvenlafaxine succinate, to processes of their preparations, pharmaceutical composition comprising such materials and their use in therapy. Form V is prepared from recrystallizing desvenlafaxine succinate in a mixture of tetrahydrofuran and ethanol. Form F is obtained from recrystallization of desvenlafaxine succinate in a mixture of cyclohexane and polar solvents such as ethanol, THF, methanol or isopropyl alcohol.

Priority: US20070878983P Applic. Date: 2007-01-08

Inventor: HUANG CAI GU [CN]; HUANG HUI MIN HE [CN]


Application No.: US20080193427A1  Published: 14/Aug/2008

Title: Means and Methods for Preventing and/or Treating Caries

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 11/662347   Filing Date: 09/Sep/2005

Abstract:The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment

and/or (ii) resistant to protease treatment

and/or (iii) calcium-dependent

and/or (iv) formed within a pH range between 4.5 and 8.5

and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase

(b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase

(c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet. Another aspect of the present invention is an analog or fragment of said microorganism which is thermally inactivated or lyophilized, wherein said analog or fragment retains the capability of specifically binding to Streptococcus mutans. In addition, the present invention encompasses compositions and additives for food, feed or drinks comprising the microorganism belonging to the group of lactic acid bacteria which specifically bind to Streptococcus mutans or an analog or fragment thereof. Moreover, uses of said microorganism or said analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing said compositions or food or feedstuff are provided by the present invention.

Priority: EP20040021591 Applic. Date: 2004-09-10; US20040608381P Applic. Date: 2004-09-10; WO2005EP09724 Applic. Date: 2005-09-09

Inventor: KAESLER BRUNO [DE]; KNOLL ROLF [DE]; BOETTNER MEWES [DE]; BUDDE ECKHARD [DE]; LANG CHRISTINE [DE]; RYSER MARTIN [DE]; VEEN MARKUS [DE]


Application No.: US20080193428A1  Published: 14/Aug/2008

Title: Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity

Applicant/Assignee: SHENZHEN PHLORA BIOTECHNOLOGY LIMITED HK PHLORA HEALTH SCIENCE & TECHNOLOGY LTD

Application No.: 11/912851   Filing Date: 27/Apr/2006

Abstract:The present invention relates to the use of benzoic acid and/or its sodium salt in combination with saccharide(s) as active components in the manufacture of a vaginal composition for modulating vaginal flora and vaginal acidity, thereby maintaining the pH value of vaginal secretion within a range from 3.5 to 4.5

and the present invention further relates to a vaginal composition and a method for modulating and maintaining normal vaginal flora and vaginal acidity.

Priority: CN20051070307 Applic. Date: 2005-04-27; WO2006CN00826 Applic. Date: 2006-04-27

Inventor: ZHOU RUYUN [CN]; ZENG ZHONGMING [CN]


Application No.: US20080193519A1  Published: 14/Aug/2008

Title: Galenic Applications of Self-Emulsifying Mixtures of Lipidic Excipients

Applicant/Assignee: AVENTIS PHARMA S.A

Application No.: 11/572402   Filing Date: 20/Jul/2005

Abstract:A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.

Priority: FR20040008269 Applic. Date: 2004-07-20; WO2005FR01853 Applic. Date: 2005-07-20

Inventor: PACHOT JEAN [FR]; SEGOT CHICQ SERGE [FR]


Application No.: US20080193527A1  Published: 14/Aug/2008

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING QUETIAPINE FUMARATE

Applicant/Assignee: LABORATORIOS LESVI, SL

Application No.: 11/737462   Filing Date: 19/Apr/2007

Abstract:A granule formulation useful for preparation of pharmaceutical compositions. The granule formulation includes a core containing quetiapine or a pharmaceutically acceptable salt thereof as an active ingredient, and a binder agent. The core is coated with a coating layer including a lubricant agent. Solid pharmaceutical compositions containing quetiapine, and their preparation, are described.

Priority: EP20070380037 Applic. Date: 2007-02-14

Inventor: RUIZ AMENOS ANNA [ES]; UBEDA PEREZ CARMEN [ES]; DIEZ MARTIN IGNACIO [ES]


Application No.: US20080193529A1  Published: 14/Aug/2008

Title: Direct Compression Formulation and Process

Applicant/Assignee:

Application No.: 11/916490   Filing Date: 08/Jun/2006

Abstract:Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with a glitazone and specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

Priority: US20050689739P Applic. Date: 2005-06-10; US20050690527P Applic. Date: 2005-06-14; US20050690814P Applic. Date: 2005-06-15; WO2006US22336 Applic. Date: 2006-06-08

Inventor: KOWALSKI JAMES [US]; LAKSHMAN JAY PARTHIBAN [US]; PATEL ARUN [US]


Application No.: US20080193531A1  Published: 14/Aug/2008

Title: COMPOSITIONS FOR IMPROVING GASTROINTESTINAL NUTRIENT AND DRUG ABSORPTION

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 12/027538   Filing Date: 07/Feb/2008

Abstract:The present invention provides pharmaceutical compositions and methods for improving the absorption of nutrients and/or drugs in the gastrointestinal tract of a subject. Typically, the pharmaceutical compositions comprise a first agent that increases the pH of the stomach, and one or more agents selected from a pH lowering agent, a vitamin, a mineral, and a drug.

Priority: US20070889047P Applic. Date: 2007-02-09

Inventor: HERMELIN MARC S [US]; BORTZ JONATHAN DAVID [US]; LEVINSON R SAUL [US]


Application No.: US20080194477A1  Published: 14/Aug/2008

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/704141   Filing Date: 07/Feb/2007

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20080194527A1  Published: 14/Aug/2008

Title: COMPOSITIONS AND COMBINATIONS 2

Applicant/Assignee: TCP INNOVATIONS LTD

Application No.: 11/674859   Filing Date: 14/Feb/2007

Abstract:Compositions and methods for preventing, inhibiting or treating a disorder associated with the loss of normal adult tissue architecture are provided.

Priority:

Inventor: GRAINGER DAVID J [GB]


Application No.: US20080194542A1  Published: 14/Aug/2008

Title: Pharmaceutical Compositions of Amlodipine and Benazepril

Applicant/Assignee:

Application No.: 11/886354   Filing Date: 25/Jan/2006

Abstract:A stable pharmaceutical composition consisting of (a) benazepril, in free or pharmaceutically acceptable salt form

and (b) amlodipine, in free or pharmaceutically acceptable salt form. The composition is free of alkali and alkaline earth metal carbonates and phosphates. The composition is also free of excipients which increase the pH of microenvironment above 5. It is therefore not required to physically separate the two drugs from each other.

Priority: IN2005MU00284 Applic. Date: 2005-03-15; WO2006IN00026 Applic. Date: 2006-01-25

Inventor: VITHALAPURAM VEENA [IN]; THOMMANDRU VIJAYA KUMAR [IN]; SEN HIMADRI [IN]


Application No.: US20080194570A1  Published: 14/Aug/2008

Title: SOLID PHARMACEUTICAL FORMULATIONS OF A HOMOGENEOUS DISPERSION OF ACTIVE PRINCIPLES HAVING pH-DEPENDENT SOLUBILITY

Applicant/Assignee:

Application No.: 12/029746   Filing Date: 12/Feb/2008

Abstract:The present invention relates to solid pharmaceutical formulations of a homogeneous dispersion of at least one active principle which possesses pH-dependent solubility, e.g. 1-[4-chloroanilino]-4-[4-pyridylmethyl]phthalazine, or a pharmaceutically acceptable salt thereof, to solid dosage forms comprising said solid pharmaceutical formulations, to methods of preparing said solid pharmaceutical formulations and said solid dosage forms, to uses of said solid pharmaceutical formulations, alone or in combination with one or more pharmaceutically active compounds, for the manufacture of a medicament for the treatment especially of a proliferative disease, such as cancer, and to a method of treatment of a proliferative disease, such as cancer.

Priority: EP20070090018 Applic. Date: 2007-02-13

Inventor: JUERGENS KAI [DE]; GYSLER JENS [DE]


Application No.: US20080194626A1  Published: 14/Aug/2008

Title: ANTIHYPERTENSIVE DRUG COMBINATION

Applicant/Assignee:

Application No.: 12/028079   Filing Date: 08/Feb/2008

Abstract:Therapeutic combinations and pharmaceutical compositions are provided comprising darusentan and an inhibitor of renin activity or release in absolute and relative amounts effective to provide a beneficial change in a subject's 24-hour pattern of systolic and/or diastolic blood pressure. There are further provided methods of using such combinations or compositions to treat hypertensive disorders, or to lower blood pressure in subjects exhibiting resistance to a baseline antihypertensive therapy.

Priority: US20070889873P Applic. Date: 2007-02-14

Inventor: GORCZYNSKI RICHARD J [US]


Application No.: US20080194662A1  Published: 14/Aug/2008

Title: CLEANSER COMPOSITION

Applicant/Assignee:

Application No.: 11/674944   Filing Date: 14/Feb/2007

Abstract:A cleanser composition composed of purified water, sodium laureth sulfate, zinc pyrithione, cocamidopropyl betaine, glycerol cocoate, polyquaternium-7, and a cross-linked polyacrylic acid polymer for topical application to an area affected by a skin disorder such as seborrheic dermatitis, perioral dermatitis, rosacea, acne, tinea versicolor, eczema and psoriasis.

Priority:

Inventor: KUNIN AUDREY [US]


Application No.: US20080200383A1  Published: 21/Aug/2008

Title: Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent

Applicant/Assignee: AMYLIN PHARMACEUTICALS, INC

Application No.: 11/910723   Filing Date: 06/Apr/2006

Abstract:The present disclosure is directed to stable pharmaceutical formulations and uses thereof.

Priority: US20050669353P Applic. Date: 2005-04-08; WO2006US13073 Applic. Date: 2006-04-06

Inventor: JENNINGS ROBERT N [US]; ONG JOHN T H [US]; RHODES CHRISTOPHER A [US]; STETSKO GREGG [US]; PRESTRELSKI STEVEN J [US]


Application No.: US20080200536A1  Published: 21/Aug/2008

Title: Pharmaceutical Formulation with High Stability and Dissolution and Manufacturing Process

Applicant/Assignee: BORAM PHARM.CO., LTD

Application No.: 12/063090   Filing Date: 26/Jun/2006

Abstract:Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation. The pharmaceutical formulation comprises a pharmacologically active substance, a solvent, a solubilizer, a surfactant, an antioxidant, and an adsorbent. According to the pharmaceutical formulation and the method, the pharmacologically active substance is mixed with the solvent, the solubilizer agent and the surfactant for improving the solubility of the pharmacologically active substance to obtain an amorphous liquid or semi-solid state, the antioxidant is melted together with the mixture to solve poor chemical stability of the pharmacologically active substance in an amorphous or liquid state, and the adsorbent is strongly adsorbed to the molten mixture so as to be transformed into a powder form so that the resulting molecules are reconstituted into very tiny crystal forms within the adsorbent to ensure chemical stability.

Priority: KR20050075266 Applic. Date: 2005-08-17; WO2006KR02452 Applic. Date: 2006-06-26

Inventor: MOON JOO MYUNG [KR]; LEE HYUN-AH [KR]


Application No.: US20080200549A1  Published: 21/Aug/2008

Title: PHARMACEUTICAL COMPOSITION OF IBUPROFEN AND PARACETAMOL AND METHODS OF USING THE SAME

Applicant/Assignee: AFT PHARMACEUTICALS LIMITED

Application No.: 12/113171   Filing Date: 30/Apr/2008

Abstract:A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol.

Priority: NZ20040533982 Applic. Date: 2004-07-07; WO2005NZ00168 Applic. Date: 2005-07-07

Inventor: ATKINSON HARTLEY CAMPBELL [NZ]


Application No.: US20080200899A1  Published: 21/Aug/2008

Title: METHODS FOR INTRAVASCULAR ENGRAFTMENT IN HEART

Applicant/Assignee:

Application No.: 12/034186   Filing Date: 20/Feb/2008

Abstract:The invention relates to a method of engrafting donor cells into injured myocardium. The method includes delivering donor cells to a delivery site adjacent to and downstream of a chronic total occlusion and treating the chronic total occlusion. The delivery device may be a catheter with a wireguide that may be provided by a retrograde approach via an un-occluded artery or antegrade approach through the chronic total occlusion. The invention also relates to a method of treating injured myocardium and cell compositions for treatment of injured myocardium.

Priority: US20070902739P Applic. Date: 2007-02-21

Inventor: MCINTOSH CHARLES L [US]


Application No.: US20080200948A1  Published: 21/Aug/2008

Title: NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME

Applicant/Assignee: PHOTOBIOMED CORPORATION

Application No.: 12/023963   Filing Date: 31/Jan/2008

Abstract:Novel biomaterials are disclosed having unique properties that make it a useful material in adhesives, local drug delivery applications and as filler or bulking material. The biomaterials are strong, safe and easily used as a surgical adhesive. Treated chitosan, modified chitosan or modified and treated chitosan compositions are disclosed displaying strengths suitable for general surgical applications. The materials can be used as a drug delivery vehicle which allows for the localization of the delivered drug as well as a programmable tether which allows for the release of the drug on a timed basis or in response to a physiological state such as the release of proteolytic enzymes. The materials of this invention can also be modified and treated to optimize the retention of water, thereby serving as a useful filler or bulking material.

Priority: US20070887559P Applic. Date: 2007-01-31

Inventor: UTECHT RONALD E [US]; KLOSTER KAIA L [US]; DOWNEY THERESE M [US]; HABERER BARBARA R [US]


Application No.: US20080206319A1  Published: 28/Aug/2008

Title: Hexosylceramides as Adjuvants and Their Uses in Pharmaceutical Compositions

Applicant/Assignee:

Application No.: 12/090279   Filing Date: 19/Oct/2006

Abstract:The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Priority: EP20050022771 Applic. Date: 2005-10-19; WO2006EP10086 Applic. Date: 2006-10-19

Inventor: EBENSEN THOMAS [DE]; MORR MICHAEL [DE]; GUZMAN CARLOS A [DE]


Application No.: US20080206348A1  Published: 28/Aug/2008

Title: Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers

Applicant/Assignee:

Application No.: 11/575000   Filing Date: 16/Sep/2005

Abstract:The present invention relates to cilostazol compositions, process for their preparation, and methods for their administration to treat a condition. In the cilostazol compositions, 90 % of the cilostazol particles have a particle size less than about 50 mum.

Priority: IN2004DE01770 Applic. Date: 2004-09-17; WO2005IB02750 Applic. Date: 2005-09-16

Inventor: MURPANI DEEPAK [IN]; BHATTI ASHIMA [IN]


Application No.: US20080207484A1  Published: 28/Aug/2008

Title: Hybrid Proteins with ErbB4 Extracellular Domain and Neuregulin Heparin-Binding Domain for Targeting

Applicant/Assignee:

Application No.: 11/631977   Filing Date: 08/Jul/2005

Abstract:Polypeptides of the neuregulin (NRG) heparin binding domain (N-HBD) and nucleic acids coding therefor are disclosed. In particular, fusion polypeptides are produced that comprise, as a targeting structure, a N-HBD polypeptide, fragment, homologue or functional derivative and a protein to be targeted. This is fused to a polypeptide or peptide being targeted (Ptrg) to cell surfaces rich in heparan sulfate proteoglycans to either activate or inhibit interactions at tyrosine kinase receptors. A preferred fusion polypeptide comprises an N-HBD, a spacer and the extracellular domain of erbB4, one of several receptors signaled by NRG, which is potent NRG antagonist. Such products are used to treat diseases or conditions where either agonism or antagonism at tyrosine kinase receptors has beneficial effects, including cancer and a multitude of diseases of the nervous system.

Priority: US20040586283P Applic. Date: 2004-07-09; US20040608096P Applic. Date: 2004-09-09; US20040616834P Applic. Date: 2004-10-08; WO2005US24279 Applic. Date: 2005-07-08

Inventor: LOEB JEFFREY A [US]


Application No.: US20080207545A1  Published: 28/Aug/2008

Title: Methods and Compositions for Treating 5Alpha-Reductase Type 1 and Type 2 Dependent Conditions

Applicant/Assignee:

Application No.: 11/885384   Filing Date: 20/Oct/2004

Abstract:The invention relates generally to the use of anti-sense oligonucleotides, small interfering RNA, and ribozymes to modulate expression of the human steroid 5alpha-reductase gene and thereby modulate levels of dihydrotestosterone (DHT). Elevated levels of DHT are associated with various disorders including, but not limited to, skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia. The invention specifically relates to formulations of these anti-sense oligonucleotides, small interfering RNA, and ribozymes for administration to treat and prevent disorders

Priority: US20030512689P Applic. Date: 2003-10-21; US20040545146P Applic. Date: 2004-02-18; WO2004US34510 Applic. Date: 2004-10-20

Inventor: HOKE GLENN D [US]; NIGRA THOMAS P [US]


Application No.: US20080207561A1  Published: 28/Aug/2008

Title: NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME

Applicant/Assignee:

Application No.: 12/023977   Filing Date: 31/Jan/2008

Abstract:A novel biomaterial is disclosed having unique properties that make it useful in ocular drug delivery applications, where the drugs selected from the group consisting of a prostaglandin, a prostamide, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid, and mixtures, derivatives, salts and esters thereof.

Priority: US20070887559P Applic. Date: 2007-01-31

Inventor: UTECHT RONALD E [US]; KLOSTER KAIA L [US]; DOWNEY THERESE M [US]; HABERER BARBARA R [US]; YOUSO PATRICK D [US]; CHANG JAMES N [US]


Application No.: US20080207716A1  Published: 28/Aug/2008

Title: Formulations and Dosing Regiment for Ppar-Alpha Modulators

Applicant/Assignee: ELI LILLY AND COMPANY PATENT DIVISION

Application No.: 11/814487   Filing Date: 25/Jan/2006

Abstract:The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 mug or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit.

Priority: US20050647903P Applic. Date: 2005-01-28; WO2006US02606 Applic. Date: 2006-01-25

Inventor: ABU-RADDAD EYAS JAMAL [US]; DERBY MICHAEL ARTHUR [US]; HARRIS CYNTHIA JOYCE [US]; HOWEY DANIEL CHARLES [US]; MICHAEL LAURA FREY [US]


Application No.: US20080213230A1  Published: 04/Sep/2008

Title: Enriched stem cell and progenitor cell populations, and methods of producing and using such populations

Applicant/Assignee: KECK GRADUATE INSTITUTE

Application No.: 11/983431   Filing Date: 07/Nov/2007

Abstract:The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor/stem cells, e.g., cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.

Priority: US20060857661P Applic. Date: 2006-11-07

Inventor: PHILLIPS MICHAEL IAN [US]; TANG YAO LIANG [US]


Application No.: US20080213356A1  Published: 04/Sep/2008

Title: Pharmaceutical Composition Containing Hmg-Coa Reductase Inhibitor And Method For The Preparation Thereof

Applicant/Assignee: PHARMATHEN S.A

Application No.: 12/063222   Filing Date: 13/Sep/2006

Abstract:The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, and a process for the preparation thereof by direct compression.

Priority: GR20050100466 Applic. Date: 2005-09-14; WO2006GR00046 Applic. Date: 2006-09-13

Inventor: KARAVAS EVANGELOS [GR]; KOUTRIS EFTIMIOS [GR]; BIKIARIS DIMITRIOS [GR]


Application No.: US20080213361A1  Published: 04/Sep/2008

Title: Method for Production of Directly Compressible Ibuprofen Formulations

Applicant/Assignee: BASF SE

Application No.: 12/089416   Filing Date: 05/Oct/2006

Abstract:A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m<2>/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.

Priority: DE200510049991 Applic. Date: 2005-10-11; WO2006EP67058 Applic. Date: 2006-10-05

Inventor: MEYER-BOHM KATHRIN [DE]; KOLTER KARL [DE]; QUADIR ANISUL [US]


Application No.: US20080213375A1  Published: 04/Sep/2008

Title: Drying of Drug-Containing Particles

Applicant/Assignee: PFIZER INC

Application No.: 11/814592   Filing Date: 16/Jan/2006

Abstract:A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas.

Priority: US20050648229P Applic. Date: 2005-01-28; WO2006IB00186 Applic. Date: 2006-01-16

Inventor: RAY RODERICK JACK [US]; DIXON DAVID [US]; BEYERINCK RONALD ARTHUR [US]; DOBRY DANIEL ELMONT [US]; GROVE KEVIN DOUGLAS [US]


Application No.: US20080214439A1  Published: 04/Sep/2008

Title: AMINO ACID SUBSTITUTED MOLECULES

Applicant/Assignee: ALLOZYNE, INC

Application No.: 12/105155   Filing Date: 17/Apr/2008

Abstract:The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Priority: US2007-894727 Applic. Date: 2007-08-20; US2007-743608 Applic. Date: 2007-05-02; US20060796752P Applic. Date: 2006-05-02; US20060796701P Applic. Date: 2006-05-02; US20060796907P Applic. Date: 2006-05-02

Inventor: GRABSTEIN KENNETH H [US]; WANG AIJUN [US]; NAIRN NATALIE WINBLADE [US]; GRADDIS THOMAS JAMES [US]


Application No.: US20080214566A1  Published: 04/Sep/2008

Title: Amorphous ziprasidone mesylate

Applicant/Assignee:

Application No.: 12/151086   Filing Date: 02/May/2008

Abstract:Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals.

Priority: US2006-354325 Applic. Date: 2006-02-13; US20050652356P Applic. Date: 2005-02-11

Inventor: ARONHIME JUDITH [IL]; MENDELOVICI MARIOARA [IL]; LEVI SIGALIT [IL]; MAINFELD ALEX [IL]; GOLD AMIR [IL]


Application No.: US20080214677A1  Published: 04/Sep/2008

Title: Chitosan-Silicon Dioxide Coprecipitate and Use as Excipient in Solid Dosage Forms

Applicant/Assignee: THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO

Application No.: 12/064659   Filing Date: 29/Aug/2006

Abstract:Chitosan silicon dioxide coprecipitate composition, method of production thereof, pharmaceutical composition comprising the chitosan silicon dioxide coprecipitate composition and use of the chitosan silicon dioxide coprecipitate composition for manufacturing a sustained or immediate release formulation.

Priority: EP20050019082 Applic. Date: 2005-09-02; WO2006EP08444 Applic. Date: 2006-08-29

Inventor: BADWAN ADNAN [JO]; AL-REMAWI MAYYAS [JO]


Application No.: US20080220042A1  Published: 11/Sep/2008

Title: Biomolecule-linked biomimetic scaffolds

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 11/811923   Filing Date: 11/Jun/2007

Abstract:The invention provides a composition comprising a nanofiber polymer in which the fibers of the nanofiber polymer are aligned, and a molecule is covalently attached, either directly or through a linker, to the nanofiber polymer. This molecule is capable of either covalently or non-covalently attaching to a member selected from an extracellular matrix component, a growth factor, and combinations thereof. The invention also provides methods of making the composition and methods of using the compositions to add new tissue to a subject, such as a human.

Priority: US2007-668448 Applic. Date: 2007-01-29; US20070924926P Applic. Date: 2007-06-05; US20060861780P Applic. Date: 2006-11-30; US20060804350P Applic. Date: 2006-06-09; US20060763111P Applic. Date: 2006-01-27

Inventor: HASHI CRAIG [US]; LI SONG [US]


Application No.: US20080220080A1  Published: 11/Sep/2008

Title: Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release

Applicant/Assignee: ROEHM GMBH

Application No.: 11/816372   Filing Date: 03/Mar/2006

Abstract:The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) a core layer comprising a substance having a modulating effect, b) an inner controlling layer which influences the delivery of the substance having a modulating effect, consisting of pharmaceutically usable polymers, waxes, resins and/or proteins, c) an active ingredient layer comprising an active pharmaceutical ingredient and, where appropriate, a substance having a modulating effect, d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth)acrylate copolymers where the layers may additionally and in a manner known per se comprise pharmaceutically usual excipients, where the outer controlling layer d)

has a thickness from 20 to less than 55 mum and contains 0.1 to 10% by weight of glycerol monostearate, where the multiparticulate pharmaceutical form contains 20 to 60% by weight of the pellets, which are compressed in mixture with 80 to 40% by weight of an outer phase which consists from 50 to 100% by weight of a cellulose or a derivate of cellulose and optionally 0 to 50% by weight of further pharmaceutical excipients.

Priority: IN2005CH00324 Applic. Date: 2005-03-29; WO2006EP01948 Applic. Date: 2006-03-03

Inventor: PETEREIT HANS-ULRICH [DE]; LIZIO ROSARIO [DE]; RAVISHANKAR HEMA [IN]; SAMEL ASHWINI [IN]


Application No.: US20080221079A1  Published: 11/Sep/2008

Title: PHARMACEUTICAL COMPOSITION OF QUETIAPINE FUMARATE

Applicant/Assignee:

Application No.: 12/044706   Filing Date: 07/Mar/2008

Abstract:A pharmaceutical composition comprising (i) quetiapine or a pharmaceutically acceptable salt thereof, especially quetiapine fumarate

(ii) a mixed excipient comprising an intimate admixture of polyvinylacetate and polyvinylpyrrolidone in a weight ratio from 5:2 to 10:2

and, optionally (iii) an acid especially fumaric acid.

Priority: US20070894064P Applic. Date: 2007-03-09

Inventor: JANSEN KORINDE ANNEMARIE [NL]


Application No.: US20080221173A1  Published: 11/Sep/2008

Title: PHARMACEUTICAL COMPOSITION AND A PROCESS THEREOF

Applicant/Assignee: INDUS BIOTECH PVT. LTD

Application No.: 12/041415   Filing Date: 03/Mar/2008

Abstract:The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s)

a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source

and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition

and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors.

Priority: US20070893075P Applic. Date: 2007-03-05

Inventor: BHASKARAN SUNIL [IN]; VISHWARAMAN MOHAN [IN]


Application No.: US20080226705A1  Published: 18/Sep/2008

Title: GEL DELIVERY SYSTEM FOR ORAL ADMINISTRATION OF MEDICAMENTS

Applicant/Assignee:

Application No.: 12/062064   Filing Date: 03/Apr/2008

Abstract:The invention relates to a swallowable delivery device fabricated from a composition including a hydrated polymeric matrix with gelatinous consistency, one or more active ingredients, and optionally one or more stiffening agent. The delivery device is of a size and shape amenable to swallowing with enhanced solubility and controlled release of the active ingredients.

Priority: US2005-590282 Applic. Date: 2005-03-24; WO2005US09548 Applic. Date: 2005-03-24; US20070910015P Applic. Date: 2007-04-04; US20040558349P Applic. Date: 2004-03-31

Inventor: SOLTERO RICHARD A [US]; COLATSKY THOMAS J [US]


Application No.: US20080226707A1  Published: 18/Sep/2008

Title: WNT compositions and methods of use thereof

Applicant/Assignee:

Application No.: 12/074766   Filing Date: 05/Mar/2008

Abstract:Methods and compositions are provided for the therapeutic use of Wnt proteins, where the Wnt protein is inserted in the non-aqueous phase of a lipid structure. In some embodiments the Wnt protein is presented in its active conformation on an outer liposome membrane or micelle. Pharmaceutical compositions of the present invention can be administered to an animal for therapeutic purposes. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.

Priority: US20070905282P Applic. Date: 2007-03-05

Inventor: HELMS JILL [US]; NUSSE ROELAND [US]; KIM JAEBEOM [US]; LEUCHT PHILIPP [US]


Application No.: US20080226711A1  Published: 18/Sep/2008

Title: PHARMACEUTICAL COMPOSITIONS OF DULOXETINE

Applicant/Assignee: TORRENT PHARMACEUTICALS LTD

Application No.: 12/045810   Filing Date: 11/Mar/2008

Abstract:The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat.

Priority: IN2007MU00469 Applic. Date: 2007-03-12

Inventor: K SHETH RAKESH [IN]; UMESH SETTY [IN]; M PATEL HASMUKH [IN]


Application No.: US20080226736A1  Published: 18/Sep/2008

Title: Inhalatory Pharmaceutical Compositions in Form of Dry Powders, Solutions or Suspensions Obtained From the Same and Process for their Preparation

Applicant/Assignee: ERATECH S.R.L

Application No.: 12/090899   Filing Date: 20/Oct/2006

Abstract:Inhalatory pharmaceutical composition comprising a drug, a soluble excipient and a surfactant, characterized by: said soluble excipient is present in an amount between 10% and less than 100% by weight

-the weight ratio between said surfactant and said drug is between 0.01 and 10

-the particle size of at least 50% of the particles of said powder is below 5 mum

-the bulk density db of said powder is between 0.1 and 0.3 g/cc

-the tapped density dt of said powder is between 0.15 and 0.7 g/cc

-the ratio db/dt is between 0.2 and 0.65.

Priority: IT2005MI01999 Applic. Date: 2005-10-21; WO2006EP67619 Applic. Date: 2006-10-20

Inventor: CAPONETTI GIOVANNI [IT]; MAGGI LORETTA [IT]; ZANELLOTTI LAURA [IT]; VENEZIANI CRISTINA [IT]


Application No.: US20080226750A1  Published: 18/Sep/2008

Title: Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions

Applicant/Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER

Application No.: 11/738294   Filing Date: 20/Apr/2007

Abstract:The present invention concerns the use of active compounds for inducing apnea and treating shock, in addition to enhancing the survivability of a subject. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving these effects.

Priority: US20060793520P Applic. Date: 2006-04-20; US20060869054P Applic. Date: 2006-12-07

Inventor: ROTH MARK B [US]; MORRISON MIKE [US]


Application No.: US20080226802A1  Published: 18/Sep/2008

Title: BEVERAGE HAVING NATURAL SWEETENERS WITH ONE OR MORE STEVIA COMPONENTS AND SOURCE OF BERRY

Applicant/Assignee: CONCENTRATE MANUFACTURING COMPANY OF IRELAND

Application No.: 11/686189   Filing Date: 14/Mar/2007

Abstract:Beverage compositions including a steviol glycoside and a berry component are provided. Beverage concentrate compositions including a steviol glycoside and a berry component are provided.

Priority:

Inventor: LEE THOMAS [US]


Application No.: US20080227825A1  Published: 18/Sep/2008

Title: Formulation

Applicant/Assignee:

Application No.: 12/067346   Filing Date: 25/Sep/2006

Abstract:This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

Priority: US20050722624P Applic. Date: 2005-09-29; WO2006US37198 Applic. Date: 2006-09-25

Inventor: JOSHI YATINDRA [US]; KOWALSKI JAMES [US]; LAKSHMAN JAY PARTHIBAN [US]; ROYCE ALAN EDWARD [US]; TONG WEI-QIN [US]; VASANTHAVADA MADHAV [US]


Application No.: US20080233174A1  Published: 25/Sep/2008

Title: HIGH DOSE FILM COMPOSITIONS AND METHODS OF PREPARATION

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/013989   Filing Date: 14/Jan/2008

Abstract:This invention relates to films incorporating high amounts of pharmaceutical agents and methods for the preparation of the same. Moreover, the invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

Priority: US20070880085P Applic. Date: 2007-01-12

Inventor: MYERS GARRY L [US]; BOONE BILL J [US]; HILBERT SAMUEL D [US]


Application No.: US20080233183A1  Published: 25/Sep/2008

Title: TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY

Applicant/Assignee: PATHFINDER MANAGEMENT, INC

Application No.: 12/052825   Filing Date: 21/Mar/2008

Abstract:The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.

Priority: US20070919554P Applic. Date: 2007-03-22

Inventor: MCCOOK JOHN PATRICK [US]; PERSAUD INDUSHEKHAR [US]; NARAIN NIVEN RAJIN [US]


Application No.: US20080233189A1  Published: 25/Sep/2008

Title: Pharmaceutical Tablets Comprising Two or More Unitary Segments

Applicant/Assignee:

Application No.: 10/598315   Filing Date: 23/May/2005

Abstract:Accurate means of dosing with a compressed, segmented pharmaceutical tablet, and tablettes formed from said tablets, is disclosed.

Priority: US20040573042P Applic. Date: 2004-05-21; US20040573134P Applic. Date: 2004-05-21; WO2005US18631 Applic. Date: 2005-05-23

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20080233193A1  Published: 25/Sep/2008

Title: ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: COSMO TECHNOLOGIES LTD

Application No.: 12/133568   Filing Date: 05/Jun/2008

Abstract:The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

Priority: IT2004MI01295 Applic. Date: 2004-06-25; US2007-571044 Applic. Date: 2007-02-05; WO2005EP52025 Applic. Date: 2005-05-03

Inventor: AIANI MAURO [IT]; BOZZELLA ROBERTA [IT]; CELASCO GIUSEPPE [IT]; VILLA ROBERTO [IT]


Application No.: US20080234179A1  Published: 25/Sep/2008

Title: ORALLY DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING A DELIVERY AGENT IN MICRONIZED FORM

Applicant/Assignee:

Application No.: 12/132642   Filing Date: 04/Jun/2008

Abstract:Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent

a crospovidone or povidone

and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

Priority: US2004-564259 Applic. Date: 2004-07-09; WO2004EP07584 Applic. Date: 2004-07-09; US20030486495P Applic. Date: 2003-07-11

Inventor: LI SHOUFENG [US]; GHOSH ANASUYA ASHOK [US]; BATEMAN SIMON DAVID [US]; AZRIA MOISE [CH]; ROYCE ALAN EDWARD [US]


Application No.: US20080234286A1  Published: 25/Sep/2008

Title: STABLE AMORPHOUS IMATINIB MESYLATE AND PRODUCTION PROCESS THEREFOR

Applicant/Assignee: CHEMAGIS LTD

Application No.: 12/051597   Filing Date: 19/Mar/2008

Abstract:Provided herein is a spray dried stable amorphous imatinib mesylate as a free-flowing solid and process for producing the amorphous imatinib mesylate in highly pure form.

Priority: US20070895840P Applic. Date: 2007-03-20

Inventor: WEISMAN ALEX [IL]; KRIVONOS SONIA [IL]; DANON EDNA [IL]; ADIN ITAI [IL]; IUSTAIN CARMEN [IL]


Application No.: US20080234291A1  Published: 25/Sep/2008

Title: Mitratapide Oral Solution

Applicant/Assignee:

Application No.: 10/585754   Filing Date: 18/Jan/2005

Abstract:The present invention concerns an oral solution comprising the MTP inhibitor mitratapide or an pharmaceutically acceptable acid addition salt thereof, a process for preparing such solutions, and their use in the treatment of MTP-related disorders such as hyperlipidemia, obesity, or type II diabetes.

Priority: EP20040100177 Applic. Date: 2004-01-21; WO2005EP50181 Applic. Date: 2005-01-18

Inventor: FRANCOIS MARC KAREL JOZEF [BE]; EMBRECHTS ROGER CAROLUS AUGUST [BE]; DRIES WILLY MARIA ALBERT CARLO [BE]


Application No.: US20080234373A1  Published: 25/Sep/2008

Title: Compound Useful For the Prevention and Treatment of Left Ventricular Hypertrophy in Dialysed Patients

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: 12/066032   Filing Date: 16/Oct/2006

Abstract:Is described the use of propionyl L-carnitine, or a pharmaceutical salt thereof, for preparing a medicament for the prevention and/or treatment of left ventricular hypertrophy in ESRD or dialysed patients.

Priority: US2005-250634 Applic. Date: 2005-10-17; WO2006EP67465 Applic. Date: 2006-10-16

Inventor: CARMINATI PAOLO [IT]; CORSI MARCO [IT]


Application No.: US20080241093A1  Published: 02/Oct/2008

Title: ION BINDING POLYMERS AND USES THEREOF

Applicant/Assignee: RELYPSA, INC

Application No.: 12/055746   Filing Date: 26/Mar/2008

Abstract:The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Priority: US2005-096209 Applic. Date: 2005-03-30; US2004-965274 Applic. Date: 2004-10-13; US2004-814527 Applic. Date: 2004-03-30; US2004-814749 Applic. Date: 2004-03-30; US2004-813872 Applic. Date: 2004-03-30

Inventor: CHARMOT DOMINIQUE [US]; CHANG HAN-TING [US]; LIU MINGJUN [US]; KLAERNER GERRIT [US]


Application No.: US20080241237A1  Published: 02/Oct/2008

Title: Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family

Applicant/Assignee:

Application No.: 12/057177   Filing Date: 27/Mar/2008

Abstract:The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.

Priority: US20070920224P Applic. Date: 2007-03-27

Inventor: VENKATESH GOPI [US]


Application No.: US20080241254A1  Published: 02/Oct/2008

Title: PHARMACEUTICAL COMPOSITION COMPRISING ATOVAQUONE PARTICLES

Applicant/Assignee:

Application No.: 11/966455   Filing Date: 28/Dec/2007

Abstract:The present invention relates to atovaquone particles having d90 value of about 4-15 mum. It further relates to a pharmaceutical composition comprising said particles.

Priority: IN2007DE00010 Applic. Date: 2007-01-02

Inventor: NAVALE SURYAKANT [IN]; DAS SURAJIT [IN]; SINGH GURVINDER [IN]; MATHUR RAJEEV SHANKER [IN]


Application No.: US20080241259A1  Published: 02/Oct/2008

Title: Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof

Applicant/Assignee:

Application No.: 12/081296   Filing Date: 14/Apr/2008

Abstract:The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: (i) preparing said microparticles from at least one bioresorbable polymer without stabilizer and without surfactant, and (ii) bonding said protein substances to the microparticles obtained in step (i) without surfactant. It further relates to the bioresorbable microparticles thus obtained and use thereof in diagnosis and therapy.

Priority: FR20030011057 Applic. Date: 2003-09-22; US2006-570948 Applic. Date: 2006-03-07; WO2004FR50447 Applic. Date: 2004-09-21

Inventor: ATAMAN-ONAL YASEMIN [FR]; DELAIR THIERRY [FR]; INCHAUSPE GENEVIEVE [FR]; JEANNIN PASCALE [FR]; PARANHOS-BACCALA GLAUCIA [FR]; VERRIER BERNARD [FR]


Application No.: US20080241261A1  Published: 02/Oct/2008

Title: PROCESS FOR PRODUCING SOLID ORAL DOSAGE FORMS WITH SUSTAINED RELEASE OF ACTIVE INGREDIENT

Applicant/Assignee:

Application No.: 12/135580   Filing Date: 09/Jun/2008

Abstract:The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, where appropriate, water-soluble polymers or lipophilic additives and, where appropriate, other conventional excipients, wherein this mixture or parts of this mixture are granulated by heating to from 40 DEG C. to 130 DEG C., and the granules are, after admixture with conventional excipients, subsequently tabletted.

Priority: DE20001029201 Applic. Date: 2000-06-19; US2001-873431 Applic. Date: 2001-06-05

Inventor: KOLTER KARL [DE]; FLICK DIETER [DE]; ASCHERL HERMANN [DE]


Application No.: US20080242707A1  Published: 02/Oct/2008

Title: Pharmaceutical Composition for the Treatment of Cancer

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/885930   Filing Date: 22/Feb/2006

Abstract:The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.

Priority: US20050658827P Applic. Date: 2005-03-07; WO2006EP01574 Applic. Date: 2006-02-22

Inventor: SCHUCKLER FRITZ [DE]; WOLLENSCHLAGER AXEL [DE]


Application No.: US20080242717A1  Published: 02/Oct/2008

Title: METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA

Applicant/Assignee:

Application No.: 12/038598   Filing Date: 27/Feb/2008

Abstract:Patients having symptoms associated with benign prostatic hyperplasia can be treated with a once daily composition containing silodosin or a pharmaceutically acceptable salt thereof.

Priority: US20070892170P Applic. Date: 2007-02-28

Inventor: SATO FUMIYASU [JP]; FURIHATA YOSHIO [JP]


Application No.: US20080242728A1  Published: 02/Oct/2008

Title: PHENOLIC ACID SALTS OF GABAPENTIN IN SOLID DOSAGE FORMS AND METHODS OF USE

Applicant/Assignee: KIEL LABORATORIES, INC

Application No.: 12/138945   Filing Date: 13/Jun/2008

Abstract:The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.

Priority: US2004-805806 Applic. Date: 2004-03-22; US20030457399P Applic. Date: 2003-03-25

Inventor: KIEL JEFFREY S [US]; THOMAS H GREG [US]; MANI NARASIMHAN [US]


Application No.: US20080247993A1  Published: 09/Oct/2008

Title: Microorganisms Inhibiting the Formation of Axillary Malodor

Applicant/Assignee: BASF SE

Application No.: 12/066277   Filing Date: 13/Sep/2006

Abstract:Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such micoorganisms in cosmetic, prophylactic or therapeutic applications.

Priority: EP20050019924 Applic. Date: 2005-09-13; US20050740225P Applic. Date: 2005-11-28; WO2006EP08923 Applic. Date: 2006-09-13

Inventor: REINDL ANDREAS [DE]; KNOLL ROLF [DE]; LANG CHRISTINE [DE]; VEEN MARKUS [DE]; BUDDE ECKHARD [DE]; BOETTNER MEWES [DE]


Application No.: US20080248052A1  Published: 09/Oct/2008

Title: Multi-Drug Ligand Conjugates

Applicant/Assignee:

Application No.: 12/064191   Filing Date: 18/Aug/2006

Abstract:Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.

Priority: US20050709950P Applic. Date: 2005-08-19; US20060787558P Applic. Date: 2006-03-30; WO2006US32561 Applic. Date: 2006-08-18

Inventor: VLAHOV IONTCHO RADOSLAVOV [US]; LEAMO CHRISTOPHER PAUL [US]


Application No.: US20080248101A1  Published: 09/Oct/2008

Title: Pharmaceutical composition containing fenofibrate and method for the preparation thereof

Applicant/Assignee: SOCIETE LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARM

Application No.: 12/155937   Filing Date: 11/Jun/2008

Abstract:A pharmaceutical composition containing fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose reduces food effect. The cellulose derivative represents less than 20 wt. % of the composition. The association of fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enhances the bioavailability of fenofibrate. Also provided is a method for preparing said composition without organic solvent.

Priority: FR19990008923 Applic. Date: 1999-07-09; US2006-509806 Applic. Date: 2006-08-25; US2002-030262 Applic. Date: 2002-04-17; WO2000FR01971 Applic. Date: 2000-07-07

Inventor: CRIERE BRUNO [FR]; SUPLIE PASCAL [FR]; CHENEVIER PHILIPPE [CA]


Application No.: US20080248102A1  Published: 09/Oct/2008

Title: Rapidly Dissolving Pharmaceutical Compositions Comprising Pullulan

Applicant/Assignee: UNIVERSITY OF KANSAS

Application No.: 12/062727   Filing Date: 04/Apr/2008

Abstract:The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent.

Priority: US20070922062P Applic. Date: 2007-04-05

Inventor: RAJEWSKI ROGER A [US]; HASLAM JOHN L [US]


Application No.: US20080248105A1  Published: 09/Oct/2008

Title: POLYMORPHIC FORMS OF 6-11 BICYCLIC KETOLIDE DERIVATIVES

Applicant/Assignee:

Application No.: 12/105482   Filing Date: 18/Apr/2008

Abstract:The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.

Priority: US2005-057476 Applic. Date: 2005-02-14; US20040546433P Applic. Date: 2004-02-20; US20040615803P Applic. Date: 2004-10-04

Inventor: TANG DATONG [US]; XU GUOYOU [US]; GAI YONGHUA [US]; WANG ZHE [US]; OR YAT SUN [US]; LI HUI-YIN [US]


Application No.: US20080249025A1  Published: 09/Oct/2008

Title: Methods and Means For Inhibition of CDK4 Activity

Applicant/Assignee: CYCLACEL LIMITED

Application No.: 12/133242   Filing Date: 04/Jun/2008

Abstract:p21interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation and cellular proliferation, indicative of therapeutic usefullness in treatment of tumors and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.

Priority: GB19960009521 Applic. Date: 1996-05-08; GB19960021314 Applic. Date: 1996-10-09; US2003-646267 Applic. Date: 2003-08-22; US1999-180269 Applic. Date: 1999-07-08; WO1997GB01250 Applic. Date: 1997-05-08

Inventor: BALL KATHRYN LINDSAY [GB]; LANE DAVID PHILIP [GB]


Application No.: US20080249076A1  Published: 09/Oct/2008

Title: Pharmaceutical Compositions Comprising Danazol

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 10/581170   Filing Date: 03/Dec/2004

Abstract:A controlled release pharmaceutical comprising danazol has the property of slow release of danazol over an extended period of time and markedly increased bioavailability compared to commercially available danazol-containing products. The pharmaceutical composition comprises danazol dissolved in a solid vehicle or carrier and is especially suitable for oral solid dosage forms. The composition significantly reduces food effect and may reduce side effects.

Priority: DK20030001785 Applic. Date: 2003-12-03; WO2004DK00844 Applic. Date: 2004-12-03

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20080249120A1  Published: 09/Oct/2008

Title: Pharmaceutical compositions

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 12/001807   Filing Date: 13/Dec/2007

Abstract:A pharmaceutical composition in solid form containing at least a therapeutically effective amount of one or more statins in the free acid form is disclosed.

Priority: IN2006MU01928 Applic. Date: 2006-11-22; US20060874658P Applic. Date: 2006-12-13

Inventor: SONI VIJAY [US]; NASARE VIJAY [IN]; DHUPPAD ULHAS [IN]; JOSHI NARENDRA [IN]


Application No.: US20080249303A1  Published: 09/Oct/2008

Title: METHODS OF SEPARATION AND DETECTION OF BAZEDOXIFENE ACETATE IN PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: WYETH

Application No.: 12/057465   Filing Date: 28/Mar/2008

Abstract:Methods are disclosed for separating and detecting bazedoxifene acetate from pharmaceutical compositions containing a mixture of bazedoxifene acetate and one or more other components that produce X-Ray diffraction patterns having interfering peaks at or near the characteristic peaks for bazedoxifene acetate.

Priority: US20070909113P Applic. Date: 2007-03-30

Inventor: TONG WEI [US]; LONGFELLOW CARL E [US]


Application No.: US20080253970A1  Published: 16/Oct/2008

Title: Stable Pharmaceutical Drug Products

Applicant/Assignee: SCHERING CORPORATION

Application No.: 12/028853   Filing Date: 11/Feb/2008

Abstract:Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more consistent fine particle size distribution (FSD) and fine particle fraction (FPF) at ambient conditions and at accelerated stability conditions over the life of the drug product. Advantageously, such products may more reliably and regularly pass testing requirements as required for an approved drug product by regulatory authorities such as the United States Food and Drug Administration (USFDA).

Priority: US20070889127P Applic. Date: 2007-02-09

Inventor: SHERWOOD JILL K [US]; SEQUEIRA JOEL [US]; DONOVAN BRENT ASHLEY [US]


Application No.: US20080254033A1  Published: 16/Oct/2008

Title: Pharmaceutical Compositions Containing Antagonists to Lrp4, Lrp8 or Megalin for Treatment of Diseases

Applicant/Assignee:

Application No.: 10/586669   Filing Date: 21/Jan/2005

Abstract:The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides

polynucleotides encoding such

modulators of LRP4, LRP8 and LRP2 activity

and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to or interfering with the activity of LRP4, LRP8, LRP2 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention.

Priority: US20040538322P Applic. Date: 2004-01-21; WO2005US01883 Applic. Date: 2005-01-21

Inventor: PIERCE KRISTEN [US]; COLLINS AMY L TSUI [US]; ZHANG HONGBING [US]; WILLIAMS LEWIS THOMAS [US]; BEAURANG PIERRE ALVARO [US]


Application No.: US20080254092A1  Published: 16/Oct/2008

Title: Acellularized Biomaterial from Embryonic Stem Cells

Applicant/Assignee: GEORGIA TECH RESEARCH CORPORATION

Application No.: 12/092863   Filing Date: 08/Nov/2006

Abstract:Compositions containing acellularized biomaterial derived from differentiating pluripotent cells, for example, embryonic stem cells are provided. The acellularized biomaterial can be used to promote wound healing, promote tissue regeneration, or inhibit scarring. Methods for using the acellularized biomaterial for treating degenerative diseases are also provided.

Priority: US20050734584P Applic. Date: 2005-11-08; WO2006US43711 Applic. Date: 2006-11-08

Inventor: MCDEVITT TODD CHRISTOPHER [US]; NAIR REHKA RAMACHANDRAN [US]


Application No.: US20080254122A1  Published: 16/Oct/2008

Title: Polymer release system

Applicant/Assignee: EGALET A/S

Application No.: 12/073692   Filing Date: 07/Mar/2008

Abstract:A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.

Priority: DK20010001377 Applic. Date: 2001-09-21; DK20020001044 Applic. Date: 2002-07-03; US2004-490308 Applic. Date: 2004-06-23; WO2002DK00620 Applic. Date: 2002-09-23

Inventor: FISCHER GINA [DK]; BAR-SHALOM DANIEL [DK]; SLOT LILLIAN [DK]; LADEMANN ANNE-MARIE [DK]; JENSEN CHRISTINE [DK]


Application No.: US20080254123A1  Published: 16/Oct/2008

Title: Morphine polymer release system

Applicant/Assignee: EGALET A/S

Application No.: 12/078312   Filing Date: 28/Mar/2008

Abstract:A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.

Priority: DK20010001376 Applic. Date: 2001-09-21; US2004-490169 Applic. Date: 2004-07-23; WO2002DK00619 Applic. Date: 2002-09-23

Inventor: FISCHER GINA [DK]; BAR-SHALOM DANIEL [DK]; SLOT LILLIAN [DK]; JENSEN CHRISTINE [DK]


Application No.: US20080254124A1  Published: 16/Oct/2008

Title: Controlled release composition

Applicant/Assignee: BM RESEARCH A/S

Application No.: 12/213087   Filing Date: 13/Jun/2008

Abstract:A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising a matrix comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to be used, and a coating having at least one opening exposing at least one surface of said matrix, the coating comprising a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The coating is a coating which crumbles and/or erodes upon exposure to the aqueous medium such as a body fluid. The first cellulose derivative may be, e.g., ethylcellulose, cellulose acetate, cellulose propionate or cellulose nitrate, and the second cellulose derivative may be, e.g. methylcellulose, carboxymethylcellulose or salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose or hydroxymethylpropylcellulose.

Priority: DK19940000222 Applic. Date: 1994-02-23; US2004-827521 Applic. Date: 2004-04-20; US1996-693254 Applic. Date: 1996-08-19; WO1995DK00080 Applic. Date: 1995-02-23

Inventor: BAR-SHALOM DANIEL [DK]


Application No.: US20080255104A1  Published: 16/Oct/2008

Title: Nsaid Compositions

Applicant/Assignee: EQUITECH CORPORATION

Application No.: 11/568551   Filing Date: 04/May/2005

Abstract:The invention is directed to a composition and method for treating acute pain using a composition comprising one or more NSAID's, a metasilicate and optionally a fatty acid ester resulting in increased absorption of poorly soluble active NSAID's and increased absorption in suppressed vagal systems. The preferred composition comprises meloxicam on a metasilicate matrix

and one or more of the following: sodium bicarbonate, Gelucire(R), and tartaric acid.

Priority: US20040567436P Applic. Date: 2004-05-04; WO2005CA00684 Applic. Date: 2005-05-04

Inventor: JAMALI FAHKREDDIN [CA]; HABASHI AGHAZADEH [CA]


Application No.: US20080255138A1  Published: 16/Oct/2008

Title: Novel Polymorphic Form Of Imatinib Mesylate And A Process For Its Preparation

Applicant/Assignee: NATCO PHARMA LIMITED

Application No.: 10/585702   Filing Date: 16/Nov/2004

Abstract:This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as alpha2 Form, which is stable at room temperature and even at higher temperatures up to 120 DEG C. and accelerated stress conditions and, freely soluble in water. This invention also discloses a pharmaceutical composition containing the novel stable alpha2 form of Imatinib mesylate and other usually employed excipients, useful in the treatment of Chronic Myelogenous Leukemia (CML). This new alpha2 Form of imatinib mesylate is prepared by slurrying Imatinib base in isopropanol at room temperature followed by addition of methane sulfonic acid and maintaining 50-60 DEG C. followed by filtration. This invention also discloses another process for the preparation of the novel, stable alpha2 crystalline form of Imatinib Mesylate by the conversion of Imatinib mesylate beta-polymorphic modification by suspending it in water and organic solvents, distilling off water azeotropically, cooling and filtering to obtain the alpha2 crystal form.

Priority: IN2004CH00105 Applic. Date: 2004-02-11; WO2004IN00352 Applic. Date: 2004-11-16

Inventor: AMALA KOMPELLA [IN]; SRINIVASA RAO THUNGATHURTHI [IN]; ADIBHATLA KALI SATYA BHUJANGA RAO [IN]; RACHAKONDA SREENIVAS [IN]; VENKAIAH CHOWDARY NANNAPANENI [IN]; PODILI KHADGAPATHI [IN]


Application No.: US20080255193A1  Published: 16/Oct/2008

Title: Pharmaceutical Composition

Applicant/Assignee:

Application No.: 12/088661   Filing Date: 28/Sep/2006

Abstract:A novel pharmaceutical composition comprising the NK3 receptor antagonist talnetant, povidone, mannitol and a surfactant, and a process for its preparation are disclosed.

Priority: US20050722153P Applic. Date: 2005-09-30; WO2006US38406 Applic. Date: 2006-09-28

Inventor: BRUM JEFFREY [US]; FAULKNER PATRICK G [US]; PAN RENNAN [US]


Application No.: US20080255247A1  Published: 16/Oct/2008

Title: Oil-In-Water Emulsion and Its Use for the Delivery of Functionality

Applicant/Assignee: NESTEC S.A

Application No.: 12/093560   Filing Date: 22/Nov/2006

Abstract:The present invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structurization with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a lipophilic additive and the oil-in-water emulsion contains an active element being present in the range comprised between 0.00001 and 79% based on the total composition.

Priority: EP20050025439 Applic. Date: 2005-11-22; WO2006EP68761 Applic. Date: 2006-11-22

Inventor: SAGALOWICZ LAURENT [CH]; LESER MARTIN [CH]; MICHEL MARTIN [CH]; WATZKE HERIBERT JOHANN [CH]; ACQUISTAPACE SIMONE [CH]; BERTHOLET RAYMOND [CH]; HOLST BIRGIT [CH]; ROBERT FABIEN [FR]


Application No.: US20080260657A1  Published: 23/Oct/2008

Title: Process for Milling Poorly Soluble Drugs in Presence of Liquid Propellants

Applicant/Assignee:

Application No.: 11/574083   Filing Date: 22/Aug/2005

Abstract:Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant.

Priority: GB20040018791 Applic. Date: 2004-08-23; WO2005GB03269 Applic. Date: 2005-08-22

Inventor: BUTLER JAMES MATTHEW [GB]; FORSTER ANGUS HARRY [GB]; PATTERSON JAMES EDON [GB]; WARR JOHN PETER [GB]


Application No.: US20080260679A1  Published: 23/Oct/2008

Title: METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES

Applicant/Assignee: RELYPSA, INC

Application No.: 12/055457   Filing Date: 26/Mar/2008

Abstract:The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Priority: US2004-814527 Applic. Date: 2004-03-30

Inventor: CHARMOT DOMINIQUE [US]; LIU MINGJUN [US]


Application No.: US20080260813A1  Published: 23/Oct/2008

Title: PHARMACEUTICAL COMPOSITION OF TOPIRAMATE

Applicant/Assignee:

Application No.: 11/927850   Filing Date: 30/Oct/2007

Abstract:The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.

Priority: US2006-467298 Applic. Date: 2006-08-25; US2003-748764 Applic. Date: 2003-12-30; US1999-259718 Applic. Date: 1999-03-01; US19980076770P Applic. Date: 1998-03-04

Inventor: THAKUR MADHAV S [US]; KOTWAL PRAMOD M [US]; GIBBS IRWIN S [US]


Application No.: US20080260815A1  Published: 23/Oct/2008

Title: Multiparticulates

Applicant/Assignee:

Application No.: 11/661478   Filing Date: 31/Aug/2005

Abstract:Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant. The present invention is preferably directed to extruded multiparticulates containing an opioid such as oxycodone, an ammonium methacrylate copolymer such as Eudragit(R) RSPO, a plasticising excipient such as preferably stearyl alcohol and a water permeability modifier such as preferably Eudragit(R) RLPO. The obtained multiparticulates show a release rate profile which is pH-independent.

Priority: GB20040019296 Applic. Date: 2004-08-31; WO2005GB50140 Applic. Date: 2005-08-31

Inventor: HAYES GEOFFREY GERARD [GB]; MARTINELLI VINCENZO [GB]; MOHAMMAD HASSAN [GB]; TAMBER HARJIT [GB]; WALDEN MALCOLM [GB]; WHITELOCK STEVE [GB]


Application No.: US20080260816A1  Published: 23/Oct/2008

Title: Particulate Lipid Pharmaceutical Composition

Applicant/Assignee:

Application No.: 12/066154   Filing Date: 11/Sep/2006

Abstract:A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media. Also disclosed is a method of producing the composition and a tablet containing it

sachets and capsules filled with the composition

use of the composition and the tablet as a medicine

a method of administering the composition to a patient.

Priority: SE20050002043 Applic. Date: 2005-09-16; WO2006SE01033 Applic. Date: 2006-09-11

Inventor: HERSLOF BENGT [SE]; TINGVALL PER [SE]; KORNFELDT ANNA DE [SE]


Application No.: US20080260827A1  Published: 23/Oct/2008

Title: RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE

Applicant/Assignee:

Application No.: 12/163278   Filing Date: 27/Jun/2008

Abstract:A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three consecutive days per month is useful for treating or preventing osteoporosis and other bone metabolic disorders.

Priority: US2004-897897 Applic. Date: 2004-07-23; US2002-321208 Applic. Date: 2002-12-17; US20010344875P Applic. Date: 2001-12-21

Inventor: BURGIO DAVID ERNEST [US]; SCHOFIELD PAMELA JEAN [US]; GATELY MAURICE KENT [US]; SHI JUN [US]


Application No.: US20080260835A1  Published: 23/Oct/2008

Title: PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS

Applicant/Assignee: F H FAULDING & CO LIMITED

Application No.: 11/763578   Filing Date: 15/Jun/2007

Abstract:The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.

Priority: AU1999PQ04854 Applic. Date: 1999-12-23; AU2000PQ07450 Applic. Date: 2000-05-12; US2002-175883 Applic. Date: 2002-06-21; WO2000AU01592 Applic. Date: 2000-12-22

Inventor: HAYES DAVID [AU]; MORELLA ANGELO MARIO [AU]


Application No.: US20080260837A1  Published: 23/Oct/2008

Title: Physically stable aqueous suspensions of active pharmaceuticals

Applicant/Assignee: QPHARMA, L.L.C

Application No.: 11/788466   Filing Date: 20/Apr/2007

Abstract:The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water

a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa.s to 50 mPa.s as a surfactant

a suspending agent

and water.

Priority:

Inventor: NAMBURI RANGA R [US]; VATTIKUTI BALA MURALI K [US]; MULAMALLA RATNA PRABHA [US]; PALKHIWALA BURGISE F [US]


Application No.: US20080261863A1  Published: 23/Oct/2008

Title: Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use

Applicant/Assignee: BAYER PHARMACEUTICALS CORP

Application No.: 11/632465   Filing Date: 10/Jun/2005

Abstract:This invention relates to modified Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 2 (VPAC2) agonists (VPAC2 agonists) comprising a VPAC2 agonist linked to a polyethylene glycol polymer, as well as related formulations, dosages, and methods of administration thereof for therapeutic purposes. These VPAC2 agonists, compositions, and methods are useful in providing a treatment option for those individuals afflicted with a metabolic disorder such as diabetes, impaired glucose tolerance, metabolic syndrome, or prediabetic states, by inducing glucose-dependent insulin secretion in the absence of the therapeutically limiting side effect of reducing or lowering blood pressure.

Priority: US20040579190P Applic. Date: 2004-06-12; WO2005US20469 Applic. Date: 2005-06-10

Inventor: WHELAN JAMES [US]; PAN CLARK [US]


Application No.: US20080261866A1  Published: 23/Oct/2008

Title: Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 10/586544   Filing Date: 19/Jan/2005

Abstract:Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are used, particularly in mammals. Also provided are process for the manufacture of such novel compositions and method to minimize the nonsteroidal anti-inflammatory drug(s) induced gastric toxicity.

Priority: WO2005IN00026 Applic. Date: 2005-01-19; IN2004DE00102 Applic. Date: 2004-01-20

Inventor: JAIN RAJESH [IN]; JINDAL KOUR CHAND [IN]; SINGH SUKHJEET [IN]


Application No.: US20080261891A1  Published: 23/Oct/2008

Title: COMPOSITIONS AND METHODS FOR USING SYRINGOPEPTIN 25A AND RHAMNOLIPIDS

Applicant/Assignee: UTAH STATE UNIVERSITY

Application No.: 12/030726   Filing Date: 13/Feb/2008

Abstract:The present invention provides a therapeutic composition having at least one syringopeptin and at least one rhamnolipid so that the composition has one or more of the following activities: antibacterial

antifungal

and antitumor activity. The therapeutic composition includes the following: a therapeutically effective amount of a syringopeptin

a therapeutically effective amount of a rhamnolipid

and a pharmaceutically acceptable carrier. Additionally, the present invention provides a method for inhibiting or treating cancer or a microbial infection in a subject, wherein the method includes the following: providing a subject in need of inhibition or treatment of cancer or a microbial infection

and administering a therapeutic amount of a therapeutic composition to the subject so as to inhibit or treat the cancer or microbial infection.

Priority: US20070890117P Applic. Date: 2007-02-15

Inventor: WEIMER BART C [US]


Application No.: US20080261897A1  Published: 23/Oct/2008

Title: Formulation Containing a Polyphenol-Containing Composition and Isomaltulose

Applicant/Assignee:

Application No.: 12/094253   Filing Date: 23/Nov/2006

Abstract:The present invention relates to formulations containing isomaltulose and a polyphenol-containing composition, uses of same and the use of isomaltulose for masking unwanted taste components, in particular bitter substances, in formulations, in particular in formulations containing tea extracts.

Priority: DE200510056652 Applic. Date: 2005-11-25; WO2006EP11219 Applic. Date: 2006-11-23

Inventor: DORR TILLMANN [DE]; HAUSMANNS STEPHAN [DE]; KOWALCZYK JORG [DE]; BECKER MARTINA [DE]; KILLEIT ULRICH [DE]


Application No.: US20080262012A1  Published: 23/Oct/2008

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN

Applicant/Assignee:

Application No.: 12/119622   Filing Date: 13/May/2008

Abstract:Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin alpha and rifaximin beta, and a poorly crystalline form referred to as rifaximin gamma, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Priority: US2007-873841 Applic. Date: 2007-10-17; US2005-135651 Applic. Date: 2005-05-24; WO2004EP12490 Applic. Date: 2004-11-04

Inventor: VISCOMI GIUSEPPE CLAUDIO [IT]; CAMPANA MANUELA [IT]; BRAGA DARIO [IT]; CONFORTINI DONATELLA [IT]; CANNATA VINCENZO [IT]; RIGHI PAOLO [IT]; ROSINI GOFFREDO [IT]


Application No.: US20080262054A1  Published: 23/Oct/2008

Title: Pharmaceutical Composition Containing Thiazolidinedione Compound

Applicant/Assignee:

Application No.: 11/922713   Filing Date: 07/Jul/2006

Abstract:[OBJECT] To provide a pharmaceutical composition containing a thiazolidinedione compound and having superior solubility. [MEANS FOR SOLUTION] A pharmaceutical composition incorporating cellulose, a cellulose derivative, a polyvinyl alcohol derivative, a polyvinyl alcohol derivative mixture or a mixture thereof with 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}thiazolidine-2,4-dione, or a pharmacologically acceptable salt thereof.

Priority: JP20050199661 Applic. Date: 2005-07-08; JP20060013679 Applic. Date: 2006-01-23; WO2006JP313548 Applic. Date: 2006-07-07

Inventor: KAWASAKI TAKAO [JP]; SUZUKI NOBUYUKI [JP]; YADA SHUICHI [JP]


Application No.: US20080262104A1  Published: 23/Oct/2008

Title: Aqueous Polyvinyl Acetate Dispersions Having High Shearing Stability

Applicant/Assignee: BASF SE

Application No.: 12/065525   Filing Date: 23/Aug/2006

Abstract:Processes comprising: providing a monomer composition comprising a vinyl acetate monomer component and second monomer component comprising an additional monomer selected from the group consisting of acrylic acid, methacrylic acid and mixtures thereof in an amount of 0.05 to 5% by weight, wherein the vinyl acetate monomer component and the second monomer component comprise 100% by weight of the monomer composition

and free-radically polymerizing the monomer composition in the presence of 0.001 to 1% by weight of an ionic emulsifier, based on the weight of the monomer composition, to form an aqueous polymer dispersion

polymer dispersions and powders prepared therewith

and uses of such dispersions and powders in pharmaceuticals and/or cosmetics.

Priority: DE200510042039 Applic. Date: 2005-09-02; WO2006EP65590 Applic. Date: 2006-08-23

Inventor: ANGEL MAXIMILIAN [DE]; KOLTER KARL [DE]


Application No.: US20080268018A1  Published: 30/Oct/2008

Title: Method for forming crystallized therapeutic agents on a medical device

Applicant/Assignee:

Application No.: 11/799263   Filing Date: 30/Apr/2007

Abstract:A method of crystallizing a therapeutic agent in a coating on an implantable medical device, and uses thereof, are disclosed.

Priority:

Inventor: PACETTI STEPHEN D [US]


Application No.: US20080268036A1  Published: 30/Oct/2008

Title: Co-processing of active pharmaceutical/nutraceutical ingredients

Applicant/Assignee: JRS PHARMA

Application No.: 12/150282   Filing Date: 24/Apr/2008

Abstract:A process for preparing agglomerated particles comprising a) preparing a slurry of a pre-manufactured agglomerated particles consisting of microcrystalline cellulose and one or more compressibility augmenting agents, and an active ingredient

and b) drying the slurry to form active agent agglomerated particles.

Priority: US20070926158P Applic. Date: 2007-04-24

Inventor: GUY ALEN [US]; SCHAIBLE DAVID [US]; MONTALTO THEODORE [US]


Application No.: US20080268046A1  Published: 30/Oct/2008

Title: Formulations with Controlled Release of Active Ingredient

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/579904   Filing Date: 29/Apr/2005

Abstract:The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts, hydrates, solvates and/or polymorphic forms thereof as active ingredient, and to the production thereof. The invention further relates to the use of these novel pharmaceutical dosage forms as medicaments, and to their use for producing medicaments for the treatment and/or prevention of disorders in humans and animals.

Priority: DE200410023069 Applic. Date: 2004-05-11; WO2005EP04615 Applic. Date: 2005-04-29

Inventor: ZULEGER SUSANNE [DE]; SERNO PETER [DE]; HANING HELMUT [DE]; PAULI KERSTIN [DE]; HEINIG ROLAND [DE]


Application No.: US20080269150A1  Published: 30/Oct/2008

Title: Intra-vascular kidney gene therapy with plasmid encoding BMP-7

Applicant/Assignee: MERIAL LIMITED

Application No.: 11/803991   Filing Date: 16/May/2007

Abstract:The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration of the recombinant vectors and pharmaceutical compositions of the invention.

Priority: US2007-801798 Applic. Date: 2007-05-11; US2006-599026 Applic. Date: 2006-11-14; US20050736452P Applic. Date: 2005-11-14

Inventor: FISCHER LAURENT BERNARD [FR]


Application No.: US20080269355A1  Published: 30/Oct/2008

Title: Novel Solubility Enhancer and Use Thereof

Applicant/Assignee:

Application No.: 12/067738   Filing Date: 22/Sep/2006

Abstract:Disclosed herein is a novel solubility enhancer capable of being employed in formulating safe and effective pharmaceutical formulations of partially soluble drugs, wherein the solubility enhancer is selected from dialkyl substituted amides of fatty acids having C6 to C16 carbon chain, preferably from N,N-dimethyl hexanamide, N,N-dimethyl octanamide, N,N-dialkyl decanamide, N,N-dialkyl dodecanamide or N,N-dialkyl hexadecanamide.

Priority: IN2005CH01345 Applic. Date: 2005-09-22; WO2006IN00390 Applic. Date: 2006-09-22

Inventor: RADHAKRISHNAN RAMACHANDRAN [IN]


Application No.: US20080274081A1  Published: 26/Jul/2007

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/706088   Filing Date: 13/Feb/2007

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20080274123A1  Published: 06/Nov/2008

Title: Specific Binding Members Against Synaptophysin

Applicant/Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

Application No.: 11/547368   Filing Date: 29/Mar/2005

Abstract:The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11

and/or an antibody VL domain selected front the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated it liver fibrosis.

Priority: GB20040007059 Applic. Date: 2004-03-29; GB20040016402 Applic. Date: 2004-07-22; WO2005GB01190 Applic. Date: 2005-03-29

Inventor: WRIGHT MATTHEW [GB]; PORTER ANDY [GB]


Application No.: US20080274155A1  Published: 06/Nov/2008

Title: Chimeric Cannulae Proteins, Nucleic Acids Encoding Them And Methods For Making And Using Them

Applicant/Assignee: VERENIUM CORPORATION

Application No.: 10/593846   Filing Date: 24/Mar/2005

Abstract:The invention provides chimeric cannulae polypeptides and nanotubules and methods for making and using them. In one aspect, the invention provides compositions and methods for the identification, separation or synthesis of proteins or ligands. In one aspect, the invention provides compositions and methods for making and using nanotubules. In one aspect, the invention provides compositions and methods for the selection and purification of chiral compositions from racemic mixtures. In one aspect, the chimeric proteins and polymers (e.g., nanotubules, tubules, bundles, balls, fibers, filaments, sheets, threads, textiles) of the invention comprise a detectable moiety, e.g., a fluorescent protein. In one aspect, the invention provides a flame retardant or heat resistant device comprising a sheeting, a covering, a coating or an adhesive comprising a chimeric protein of the invention.

Priority: US20040556393P Applic. Date: 2004-03-24; US20040605192P Applic. Date: 2004-08-27; WO2005US09927 Applic. Date: 2005-03-24

Inventor: BARTON NELSON R [US]; O'DONOGHUE EILEEN [US]; SHORT RYAN [US]; FREY GERHARD [US]; WEINER DAVID [US]; ROBERTSON DAN E [US]; BRIGGS STEVEN [US]; ZORNER PAUL [US]


Application No.: US20080274176A1  Published: 06/Nov/2008

Title: Pharmaceutical Lipid Compositions

Applicant/Assignee: CAMURUS AB

Application No.: 11/795243   Filing Date: 09/Dec/2005

Abstract:The present invention relates to a particulate composition containing

a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration.

Priority: GB20050001364 Applic. Date: 2005-01-21; GB20050007812 Applic. Date: 2005-04-18; WO2005GB04745 Applic. Date: 2005-12-09

Inventor: JOHNSSON MARKUS [SE]; TIBERG FREDRIK [SE]


Application No.: US20080274180A1  Published: 06/Nov/2008

Title: Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It

Applicant/Assignee: NICHOLAS PIRAMAL INDIA LIMITED

Application No.: 12/065334   Filing Date: 22/Aug/2006

Abstract:A pharmaceutical composition in the form of tablets constitutes an orally administered, controlled drug delivery system that will provide increased retention time of the device in the stomach over conventional dosage forms and release metformin or its pharmaceutically acceptable salt in a controllable manner, and further that is easy and inexpensive to manufacture.

Priority: IN2005MU01035 Applic. Date: 2005-08-30; WO2006IB52892 Applic. Date: 2006-08-22

Inventor: JATHAR SHRIPAD RHUSHIKESH [IN]; SIRWANI RAJESH PRABHAMAL [IN]


Application No.: US20080274188A1  Published: 06/Nov/2008

Title: Oral Vehicle For Systemic Pharmaceuticals

Applicant/Assignee: PBL MANUFACTURING LIMITED

Application No.: 12/067817   Filing Date: 22/Sep/2006

Abstract:Systemic drug delivery includes boluses of a semi-solid agar gel, each containing active ingredients, packed singly or in co-operating sets in blister packs, or loose in a container. When placed in the mouth the bolus is disrupted, comes apart, and releases the active ingredients. Sialogogues, flavours, and other additives assist in swallowing. Grains of the active ingredients may be encapsulated inside harder gel capsules. Active ingredients include over-the-counter medications and prescription medications. Applications include self-medication particularly in water-free situations such as public transport, medication for children, stroke victims or the aged.

Priority: GB20050019290 Applic. Date: 2005-09-22; WO2006NZ00246 Applic. Date: 2006-09-22

Inventor: ALEXANDER CARL ERNEST [NZ]


Application No.: US20080274215A1  Published: 06/Nov/2008

Title: COMPOSITION FOR TREATMENT OF COLD AND FLU

Applicant/Assignee: NORTHERN HOLDINGS INC

Application No.: 12/114863   Filing Date: 05/May/2008

Abstract:The present invention is a composition delivering therapeutically effective amounts of Andrographis Paniculata standardized to 5.6% of Andrographolide:Siberian Ginseng:American Ginseng:Vitamin C in a single dosage unit.

Priority: US20070915711P Applic. Date: 2007-05-03

Inventor: MORROW JARRET [US]


Application No.: US20080274999A1  Published: 06/Nov/2008

Title: Hyaluronic Acid Fraction with Moisturizing and Anti-Wrinkle Properties

Applicant/Assignee: NOVOZYMES BIOPOLYMER A/S

Application No.: 11/722814   Filing Date: 22/Dec/2005

Abstract:A moisturizing, cosmetic, or anti-wrinkle product comprising hyaluronic acid or a salt thereof, wherein the hyaluronic acid or salt thereof has an average molecular weight in the range of 0.7-0.9 MDa, compositions comprising said product, and uses of said product.

Priority: DK20050000006 Applic. Date: 2005-01-03; US20050641857P Applic. Date: 2005-01-06; WO2005DK00822 Applic. Date: 2005-12-22

Inventor: ABDELLAOUI KHADIJA SCHWACH [DK]; HALBYE SOREN [DK]


Application No.: US20080275076A1  Published: 06/Nov/2008

Title: Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof

Applicant/Assignee:

Application No.: 11/885992   Filing Date: 08/Mar/2006

Abstract:The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising sirolimus (rapamycin) and/or derivatives and/or analogues thereof. Compositions of the invention exhibit an acceptable bioavailability of sirolimus and/or a derivative and/or an analogue thereof. The pharmaceutical compositions of the invention are designed to release sirolimus in a controlled manner so that the plasma levels stays within the narrow therapeutic window that exist for this class of substances. An extended release profile, where the peak concentration has been reduced without loosing significant bioavailability, together with less variable absorption, is expected to improve the safety/efficacy ratio of the drug. Furthermore, compositions according to the invention provide for a significant reduced food effect and a delayed release of sirolimus is expected to reduce the number of gastro-intestinal related side effects.

Priority: DK20050000344 Applic. Date: 2005-03-08; WO2006DK00135 Applic. Date: 2006-03-08

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20080275082A1  Published: 06/Nov/2008

Title: Pharmaceutical Composition

Applicant/Assignee:

Application No.: 12/088647   Filing Date: 28/Sep/2006

Abstract:A novel pharmaceutical composition comprising the NK3 receptor antagonist talnetant, povidone, erythritol and a surfactant, and a process for its preparation are disclosed. The use of erythritol as soluble filler in the preparation of a stable pharmaceutical composition is disclosed.

Priority: US20050722761P Applic. Date: 2005-09-30; WO2006US38067 Applic. Date: 2006-09-28

Inventor: BRUM JEFFREY [US]; GEBREKIDAN SISAY [US]; PAN RENNAN [US]


Application No.: US20080275091A1  Published: 06/Nov/2008

Title: COMPOSITIONS AND METHODS FOR TREATING NOCTURNAL ACID BREAKTHROUGH AND OTHER RELATED DISORDERS

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 12/173493   Filing Date: 15/Jul/2008

Abstract:The present invention relates to, inter alia, pharmaceutical compositions comprising an acid labile proton pump inhibitor and a buffering agent

to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.

Priority: US2006-380177 Applic. Date: 2006-04-25; US20050675123P Applic. Date: 2005-04-26

Inventor: PHILLIPS JEFFREY OWEN [US]


Application No.: US20080275118A1  Published: 06/Nov/2008

Title: HEALTH AND COSMETIC COMPOSITION AND REGIME FOR STIMULATING HAIR GROWTH AND THICKENING ON THE HEAD, INCLUDING THE SCALP, EYELASHES, AND EYEBROWS, AND WHICH DISCOURAGES HAIR LOSS

Applicant/Assignee:

Application No.: 12/137799   Filing Date: 12/Jun/2008

Abstract:This invention relates to compositions and processes for stimulating the growth of mammalian hair comprising the topical application of compositions comprising a hair growth stimulating and/or hair loss prevention agent, and a hair and/or skin lightening and/or neutralization agent, in association with a topical pharmaceutical carrier. Unlike other products, the composition of the invention can be used with dyed/treated hair so as to not affect the color of the hair.

Priority:

Inventor: SHAW MARI M [US]; COHEN MARC S [US]; SWARTZ NANCY G [US]


Application No.: US20080275138A1  Published: 06/Nov/2008

Title: Liquid Dispersion Polymer Compositions, Their Preparation And Their Use

Applicant/Assignee:

Application No.: 11/547214   Filing Date: 30/Mar/2005

Abstract:Liquid dispersion polymer compositions which comprise microparticles of a hydrophilic, water soluble or swellable polymer with a neutralization level of from about 25% to about 100%, preferably an acrylic-based polymer, dispersed in a suitable non-aqueous carrier fluid and an oil-in-water surfactant, are useful to prepare microparticulate thickening systems to thicken aqueous or aqueous/organic compositions, particularly for use in personal care and pharmaceutical formulations.

Priority: EP20040101419 Applic. Date: 2004-04-06; WO2005EP51429 Applic. Date: 2005-03-30

Inventor: RIDLEY ELEANOR BERNICE [GB]; GREEN MICHAEL [GB]; NORMINGTON DAVID [GB]


Application No.: US20080279879A1  Published: 13/Nov/2008

Title: INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE

Applicant/Assignee: NEW YORK UNIVERSITY

Application No.: 11/942634   Filing Date: 19/Nov/2007

Abstract:Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise a "carrier" protein fusion partner, preferably a truncated form of the MuLV gp70 Env protein, and a desired HIV neutralizing epitopes. Preferred epitopes are epitopes of V3 from one or more HIV clades. Immune sera from such immunized subjects neutralized primary isolates from virus strains heterologous to those from which the immunogens were constructed. Neutralizing activity was primarily due to V3-specific antibodies and cross-clade neutralizing Abs were present. This approach results in more potent and broader neutralizing antibody levels, a result of "immunofocusing" the humoral immune response on neutralizing epitopes such as V3.

Priority: US20060859486P Applic. Date: 2006-11-17

Inventor: ZOLLA-PAZNER SUSAN [US]


Application No.: US20080279931A1  Published: 13/Nov/2008

Title: COMPOSITION FOR TREATMENT OF PAIN

Applicant/Assignee: NORTHERN HOLDINGS INC

Application No.: 12/117170   Filing Date: 08/May/2008

Abstract:The present invention is a composition delivering effective amounts of Glucosamine, Devils Claw, SAM, and NSAID in a single dosage unit.

Priority: US20070916870P Applic. Date: 2007-05-09

Inventor: MORROW JARRET [US]


Application No.: US20080279932A1  Published: 13/Nov/2008

Title: Compounds

Applicant/Assignee:

Application No.: 11/996646   Filing Date: 02/Aug/2006

Abstract:The present invention relates to novel salt forms of vildagliptin (LAF237), i.e. salt forms of(S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine.

Priority: US20050705592P Applic. Date: 2005-08-04; WO2006US30335 Applic. Date: 2006-08-02

Inventor: REBER JEAN-LOUIS [FR]; VILLHAUER EDWIN BERNARD [US]


Application No.: US20080279933A1  Published: 13/Nov/2008

Title: FLURBIPROFEN AND MUSCLE RELAXANT COMBINATIONS

Applicant/Assignee: SANOVEL ILAC SANAYI VE TICARET A.S

Application No.: 12/117378   Filing Date: 08/May/2008

Abstract:This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an alpha-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.

Priority: TR20070003092 Applic. Date: 2007-05-08

Inventor: CIFTER UMIT [TR]; TURKYILMAZ ALI [TR]; TURP HASAN ALI [TR]


Application No.: US20080279945A1  Published: 13/Nov/2008

Title: GEL-BASED DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: 12/100688   Filing Date: 10/Apr/2008

Abstract:Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery/transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue.

Priority: US2005-055497 Applic. Date: 2005-02-10; US20040543508P Applic. Date: 2004-02-10

Inventor: MAH CATHRYN S [US]; FRAITES JR THOMAS J [US]; BYRNE BARRY J [US]


Application No.: US20080280921A1  Published: 13/Nov/2008

Title: Amorphous Aripiprazole and Process for the Preparation thereof

Applicant/Assignee: HELM AG

Application No.: 12/131618   Filing Date: 02/Jun/2008

Abstract:Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Priority: EP20060117595 Applic. Date: 2006-07-20; EP20080150576 Applic. Date: 2008-01-23; US2006-463062 Applic. Date: 2006-08-08

Inventor: DREYER KATJA [DE]; LOEFFLER UWE [DE]; GLAENZER KLAUS [DE]


Application No.: US20080280937A1  Published: 13/Nov/2008

Title: Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives

Applicant/Assignee:

Application No.: 12/064163   Filing Date: 18/Aug/2006

Abstract:Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of cytotoxic drugs and vitamin receptor binding ligands. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers.

Priority: US20050709936P Applic. Date: 2005-08-19; WO2006US32560 Applic. Date: 2006-08-18

Inventor: LEAMON CHRISTOPHER PAUL [US]; VLAHOV IONTCHO RADOSLAVOV [US]


Application No.: US20080286356A1  Published: 20/Nov/2008

Title: Pharmaceutical compositions containing terbinafin and use thereof

Applicant/Assignee:

Application No.: 12/218806   Filing Date: 18/Jul/2008

Abstract:Pharmaceutical compositions for oral administration comprising terbinafine and a method for administering high dosages while minimizing effects associated with e.g. a high dosage load, e.g. coated tablets or multiparticulate formulations such as minitablets or pellets, e.g. in capsules.

Priority: GB20010017760 Applic. Date: 2001-07-20; GB20010028993 Applic. Date: 2001-12-04; GB20020012209 Applic. Date: 2002-05-27; US2004-483436 Applic. Date: 2004-05-21; WO2002EP08095 Applic. Date: 2002-07-19

Inventor: ALLES RAINER [DE]; BECKER DIETER [DE]; BONNY JEAN-DANIEL [CH]; HIRSCH STEFAN [DE]; KALB OSKAR [DE]; KOLLE ERNST ULRICH [DE]; MAYER FRIEDRICH KARL [CH]; STUTZ ANTON [AT]; WILLIAMS ANTHONY [SG]


Application No.: US20080286389A1  Published: 20/Nov/2008

Title: PROCESSES OF MAKING NORTH AMERICAN GINSENG FRACTIONS, PRODUCTS CONTAINING THEM, AND USE AS IMMUNOMODULATORS

Applicant/Assignee: FX LIFE SCIENCES INTERNATIONAL GMBH FX LIFESCIENCES AG

Application No.: 12/173966   Filing Date: 16/Jul/2008

Abstract:The invention is directed to chemical processes of preparing fractions form North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

Priority: US2005-114089 Applic. Date: 2005-04-26; US2002-187289 Applic. Date: 2002-07-02; US2000-581161 Applic. Date: 2000-07-27; WO1998US25724 Applic. Date: 1998-12-11; US19970069534P Applic. Date: 1997-12-12

Inventor: SHAN JACQUELINE J [CA]; PANG PETER K T [CA]; HUANG BUHAN [CA]; LING LEI [CA]


Application No.: US20080287380A1  Published: 20/Nov/2008

Title: Antisense Oligonucleotides Against Cpla2, Compositions and Uses Thereof

Applicant/Assignee: MOR RESEARCH APPLICATIONS LTD BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY

Application No.: 11/568169   Filing Date: 17/Apr/2005

Abstract:Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same may be used in methods of treatment of such diseases.

Priority: IL20040161579 Applic. Date: 2004-04-22; WO2005IL00399 Applic. Date: 2005-04-17

Inventor: LEVY RACHEL [IL]


Application No.: US20080289630A1  Published: 27/Nov/2008

Title: Pre-metered dry powder inhaler for moisture-sensitive medicaments

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/186577   Filing Date: 06/Aug/2008

Abstract:The invention discloses a pre-metered dry powder inhaler for use in treatment of respiratory disorders. The inhaler comprises a foil cutter arranged for opening a dry, moisture-tight seal formed by a dose container with tiotropium particles and a seal foil fixed to the container. The tiotropium-containing dose protected from moisture ingress by the moisture-tight barrier seal is loaded in the container using volumetric or electric field dose forming techniques.

Priority: US2004-933219 Applic. Date: 2004-09-03; SE20030003269 Applic. Date: 2003-12-03; SE20030003569 Applic. Date: 2003-12-22

Inventor: NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]


Application No.: US20080292562A1  Published: 27/Nov/2008

Title: Medicaments For Inhalation Comprising Pde IV Inhibitors and Enantiomerically Pure Glycopyrrolate Salts

Applicant/Assignee:

Application No.: 11/572199   Filing Date: 13/Jun/2005

Abstract:The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors (2) and salts of formula (1) wherein X may have the meanings defined in the description and claims, and their use in the treatment of respiratory complaints.

Priority: EP20040016878 Applic. Date: 2004-07-16; WO2005EP52704 Applic. Date: 2005-06-13

Inventor: PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]


Application No.: US20080292642A1  Published: 27/Nov/2008

Title: Crystalline anti-human IL-12 antibodies

Applicant/Assignee:

Application No.: 12/079434   Filing Date: 27/Mar/2008

Abstract:The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.

Priority: US20070920608P Applic. Date: 2007-03-29

Inventor: BORHANI DAVID W [US]; FRAUNHOFER WOLFGANG [US]; KRAUSE HANS-JUERGEN [DE]; KOENIGSDORFER ANETTE [DE]; WINTER GERHARD [DE]; GOTTSCHALK STEFAN [DE]


Application No.: US20080292683A1  Published: 27/Nov/2008

Title: Film shreds and delivery system incorporating same

Applicant/Assignee: MONOSOLRX, LLC

Application No.: 11/805753   Filing Date: 24/May/2007

Abstract:Compositions are provided that include water soluble or water dispersible film shreds, a carrier and an active, such as, but not limited to a drug, flavoring agent or coloring agent. Also provided are methods of use of the film shreds, such as in improving the dissolution, stability, aesthetics, or taste of a composition or its components, and in reducing a disease risk associated with an active.

Priority:

Inventor: SANGHVI PRADEEP [US]; FUISZ RICHARD C [US]


Application No.: US20080292698A1  Published: 27/Nov/2008

Title: PHARMACEUTICAL COMPOSITIONS OF ISOLATED ORTHORHOMBIC CRYSTALLINE 4-[6-ACETYL-3-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO)PROPOXY]-2-PROPYLPHENOXY]BUTYRIC ACID AND METHODS OF USE

Applicant/Assignee: MEDICINOVA, INC

Application No.: 12/106939   Filing Date: 21/Apr/2008

Abstract:A pharmaceutical composition comprising a compound of formula (1) in polymorphic crystalline Form A: together with a pharmaceutically acceptable carrier or excipient, wherein the compound of formula (1) is present in polymorphic Form A (see, e.g., FIG. 6) substantially free of other polymorphic forms.

Priority: US2005-319272 Applic. Date: 2005-12-29; US2003-601862 Applic. Date: 2003-06-24

Inventor: LOCKE KENNETH WALTER [US]; ROE DAVID GREGORY [CA]


Application No.: US20080299050A1  Published: 04/Dec/2008

Title: TOPICAL THERAPIES FOR ORAL MUCOSITIS AND OTHER CONDITIONS

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 11/865476   Filing Date: 01/Oct/2007

Abstract:A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenyloin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination with the phenyloin or salt thereof, to reduce pain associated with the oral mucositis. The phenyloin or salt thereof and optionally the analgesic agent can be administered in a pharmaceutical composition comprising an excipient vehicle suitable for intraoral administration, said composition being bioadhesive to an oral mucosal surface, for example having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to said surface.

Priority: US20060828319P Applic. Date: 2006-10-05

Inventor: BORTZ JONATHAN DAVID [US]; LEVINSON R SAUL [US]; GE JISHENG [US]; WANG JEREMY DONALD [US]


Application No.: US20080299069A1  Published: 04/Dec/2008

Title: Polymer Derivatives Comprising an Acetal or Ketal Branching Point

Applicant/Assignee:

Application No.: 11/579465   Filing Date: 03/May/2005

Abstract:The invention provides a polymer comprising (i) a first water-soluble polymer segment that is covalently attached, either directly or through one or more atoms, to a first oxygen atom that is covalently attached to a linking carbon atom

(ii) a second water-soluble polymer segment is covalently attached, either directly or through one or more atoms, to a second oxygen atom that is covalently attached to the linking carbon atom

and (iii) a reactive group that is covalently attached, either directly or through one or more atoms, to the linking carbon atom. The invention also provides, among other things, methods for preparing polymers, conjugates, pharmaceutical compositions and the like.

Priority: US20040587859P Applic. Date: 2004-07-15; WO2005US15144 Applic. Date: 2005-05-03

Inventor: MCMANUS SAMUEL P [US]; KOZLOWSKI ANTONI [US]


Application No.: US20080299189A1  Published: 04/Dec/2008

Title: CONTROLLED RELEASE DOPAMINE AGONIST COMPOSITIONS

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 12/126575   Filing Date: 23/May/2008

Abstract:The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.

Priority: US20070933271P Applic. Date: 2007-06-04

Inventor: BORTZ JONATHAN DAVID [US]; GRIMSHAW MICHAEL [US]; ERKOBONI DAVID F [US]


Application No.: US20080299193A1  Published: 04/Dec/2008

Title: Pharmaceutical composition comprising eszoplicone

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 12/156051   Filing Date: 29/May/2008

Abstract:The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size.

Priority: EP20070109085 Applic. Date: 2007-05-29

Inventor: JERALA-STRUKELJ ZDENKA [SI]; LEGEN IGOR [SI]; REVEN SEBASTJAN [SI]


Application No.: US20080299194A1  Published: 04/Dec/2008

Title: Pharmaceutical Formulation For Producing Rapidly Disintegrating Tablets

Applicant/Assignee: BASF SE

Application No.: 12/158236   Filing Date: 11/Dec/2006

Abstract:A pharmaceutical formulation in the form of agglomerates comprising a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 1-15% by weight of water-insoluble, film-forming polymers, d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients, the sum of the components a) to e) being 100% by weight.

Priority: EP20050112654 Applic. Date: 2005-12-21; EP20050112969 Applic. Date: 2005-12-23; WO2006EP69515 Applic. Date: 2006-12-11

Inventor: KOLTER KARL [DE]; WICHTNER MARCUS [DE]; SCHOENHERR MICHAEL [DE]; MITTWOLLEN JAN-PETER [DE]


Application No.: US20080299196A1  Published: 04/Dec/2008

Title: Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester

Applicant/Assignee: ADITECH PHARMA AB

Application No.: 12/089074   Filing Date: 06/Oct/2006

Abstract:The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Priority: WO2005DK00648 Applic. Date: 2005-10-07; DK20060000510 Applic. Date: 2006-04-07; US20060744455P Applic. Date: 2006-04-07; WO2006DK00561 Applic. Date: 2006-10-06

Inventor: NILSSON HENRIK [DK]; MULLER BERND W [DE]


Application No.: US20080299199A1  Published: 04/Dec/2008

Title: Swellable Dosage Form Comprising Gellan Gum

Applicant/Assignee: EGALET A/S

Application No.: 11/596123   Filing Date: 11/May/2005

Abstract:A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25 DEG C. In one embodiment of the invention, the particulate matter can be moulded into a desired shape or pressed onto a dispensing unit such as a spoon.

Priority: DK20040000755 Applic. Date: 2004-05-11; WO2005DK00317 Applic. Date: 2005-05-11

Inventor: BAR-SHALOM DANIEL [DK]; SLOT LILLIAN [DK]; FISCHER GINA [DK]; HEMMINGSEN PERNILLE HOYRUP [DK]


Application No.: US20080299208A1  Published: 04/Dec/2008

Title: Anisometric Particles In The Form Of Nanofibers/Mesofibers,Nanopipes, Nanocables/Mesocables, Nanobands/Mesobands, And The Curved Or Branched Variations Thereof

Applicant/Assignee:

Application No.: 11/666653   Filing Date: 22/Oct/2005

Abstract:The invention relates to novel anisometric mesoparticles and nanoparticles in the form of anisometric mesofibers/nanofibers, mesopipes/nanopipes, mesobands/nanobands, mesocables/nanocables, and the curved and branched or superimposed variations thereof as well as a novel method for the production thereof. The invention particularly relates to anisometric mesoparticles and nanoparticles which have an aerodynamic diameter <5 mum, the production thereof, loading thereof with active substances if the same cannot directly be utilized as an active substance, and the use thereof especially for producing medicaments against lung diseases or systemic diseases in humans and animals if the particles cannot directly be utilized as medicaments without carriers.

Priority: DE200410053373 Applic. Date: 2004-11-02; WO2005DE01897 Applic. Date: 2005-10-22

Inventor: WENDORFF JOACHIM H [DE]; GREINER ANGREAS [DE]; SCHMEHL THOMAS [DE]; GESSLER TOBIAS [DE]


Application No.: US20080300233A1  Published: 04/Dec/2008

Title: Pharmaceutical Composition Comprising Simvastatin and Ezetimibe

Applicant/Assignee: KRKA

Application No.: 11/994782   Filing Date: 30/Jun/2006

Abstract:The present invention relates to the field of pharmaceutical technology and in particular to novel dosage forms of medicaments containing as active ingredients simvastatin and ezetimibe, or pharmaceutically acceptable salts thereof. The present pharmaceutical compositions are characterized in that the contact of the compositions with oxygen is substantially reduced, such as by coating the composition, providing a medicament useful for the treatment and prevention of atherosclerosis and related conditions, in an environment having an essentially reduced oxygen or humidity, respectively, content.

Priority: EP20050014680 Applic. Date: 2005-07-06; WO2006EP06369 Applic. Date: 2006-06-30

Inventor: KROSELJ VESNA [SI]; LAKSE RENATA [SI]; TOPORISIC REBEKA [SI]; KASTELIC JOZE [SI]


Application No.: US20080305038A1  Published: 11/Dec/2008

Title: Transport of Nano-and Macromolecular Structures Into Cytoplasm and Nucleus of Cells

Applicant/Assignee: LUDWIG-MAXIMILIANS-UNIVERSITAET TECHNISCHE UNIVERSITAET MUENCHEN

Application No.: 11/816989   Filing Date: 15/Feb/2006

Abstract:The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present invention refers to conjugate molecules containing a carrier, preferably thiopyridyl moieties, and a cargo moiety. Thereby, the thiopyridyl moiety is bound to the cargo moiety to act as a carrier, particularly for efficient intracellular and/or intranuclear delivery of drugs, nano-or macromolecular structures, etc. The novel conjugate molecules are provided for the manufacture of a medicament for gene therapy, apoptosis, or for the treatment of diseases such as cancer, autoimmune diseases or infectious diseases.

Priority: EP20050003904 Applic. Date: 2005-02-23; WO2006EP01362 Applic. Date: 2006-02-15

Inventor: ROSENECKER JOSEPH [DE]; RUDOLPH CARSTEN [DE]; PLANK CHRISTIAN [DE]; ELFINGER MARKUS [DE]


Application No.: US20080305158A1  Published: 11/Dec/2008

Title: Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine

Applicant/Assignee: RANBAXY LABORATORIES LIMITED

Application No.: 11/722620   Filing Date: 22/Dec/2005

Abstract:The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation.

Priority: IN2004DE02012 Applic. Date: 2004-12-28; WO2005IB03857 Applic. Date: 2005-12-22

Inventor: CHAUDHARI SHRIKANT S [IN]; SINGH ROMI BARAT [IN]; NAGAPRASAD VISHNUBHOTLA [IN]


Application No.: US20080305159A1  Published: 11/Dec/2008

Title: Ibuprofen-Hydrocodone-Antihistamine Composition

Applicant/Assignee: MIKART, INC

Application No.: 12/134612   Filing Date: 06/Jun/2008

Abstract:A pharmaceutical composition for use in relieving cold and cough symptoms in a mammal includes ibuprofen, hydrocodone bitartrate and an antihistamine (or a decongestant). The ibuprofen is in a therapeutically effective amount sufficient to act as an analgesic and an anti-inflammatory. The hydrocodone bitartrate is in a therapeutically effective amount sufficient to act as an antitussive and an analgesic. The antihistamine is in a therapeutically effective amount to act as an antihistamine. A fatty excipient may be added to the active ingredients to facilitate encapsulation. Multiple layers of the fatty excipient may be employed in varying release formulations and to facilitate identification of the composition.

Priority: US20070942372P Applic. Date: 2007-06-06

Inventor: GROENEWOUD PIETER J [US]


Application No.: US20080311162A1  Published: 18/Dec/2008

Title: Solid form

Applicant/Assignee:

Application No.: 11/803825   Filing Date: 16/May/2007

Abstract:A solid form comprising at least one film enrobing a compacted fill material comprising a pressure sensitive multiparticulate and at least one cushioning agent, in which the multiparticulate and/or the cushioning agent comprises at least one active material, having low friability and wherein the compacted fill material has a density of at least 0.5 g/ml based on the total solid volume of the solid form and a tensile strength of less than 0.9 MPa.

Priority:

Inventor: DARMUZEY OLIVIA [BE]; MACLEOD GRAEME [BE]; CENGIC DZENANA [BE]


Application No.: US20080311191A1  Published: 18/Dec/2008

Title: Multi-Layer Tablets and Bioadhesive Dosage Forms

Applicant/Assignee:

Application No.: 11/661541   Filing Date: 29/Aug/2005

Abstract:Bioadhesives coatings increase the gastrointestinal retention time of orally-ingested medicaments. Certain bioadhesive coatings producing a fracture strength of at least 100 N/m2, as measured on rat intestine, when applied to at least one surface of a pharmaceutical dosage form for oral delivery of a drug, result in a gastrointestinal retention time of at least 4 hours in a fed beagle dog model, during which the drug is released from the dosage form. Multi-layer tablets, particularly those including hydrophobic excipients, are useful in administering hygroscopic and/or deliquescent drugs. In addition, varying the amount of drug in multi-layer tablets allows the release rate of the drug to be controlled.

Priority: US2004-009327 Applic. Date: 2004-12-09; US20040604991P Applic. Date: 2004-08-27; US20040604990P Applic. Date: 2004-08-27; US20040605198P Applic. Date: 2004-08-27; US20040605199P Applic. Date: 2004-08-27; US20040605200P Applic. Date: 2004-08-27; US20040605201P Applic. Date: 2004-08-27; US20040607905P Applic. Date: 2004-09-08; US20040638512P Applic. Date: 2004-12-22; US20050650191P Applic. Date: 2005-02-04; US20040630375P Applic. Date: 2004-11-23; US20050676383P Applic. Date: 2005-04-29; WO2005US30651 Applic. Date: 2005-08-29

Inventor: NANGIA AVINASH [US]; JACOB JULES [US]; MATHIOWITZ EDITH [US]; RICKETTS THOMAS [US]; KREITZ MARK R [US]


Application No.: US20080311192A1  Published: 18/Dec/2008

Title: Enteric-Coated Glucosinolates And Beta-Thioglucosidases

Applicant/Assignee: KRAFT FOODS HOLDINGS, INC

Application No.: 11/761843   Filing Date: 12/Jun/2007

Abstract:The present invention relates to a particulate composition comprising enteric-coated glucosinolate and beta-thioglucosidase particles. The present invention further provides a method of converting glucosinolate to isothiocyanate in the small intestine comprising orally administering to a subject an enteric-coated chemoprotectant precursor composition comprising enteric-coated glucosinolate and beta-thioglucosinodase particles. In another aspect, uncoated glucosinolate and beta-thioglucosinodase particles may be provided in an enteric-coated capsule. Preferably, the glucosinolate is glucoraphanin and the beta-thioglucosidase is myrosinase. The enteric coating targets the compound for release in the small intestine where beta-thioglucosinodase enzyme converts glucosinolate to chemoprotectant isothiocyanate.

Priority:

Inventor: WEST LESLIE GEORGE [US]; WINDSOR NICOLE LEE [US]; GAONKAR ANILKUMAR GANAPATI [US]; MATUSHESKI NATHAN V [US]; KIM NAM-CHEOL [US]; LUDWIG CATHY JEAN [US]; LAWRENCE LESLIE LEWIS [US]


Application No.: US20080311193A1  Published: 18/Dec/2008

Title: Sustained Release Formulation of Alprazolam

Applicant/Assignee:

Application No.: 11/996377   Filing Date: 20/Jul/2006

Abstract:The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner.

Priority: IN2005MU00880 Applic. Date: 2005-07-22; WO2006IB01987 Applic. Date: 2006-07-20

Inventor: JOSHI MANJUSHA [IN]; GAT GANESH VINAYAK [IN]; MEHTA SATISH RAMANLAL [IN]


Application No.: US20080311205A1  Published: 18/Dec/2008

Title: Abuse resistant drug formulation

Applicant/Assignee: CIMA LABS, INC

Application No.: 12/075543   Filing Date: 12/Mar/2008

Abstract:A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.

Priority: US2007-900851 Applic. Date: 2007-09-13; US20060845126P Applic. Date: 2006-09-15; US20060845127P Applic. Date: 2006-09-15; US20060845128P Applic. Date: 2006-09-15; US20060845151P Applic. Date: 2006-09-15; US20060850456P Applic. Date: 2006-10-10

Inventor: HABIB WALID A [US]; HAMED EHAB [US]; VEGA ZEPEDA MANUEL A [US]


Application No.: US20080311212A1  Published: 18/Dec/2008

Title: CRYSTALLINE ISOXAZOLE DERIVATIVE AND PHARMACEUTICAL PREPARATION THEREOF

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: 12/195201   Filing Date: 20/Aug/2008

Abstract:Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2theta) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation. 2theta ( DEG ) Relative intensity (%)

6.1 100 14.1 55 16.0 74 18.5 36 20.0 43 25.4 39

Priority: JP20010089119 Applic. Date: 2001-03-27; US2003-473005 Applic. Date: 2003-09-26; WO2002JP02937 Applic. Date: 2002-03-26

Inventor: OCHIAI YASUSHI [JP]; TOMOMURA KAZUHIKO [JP]; NISHII HIROYUKI [JP]


Application No.: US20080312154A1  Published: 18/Dec/2008

Title: ADMINISTRATION OF ADIPOCYTOKINE AND ADIPONECTIN FOR TREATING HEADACHE AND METHODS OF DIAGNOSING HEADACHE BY MEASURING ADIPONECTIN

Applicant/Assignee:

Application No.: 12/138812   Filing Date: 13/Jun/2008

Abstract:Methods for treating a headache, such as a migraine, in a subject comprising administering a therapeutically effective amount of an adipocytokine, for example, adiponectin, to the subject are disclosed. Pharmaceutical compositions comprising adipocytokine, for example, adiponectin, are disclosed. Methods of diagnosing the presence or absence of a headache in a subject, such as a migraine, by assessing the level of adiponectin in the subject are disclosed.

Priority: US20070934690P Applic. Date: 2007-06-15; US20070981852P Applic. Date: 2007-10-23

Inventor: PETERLIN BARBARA LEE [US]


Application No.: US20080312168A1  Published: 18/Dec/2008

Title: Novel Dispersible Tablet Composition

Applicant/Assignee: RUBICON RESEARCH PVT. LTD

Application No.: 11/996266   Filing Date: 24/Jul/2006

Abstract:The present invention relates to a novel dispersible tablet composition, which comprises of a pharmacologically active ingredient and at least one excipient, which reduces the sedimentation rate of active ingredient. This invention further relates to a process for the preparation of a dispersible tablet of a pharmacologically active ingredient.

Priority: IN2005MU00879 Applic. Date: 2005-07-22; WO2006IN00291 Applic. Date: 2006-07-24

Inventor: PILGAONKAR PRATIBHA SUDHIR [IN]; RUSTOMJEE MAHARUKH TEHMASP [IN]; GANDHI ANILKUMAR SURENDRAKUMAR [IN]; BAGDE PRADNYA [IN]; BARVE VARSHA [IN]


Application No.: US20080317842A1  Published: 25/Dec/2008

Title: Fast Wet-Massing Method for the Preparation of Calcium-Containing Compositions

Applicant/Assignee:

Application No.: 11/883536   Filing Date: 02/Feb/2006

Abstract:The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with a composition comprising the calcium-containing compound, ii) wet-massing the composition with a granulation liquid optionally comprising a pharmaceutically acceptable binder for a time period of at the most 30 sec to obtain a wet granulate, iii) drying the thus obtained wet granulate. A granulate obtained by the present method is especially suitable in the preparation of solid dosage forms, in particular in the preparation of tablets.

Priority: DK20050000168 Applic. Date: 2005-02-03; WO2006IB00195 Applic. Date: 2006-02-02

Inventor: BERTELSEN POUL E [DK]; OLSEN PEDER M [DK]; NIELSEN CARSTEN M [DK]; TOLLESHAUG MAGNUS W [DK]


Application No.: US20080317843A1  Published: 25/Dec/2008

Title: NANOPARTICULATE FORMULATIONS OF MODAFINIL

Applicant/Assignee: ELAN CORPORATION PLC

Application No.: 11/776770   Filing Date: 12/Jul/2007

Abstract:The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms.

Priority: US20070908067P Applic. Date: 2007-03-26; US20060882740P Applic. Date: 2006-12-29; US20060807126P Applic. Date: 2006-07-12

Inventor: JENKINS SCOTT A [US]; LIVERSIDGE GARY [US]; MANSER DAVID [IE]


Application No.: US20080317847A1  Published: 25/Dec/2008

Title: HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED DELIVERY OF AGENT

Applicant/Assignee:

Application No.: 12/131807   Filing Date: 02/Jun/2008

Abstract:The present invention provides a hydrostatic delivery system including a hydrostatic couple and an agent of interest. The hydrostatic couple includes at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agents of interest within a fluid environment following zero-order kinetics.

Priority: US20000251751P Applic. Date: 2000-12-05; US2002-006740 Applic. Date: 2002-04-02

Inventor: MACGREGOR ALEXANDER [CA]


Application No.: US20080317852A1  Published: 25/Dec/2008

Title: Pharmaceutical Combination

Applicant/Assignee:

Application No.: 12/097387   Filing Date: 14/Dec/2006

Abstract:A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior art combination therapies. The invention also provides a pharmaceutical product containing the formulation.

Priority: IN2005MU01566 Applic. Date: 2005-12-14; IN2006MU01878 Applic. Date: 2006-11-13; WO2006GB04687 Applic. Date: 2006-12-14

Inventor: LULLA AMAR [IN]; MALHOTRA GEENE [IN]


Application No.: US20080317853A1  Published: 25/Dec/2008

Title: Mouth Dissolving Pharmaceutical Composition and Process for Preparing the Same

Applicant/Assignee: JUBILANT ORGANOSYS LTD

Application No.: 12/097813   Filing Date: 30/Aug/2006

Abstract:Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time.

Priority: IN2005DE03482 Applic. Date: 2005-12-27; WO2006IN00319 Applic. Date: 2006-08-30

Inventor: KASHID NAMDEV [IN]; MUKHERJI GOUR [IN]


Application No.: US20080317856A1  Published: 25/Dec/2008

Title: Compositions Containing A Capillary -Active System With Application -Relevant Differentiability, And The Use Thereof

Applicant/Assignee:

Application No.: 11/659393   Filing Date: 26/Jul/2005

Abstract:This invention relates to compositions with a capillary-active system with application-relevant differentiability and synergistic potential for use in mammals, especially humans. The invention accordingly relates to a composition that has a capillary-active system C optionally containing a capillary activator system CA consisting of drugs that increase blood flow, stabilize the vascular wall, and/or dilate the blood vessels

and/or a capillary-protective system CP comprising drugs for endothelial stabilization, lipoprotein protection, and for stabilization of leukocytes/platelets

and/or a capillary energy supply system CE comprising redox systems and cofactors in energy provision and energy carriers. This system C is combined with a selective action system S. The invention also relates to the use of such compositions, in particular systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents.

Priority: DE200410041270 Applic. Date: 2004-08-26; WO2005EP08087 Applic. Date: 2005-07-26

Inventor: BEUTLER ROLF D [DE]; SCHMIDT KARL-HEINZ [DE]; FUNKE BETTINA [DE]; BECKER KIRSTIN [DE]


Application No.: US20080317857A1  Published: 25/Dec/2008

Title: V-Atpase Inhibitors of Use in the Treatment of Septic Shock

Applicant/Assignee: BRANE DISCOVERY S.R.L

Application No.: 12/091740   Filing Date: 27/Oct/2006

Abstract:The use of vacuolar ATPase inhibitors in the prevention and/or treatment of septic shock is herein described. Vacuolar ATPase inhibitors are selected among products of natural, semi-synthetic or synthetic origin.

Priority: EP20050110163 Applic. Date: 2005-10-28; WO2006EP67890 Applic. Date: 2006-10-27

Inventor: FARINA CARLO [IT]; CONSTANTIN GABRIELA [IT]; LAUDANNA CARLO [IT]; MISIANO PAOLA [IT]


Application No.: US20080318910A1  Published: 25/Dec/2008

Title: Controlled-Release Oral Dosage Form

Applicant/Assignee: MISTRAL PHARMA, INC

Application No.: 12/089068   Filing Date: 03/Oct/2006

Abstract:A controlled-release oral dosage form suitable for administration to a mammal. The dosage form comprises a drug and an organic acid or a salt thereof. The dosage form releases no more than 60% the total amount of the drug within about a first hour, the remaining amount of the drug being released over a period of time of about 5 to about 8 hours subsequent to the first hour. Such a dosage form can be particularly useful for delivery of various pH-dependent solubility drugs.

Priority: US20050722971P Applic. Date: 2005-10-04; WO2006CA01633 Applic. Date: 2006-10-03

Inventor: DESJARDINS ALAIN [CA]; BOLDUC BERTRAND [CA]


Application No.: US20080319091A1  Published: 25/Dec/2008

Title: Polymer Derivatives Comprising an Imide Branching Point

Applicant/Assignee:

Application No.: 11/579475   Filing Date: 03/May/2005

Abstract:The invention provides a water-soluble polymer comprising (i) an imide group comprising a linking nitrogen atom, a first carbonyl group covalently attached to the linking nitrogen atom, and a second carbonyl group covalently attached to the linking nitrogen atom

(ii) a first water-soluble polymer segment covalently attached, either directly or through one or more atoms, to the first carbonyl group of the imide group and (iii) a second water-soluble polymer segment covalently attached, either directly or through one or more atoms, to the second carbonyl group of the imide group. The invention also provides, among other things, methods for preparing polymers, conjugates, pharmaceutical compositions and the like.

Priority: WO2005US15145 Applic. Date: 2005-05-03; US20040567494P Applic. Date: 2004-05-03

Inventor: MCMANUS SAMUEL P [US]; KOZLOWSKI ANTONI [US]

US Patent Applications in Excipients, Delivery and Release of
Pharmaceutical Compositions and Actives Published in 2008
US Applications Published in 2009
US Applications Published in 2007
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
US PROVISIONAL PATENT APPLICATIONS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS PUBLISHED IN 2008
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release;
polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular
or buccal administration of medications, etc.
Clck to enlarge and view details